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Tumor cells can develop drug resistance via repair mechanisms that counteract the 
DNA damage from chemotherapy or radiation therapy. The Apurinic/apyrimidinic 
endonuclease 1 (APE1) is an enzyme involved in the DNA base excision repair (BER) 
pathway. It confers resistance to chemotherapy or radiotherapy treatments in different 
kind of tumors like breast, hepatocellular carcinoma (HCC) and lung for this reason it 
could be considered as a possible target for novel anticancer strategies. Many other 
non-repair activities are ascribable to APE1, such as the cell response to oxidative 
stress, the regulation of gene expression and miRNA processing. There are also 
consistent recent evidences concerning the secretion of APE1, for which elevated 
intracellular protein levels in cancer are linked to poor prognosis. It was in fact, 
demonstrated that APE1 is a non-classically secreted protein, and its extracellular 
release is regulated by the acetylation of K6/K7 residues of the N-Term domain. No 
data regarding secreted APE1 are still available in HCC. In this study we proved that 
serum secreted APE1 (sAPE1) could be considered as a diagnostic biomarker in 
hepatocellular carcinoma (HCC). We provided indications about sAPE1 biological role 
in HCC, elucidating sAPE1 paracrine function in the regulation of IL-6 and IL-8 mRNA 
expression. We elucidated also the mechanisms responsible for APE1 secretion using 
a HCC cell line. Our findings suggest a role of extracellular APE1 as a paracrine pro- 
inflammatory molecule, and provide a characterization of the APE1 exogenous 
function, which may modulate the inflammatory status in cancer microenvironment, 
contributing in the evolution of HCC. 
According to previous evidences about APE1 involvement in oncogenic miRNA 
processing under genotoxic stress, we also provide new indication about its role in 
miRNAs biology, elucidating its important contribute in miRNA 
expression/processing regulation and also in miRNA sorting in EVs, which could have 
great implication in tumor progression and in chemoresistance processes. 
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APE1 general overview 
 
Apurinic/Apyrimidinic endonuclease 1/Redox factor 1 (APE1/Ref1), is very well known 
enzyme that has a great impact in cell viability. It mainly co-operates with other DNA 
repair proteins for the maintenance of genome stability, being a main actor of the Base 
Excision Repair pathway (BER), but it is also known as master regulator of cellular 
responses to oxidative stress1. The importance of this enzyme is due to its pleiotropic 
activity. Beside the two previously described functions, many other non-canonical 
roles of the protein have been already characterized1. In particular, APE1 is a main 
player in controlling the redox homeostasis, participates in RNA metabolism, RNA 
stability and decay2, and has also influence in the regulation of microRNA (miRNA) in 
quality of  DROSHA partner for the miRNA processing3. 
Although its multiple functions seem disconnected from each other, APE1 
characteristic is to coordinate different activities promoting multiple responses for 
maintaining cells sustainability. 
APE1 is overexpressed in many different tumors and it can support cell proliferation 
and induce tumor chemoresistance phenomena, for this reason is considered as a good 
target for cancer therapy. 
In the following paragraphs at first will be deeper described APE1 gene and the 
multiple canonical and non-canonical APE1 functions, later APE1 contribution in 
cancer will be provided. 
 
APE1 gene description and transcriptional regulation 
 
APE1 gene, called APEX1 is located into chromosome 14q11.2. It is a ̴ 3000bp gene 
constituted of 5 exons interspersed by four small introns. All the exons are translated 
except for the first one4. APEX1 is a TATA less gene, and has multiple transcription 
start sites (TSS) located 130bp upstream the first splice junction1. The activation of 
APEX1 gene transcription occurs constitutively at basal levels and also before and 
during the S-phase of the cell cycle. The transcription is dependent by Sp1 binding 
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sites. Two Sp1 binding sites, called respectively Sp1-1 and Sp1-2, are located in the 
proximal promoter region of the gene. The first one is located upstream the CCAAT 
box and the second one is downstream the TSS. Sp1-1 site is required for the basal 
APEX1 gene expression, while Sp1-2 is required for the transcription coordinated to 
cell cycle5. The activation of gene transcription is also induced in mild oxidative stress 
condition. Sub-toxic ROS doses indeed induce the transcription of APEX1 gene and 
stimulate a sort of “adaptive response” for the following stresses exposure6. APEX1 
repression on the contrary is regulated by three negative calcium responsive elements 
(nCaRE) elements, that are located ̴2000bp upstream into the promoter region, which 
function is related to a self-negative regulation of APEX1 gene transcription mediated 
by APE1 protein itself7. Also p53 protein seems to have a role in the repression of the 
APEX1 gene. Even if no p53 binding sites have been found in the promoter of the gene, 
and no mechanisms have been elucidated yet, it is hypothesised that p53 could 
indirectly repress APEX1 gene expression, interacting with Sp1 located into Sp1-1 
region and inhibiting therefore the basal transcription of the gene8. 
 
 
APE1 protein structure and functions 
 
APE1 is a monomeric protein of 318 amino-acids, consisting of an unstructured portion 
of 33-35 amino-acids at the N-terminal region and a structured globular portion from 
residue 44 to residue 318, consisting of two domains, the first one, called N-terminal 
domain core, from amino-acid 44 to 146 and from 295 to 318, and the second one, called 
C-terminal domain core, from amino-acid 137 to 260. Every domain is made of six β- 
sheets surrounded by α-helices which form a four layered α-β sandwich9 (Figure1). 
Actually the information about the tri-dimensional structure of the protein is partial 
because the X-ray crystallographic structure was performed in the truncated form, 
lacking of the first 39 unstructured amino-acids1. For this reason, nowadays there is no 
a complete description about the interaction of the unstructured N-terminal region 
with the globular portion and as a consequence of this lacking information no  details 
8  








Figure 1: X-ray crystallographic structure of APE1 truncated form. The interaction with the abasic DNA (green) is 




The N-terminal region is composed by the first 127 residues. The 1-33 amino-acid 
residues contain the nuclear localization signal (NLS). This region is involved in protein- 
protein interaction and RNA–protein interaction. The residues from 34 to 127 are 
deputies to the redox activity11, while the C-terminal region is in charge for the 




Figure 2: Representation of APE1 protein regions. In red the first 33 amino-acid residues deputies to protein-protein 
interaction and to RNA-protein interaction. In black are indicated the NLS. In purple the region from aa 34 to aa 
127 involved in the redox activity, in blue the C-terminal domain responsible for the endonuclease activity. 




APE1 N-terminal region 
 
It seems that the unstructured N-terminal region of the proteins has an important role 
in controlling the activity of the enzyme, because of its capability to interact with other 
protein partners and with RNA11. While the C-terminal region of the protein is 
structurally conserved in the species during the evolution, the N-terminal domain 
doesn’t and just among mammalian species seems to be conserved with an homology 
that rises the 90%13. The N-terminal region is responsible for the modulation of the 
multiple APE1 activities11, because of its competence to interact with other proteins 
like X-ray repair cross complementing 1 (XRCC1)14 and nucleophosmin 1 (NPM1)15. The 
refinement of APE1 function, could be determinate by post translational modifications 
(PTMs) that fall into the N-terminal region11. The acetylation for instance of the 
residues K6 and K7 and the ubiquitination of the residues K24, K25, and K27 are 
accountable respectively for the PTEN transcriptional regulation16, and for the APE1 
cytosolic localization and degradation mediated by MDM217. The acetylation is 
actually the only PTM find out in vivo18. This modification promotes a neutralization 
of the positive charge of the N-tail, determining a conformational variation of   APE1. 
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Due to this conformational change, APE1 is much more prone to interact with 
chromatin and less inclined to interact with its protein partners. This event was very 
well characterized studying the dynamic of APE1 and NPM1 interaction19. The 
interaction between these two proteins occurs through the K27, K31, K32, K35 residues 
of APE1 protein. If acetylation of these residues occurs, as demonstrated under 
genotoxic stresses, the interaction between the two protein fails. As a consequence of 
this event, APE1 is delocalized from nucleoli and is released into the nucleus, where it 
can exert the repair activity with a better efficiency19 20. This is a very suitable example 
of APE1 PTMs that affect its functions according to the biological conditions. 
Furthermore, the acetylation at the N-terminal region seems to be part to the BER 
pathway because in its absence an accumulation of AP site in the genome and an 
increase of sensitivity to stress occurs20. The most glaring PTM that occurs in the N-tail 
is its cleavage. The loss of the first 33 amino-acid residues of the protein determinates 
the loss of the NLS and the cytosolic accumulation of the protein as a consequence. 
The cleavage does not completely abolish APE1 nuclear presence1, suggesting that 
other events affect APE1 cellular distribution1. What is sure is that this PTM affects the 
usual APE1 protein-protein interactions, while the endonuclease activity of the protein 
is emphasized11. Nowadays the proteases able to cleave APE1 have not yet been 
identified, even if during pro-apoptotic stimuli the serine protease Granzyme A is 
suspected to do it, because of its capability to bound APE1 present in endoplasmic 
reticulum-associated complex (SET)21. The N-tail of the protein is important also for 
supporting cell growth, due to its capacity to interact with RNA molecules. APE1 in 
fact exerts through these interactions the RNA quality control and the post- 
transcriptional regulation of gene expression11. 
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APE1 redox activity 
 
As mentioned before, the APE1 region that lies between amino-acid 34 to amino-acid 
127 is involved in the redox activity of the protein1, which simply exerts the reduction 
of some TFs conferring their activation. The redox domain takes place in a loop at the 
N-terminal central core of the globular protein. The identified residues that absolve 
redox activity are located in a hydrophobic pocket within the core, for this reason 
probably the protein acquires conformational adjustments which allow the redox 
reactions22,23. APE1 is a redox factor different from the others because of its capability 
to makes intermolecular disulphide bounds and to make a complex with thioredoxin 
(TRX) through the formation of mixed disulphide bounds22. The cysteine (Cys) 
residues, responsible for redox activity, that can change their oxidative state through 
the formation of disulphide bridges or through their switch into a thiol state are the 
Cys65, Cys93, and Cys9922 (Figure3). The cysteine 65 acts as a nucleophilic cysteine 
which favours the reduction of TFs disulphide bridges, the residues Cys93 and Cys99 
instead act as a resolving disulphide bounds, which are made upon APE1 oxidation22. 
Three are the possible hypothesised mechanisms by which APE1 could promote the 
reduction of the TFs. The first one is called the recruitment model, where APE1 acts as a 
bridge between the oxidised TF and the reducing agent. The second one is called the 
conformational change model, in which APE1 promotes some conformational changes to 
the TFs that allow an exposure of the reducible residues to the reducing agents. The 
third one is called the oxidation barrier model, where APE1 stabilizes the reduced state 
of TFs through a direct formation of hydrogen bound with the thiol group of the TFs1. 
As already mentioned before, APE1 is able to reduce different transcription factors, 
such as AP-1, p53, NF-κB, and HIF-1α through a thiol-based mechanism23. Due to the 
variety of TFs that APE1 is able regulate, it can induce pro-apoptotic, but also pro- 
proliferative signalling, according to the different cellular conditions1. The different 
TFs regulated by APE1 have a peculiar role in the progression of many tumors, for this 
reason  the   inhibition   of   APE1   redox  function  could  significantly   be   taken  in 
12  
consideration alone or better in combination with other chemotherapy treatments24. 
E3330, is the must specific APE1 redox inhibitor that actually is in clinical trial for 
cancer treatment24. It is a quinone that specifically promotes the disulphide bound of 
Cys65 and Cys93 of the protein, keeping the protein in a oxidised state preventing its 








Figure 3: APE1 ribbon representation where cys residues involved in redox activity are represented. The disulphide 
bounds formation is shown in the reaction scheme on the left22. 
13  
APE1 C-terminal region and its enzymatic activities 
 
The C-terminal domain of the protein is deputy for the endonuclease activity. APE1 is 
mainly known as a DNA repair protein which participates to BER. BER pathway is a 
DNA repair process, activated as a consequence of the presence of alkylation or 
oxidative lesions in DNA that could be caused by endogenous or exogenous stresses, 
such as chemotherapy treatments26. It is specifically involved in the recognition and 
the following substitution of damaged nucleotides embedded in DNA. This process is 
characterized by the high coordination of 5 reaction steps and two different sub- 
pathways are delineated for its execution (Figure 4). The first one is called Single 
Nucleotide Base Excision Repair (SN BER) and is characterized by the substitution of a 
single damaged nucleotide with an undamaged one through a template directed DNA 
synthesis27. The second one is called Long Patch Base Excision Repair (LP BER), where 
the damaged nucleotide together with two or more surrounding nucleotides are 
substituted27. According to the activated sub-pathways different players are involved 
once the generation of a nick into the DNA is completed. As soon as DNA damage 
occurs, mono or bi-functional glycosylases recognize the damaged 
deoxyribonucleotide and remove the injured base, generating a deoxy abasic site. The 
deoxy abasic site is later recognized and processed by APE1, whose function is to 
remove the deoxy abasic site, generating a nick on the DNA backbone that is 
subsequently filled by the activity of DNA polymerase β (Pol β), and sealed by the 
activity of the complex XRCC1-DNA ligase III (LigIII) if the repair occurs through the 
SN BER, when instead the repair occurs through the LP BER, Polymerase δ (Pol δ) or 
Polymerase ε (Pol ε) together with proliferating cell nuclear antigen (PCNA) are deputies 
to fill the gap, generating a 2-12 nucleotide stretch. Flap endonuclease 1 (FEN1) later 









APE1 not only removes deoxy-abasic sites embedded in DNA, but exerts also 
enzymatic activities upon non-canonical substrates. It in fact, possesses endonuclease 
activity on abasic single stranded RNA, weak 3’-5’ exoribonuclease activity, and it also 
takes part to the nucleotide incision repair pathway (NIR)29. NIR pathway is an APE1 
enzymatic activity recently discovered. In this process, APE1 directly removes specific 
damaged by oxidative stress bases such as, 5-hydroxy-2 –deoxyuridine, 5,6-dihydro-2 
-deoxyuridine, bypassing the action of the glycosylases. The N-tail of the protein is 
essential for this repair pathway, because NIR activity is strongly reduced in APE1 
lacking of the first 33 amino-acids (APE1NΔ33)30. Therefore, others non canonical APE1 
substrates were recently characterized by our laboratory. APE1 in fact, is able to 
remove ribo-abasic sites and deoxy-ribonucleotides embedded in DNA29. All of these 
activities strengthen the importance of APE1 in the maintenance of genome stability. 
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APE1 as a regulator of gene expression 
 
One of the non-repair activity exerted by APE1 and supported by post-translational 
modification is the regulation of gene expression. APE1 in fact can act as a co-activator 
or as a co-repressor of gene transcription through redox dependent and redox 




Indirect mechanisms of APE1 gene expression regulation 
 
The indirect mechanism of gene expression regulation is related to APE1 capability to 
modify the redox status of many TFs, promoting their activation, as already described. 
Nowadays numerous are the identified TFs regulated by APE1 such as p53, NF-κB, 
PEBP-2, CREB, HIF-1α, AP-1, Egr-131–33 and the majority of them have a relevant role 
in controlling cell proliferation and apoptosis, confirming APE1 important role in the 
maintenance of cellular homeostasis16,33,34. 
 
 
Direct mechanisms of APE1 gene expression regulation 
 
Besides the indirect way to participate in gene regulation, recent evidences about a 
direct mechanism of controlling gene transcription have been found. In particular, it 
seems that APE1 can regulate gene expression also through epigenetic modifications35. 
One example is related to its capability to interact with specific promoter regions of 
the regulated genes called nCaRE36. The nCaRE-sequences are DNA regulatory regions 
which APE1 interacts with through its N-terminal domain36. They are sequences 
characterized by having ALU repeats and are used to be in correspondence of many 
gene promoters37. APE1 interacts with these regions together with other proteins like 
the Heterogeneous nuclear ribonucleoprotein L (hnRNPL), PARP1 and Ku70/8036. 
Examples of negative regulation of gene expression mediated by APE1 through its 
interaction with nCaRE-sequences are the inhibition of parathyroid hormone (PTH), 
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renin and Bax transcription36,38–40. On the contrary, one example of positive regulation 
through nCaRE-sequences is the activation of SIRT1 gene upon oxidative stress. APE1 
lies in the nCaRE-sequences of the promoter of SIRT1. During genotoxic stress, 
oxidised deoxy-nucleotides located in this region are recognized and repaired by 
APE1. The endonuclease activity of the protein, probably favours important chromatin 
changes at level of the promoter that allows the transcription of the gene36. Other 
example of direct regulation of gene expression mediated by the endonuclease action 
of APE1 upon oxidised guanine located in G-quadruplex structures of some gene 
promoter it has been recently described. This mechanism it has been elucidated for the 
activation of VEGF gene. Oxidative stress causes the oxidation of guanine present in 
G-quadruplex. First intervenes the glycosylase OGG1 to remove the injured base and 
later APE is recruited in correspondence of the a-basic site. It seems that APE1 role in 
this context is much more associated to the recruitment of the transcription factor 
machinery to the gene promoter rather than for the execution of its endonuclease 
activity upon the generated a-basic site41. The aforementioned examples suggest that 
the activation of DNA repair processes could be an instrument for the regulation of 
gene expression for better controlling the sustainability of living cells41. Noteworthy, 
sometimes both direct and indirect mechanisms intervene together. This is what 
happens during the activation of VEGF transcription in hypoxic conditions of solid 
tumors42. Under hypoxic conditions HIF-1 is activated by APE1 through a redox- 
dependent manner. Therefore, the oxidative stress induced by hypoxia causes the 
oxidation of guanine located in correspondence of hypoxic response element (HRE) of the 
VEGF gene. The originated 8-oxoguanine are recognised by OGG1, and later APE1 
exerts the endonuclease activity. The originated single strand breaks cause the 
modification of VEGF promoter topology which favours the activation of gene 
transcription42. 
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The non-canonical APE1 functions 
 
After the description of the canonical APE1 functions, an overview about the non- 




Identification  of  APE1  protein  partners   to  comprehend  the      non- 
 
canonical role of the protein 
 
APE1 interactome analysis shows the plethora of APE1 protein partners offering a 
general overview of APE1 contribution to cell sustainability, DNA repair and 
regulation of gene expression. Through the analysis of APE1 protein partners is much 
more immediate to comprehend not only its contribution in canonical function but also 
in its non-canonical ones. APE1 is able to interact with 103 proteins species3. Analysing 
APE1 interactors, five functional annotation clusters have been delineated, and 
consequently APE1 participates in the following five biological pathways: RNA 
processing, DNA Repair, Double Strand Breaks (DSB) repair, Transcriptional Regulation 
and Apoptosis. These clusters are not independent each other, but many factors 
participate in more than one group (Figure 5), interconnecting different pathways3,26. 
This analysis gives information about the multifunctional role of APE1, which is not 
only associated to DNA Repair pathway and transcriptional regulation, but is also able 
to contribute in RNA processing, and RNA metabolism, due to its capability to interact 
with ribonucleoproteins like hnRNPK and factors involved in miRNA processing like 
SFPQ43. The majority of APE1 protein partners that has been found ( ̴60%), contributes 
to the RNA processing3. Moreover, has been also observed that the interaction between 
APE1 and many protein partners is mediated by RNA molecules, suggesting that 




Figure 5: Functional annotation clusters of APE1 interactors. APE1 is represented as the fulcrum of the interactome 
and proteins partners are listed in five charts corresponding to the biological pathways3. 
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APE1 role in controlling gene expression through miRNA processing 
 
One of the first non-canonical APE1 functions is its capability to interact with damaged 
abasic RNA and to process it44. APE1 in fact is able to recognize and interact with RNA 
through its N-terminal domain and possesses 3’ RNA phosphatase, 3’ exoribonuclease 
activity45 and also endoribonuclease activity on abasic sites containing RNA. The 
endoribonuclease activity is due to its capability to cleave abasic single stranded RNA 
contributing to the RNA decay. This activity of the protein has been observed in 
mRNA molecules, for instance in c-myc mRNA46, but also in microRNAs such as miR- 
21 and miR-10b44, giving suggestions about a duplex APE1 role in controlling post- 
translational regulation, not only directly affecting the mRNA half-life, but also 
through the control of microRNAs3,44. 
MicroRNAs are small non coding RNA molecules ̴ 23nt long, in charge to post- 
translational regulation of gene expression. These molecules in fact through a base 
pairing with the mRNA targets prevent their translation and cause their degradation. 
MicroRNAs undergo maturation processes. They are transcribed by RNA Polymerase 
II (Pol II) and are organized in a stem and loop RNA structure having unpaired 3’ and 
5’ ends. The RNAse III Drosha, together with the RNA binding protein DiGeorge critical 
region 8 (DGCR8) are delegate to cleave the unstructured tails of the pri-miRNA, 
originating the pre-miRNA hairpin precursor. The pre-miRNA is later exported from 
nucleus to cytoplasm through Exportin-5 protein (XPO-5), where another RNase III, 
called Dicer, processes the pre-miRNA in a mature 22nt RNA duplex miRNA. Just the 
complementary strand of the target mRNA is finally loaded into the RNA induced 
silencing complex (RISC), which has the function to guide base pairing between the new 
synthetized miRNA with its own mRNA target. Argonaute (AGO) proteins at the end 
of the process are the effectors for the translational repression and mRNA decay47,48. 
RNA molecules can be modified upon oxidative stress. The oxidation events are not 
random in the transcriptome but some RNAs are much more susceptible than others. 
20  
In Alzheimer’s disease for example, oxidation events upon certain mRNAs strongly 
contribute to the pathogenesis of the illness impairing protein synthesis49. 
Recent evidences suggest also that microRNAs can be modified by oxidative stress. 
The oxidation events can make microRNAs prone to recognize their own target. 
Worthy of note is the case of microRNA 184 (miR-184), that becomes able to recognize 
its targets Bcl-xL and Bcl-w inducing apoptosis50 after oxidative modifications events 
that occur in its own sequence. Moreover, sometimes oxidative modifications which 
occurs to miRNA molecules are responsible for modulating their activity promoting 
an exchange of targets47. 
Recently our laboratory found APE1 contribution in the regulation of miRNA 
processing. Nanostring analyses performed in knock down APE1 HeLa cell lines 
showed that the absence of the protein caused a substantial dysregulation of mature 
microRNAs, suggesting APE1 peculiar role in their regulation. 
Moreover, experiments performed upon HeLa cell lines subjected to genotoxic stress 
through hydrogen peroxide (H2O2) treatment, showed an up-regulation of many 
microRNAs, among them the miR-221 and miR-222. Because of miRNA 221 and 222 
are responsible for the post-translational regulation of the tumor-suppressor PTEN, 
which transcription is regulated by APE116, our laboratory decided to proper 
characterize this regulation trying to discover the hypothetic APE1 role in the 
regulation of modified oxidised miRNAs. APE1 is overexpressed in many tumors and 
the analysis of its interactome suggested its important contribution in the regulation 
of gene expression through the miRNA processing. The obtained results showed that 
APE1 is responsible for regulating the onco-miR 221 and 222 who interact with. It 
seems in fact that under genotoxic stress APE1 intensifies its interaction with the 
RNAse III Drosha, which is deputy for the processing of pri-miRNA (Figure 6). The 
endonuclease activity of APE1 protein seems indispensable for the processing of these 
two pri-miRNAs, because treating the cells with the inhibitor of APE1 endonuclease 
activity compound 3 (#3) an accumulation of pri-miRNA 221 and 222 was   observed, 
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demonstrating the impairment of pri-miR processing when this activity of the protein 
is compromised. All of these data suggested that APE1 has a role in regulating PTEN 
expression not only directly acting to the transcription but also through post- 
transcriptional regulation, in particular controlling miRNA 221 and 222 processing 
and/or stability during genotoxic stress3. This mechanism could be probably extended 








Figure 6: Cartoon illustrating APE1 putative role in controlling miRNA processing. APE1 could take part together 
with Drosha in processing of newly transcribed oxidised pri-miRNAs26. 
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The APE1 protein partner hnRNPA2B1 is involved in miRNAs 
 
assembly in EVs 
 
APE1 is able to interact with different ribonucleoproteins, as already mentioned 
before. The ribonucleoproteins belong to a family of more than 20 polypeptides, which 
range size goes from 34 to 120kDa51. Their heterogeneous nature makes them able to 
absolve different functions. They interact with DNA and mostly with RNA, through 
their RNA recognition motifs, taking part to a series of nuclear processes such as 
telomere maintenance, transcription, DNA replication and repair, pre-mRNA splicing 
and nucleus-cytosol mRNA export51. 
According to interactome analysis, one APE1 protein partner is the ribonucleoprotein 
SNRPD, also called hnRNPA2B13. hnRNPA2B1 is composed by two different isoforms 
hnRNP A2, of 341 amino-acids, and B1 of 353 amino-acids, both transcribed by 
HNRNPA2B1 gene and characterized by having two tandem RNA recognition motifs 
followed by a Glycine reach region consisting of an arginine/glycine-rich (RGG) box and 
a M9 domain. The last one is a non-canonical NLS, indispensable for the nuclear 
localization of both subunits. hnRNPA2B1 protein is structured in a tetramer 
consisting of three A2 and one B1 subunits and is involved in many activities in 
particular in alternative splicing (AS) regulation51–54, RNA degradation, microRNAs 
sorting55,56. hnRNPA2B1 deregulation is a feature of many diseases such as cancer57, 
amyotrophic lateral sclerosis (ALS)53 and other neurodegenerative disorders such us 
multisystem proteinopathy (MSP). MSP consists in muscles, brain and moto-neuron 
degenerations, due to mutations occurrence in RGG box of the protein which cause the 
formation of fibrils structures between the mutated subunits (self-seed fibrils) and also 
between the mutated and the wild type ones (cross-seed fibrils). These fibrils are later 
accumulated in cellular stress granules and are probably responsible for neuro- 
degenerative diseases initiations58. hnRNPA2B1 is overexpressed in many tumor like 
breast cancer, glioblastoma and lung cancer, where is considered a biomarker for early 
stage  of  tumor  detection,  because  is  responsible  to  induce  Sp1  protein synthesis 
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through its ability to interact with Sp1 5’UTR mRNA and to promote the CAP 
independent translation of the transcript57,59–61. hnRNPA2B1 is involved in exons 
inclusion of many AS mRNAs in the whole transcriptome53,54. An alteration of AS 
provokes many cellular disorders such as cancer54 and ALS. In ALS for instance, a 
depletion of hnRNPA2B1 causes the synthesis of a shorter D-amino acid oxidase (DAO), 
an enzyme involved in serine metabolism, which works less efficiently as a 
consequence of an altered splicing event and is responsible for ALS excitotoxicity53. 
HnRNPA2B1 is also able to recognizes UAGG motifs in 3’UTR of many central 
nervous system transcripts53 and through targeting of 3’UTR RNAs motifs, is able to 
promote RNAs decay55. Moreover, HnRNPA2B1 has an important role for miRNA 
processing62. The protein in fact, recognizes N6-methiladenosine (m6A), an RNA specific 
modification, and directly interacting with DGCR8, induces the processing of the pri- 




Figure 7: Representation of hnRNPA2B1 miRNA processing regulation. hnRNPA2B1 recognizes m6A upon new 




HnRNPA2B1 is not only important for promoting a regulated miRNA processing but 
is also involved in promoting miRNAs sorting into exosomes (Figure 8). The miRNAs 
selected carry a specific motifs called EXO motifs, a short GGAG sequence, which is 
recognised by a sumoylated hnRNPA2B1, which is in charge of loading the   selected 




Figure 8: Representation of miRNA sorting process exerted by hnRNPA2B1. Sumoylated hnRNPA2B1 is able to 
recognize EXO motifs of selected miRNAs and participates in their loading into exosomes56. 
HnRNPA2B1 has also important role in the regulation of gene expression of clustered 
genes flanked by DSBs hot spots. The DSBs hot-spots are extended regions 50-250kb 
long, where hnRNPA2B1 and Poly ADP Ribose Polymerase 1 (PARP1) interact and 
participate for their transcriptional regulation63. The DSBs hot-spots seem to be a 
peculiar chromatin organization for rDNA, where the transcription is controlled by 
H₃K₄me₃ epigenetic marker, which occurs in correspondence of the CTCF binding 
sites. Also in correspondence of rDNA DSBs hot-spots hnRNPA2B1 interaction occurs, 
suggesting its contribution in rDNA expression through epigenetic modifications64. 
Among its numerous functions hnRNPA2B1 offers also a contribution in telomere 
maintenance, because it favours telomere elongation promoting telomere G- 
quadruplex unfolding and allows DNA template and RNA telomerase components 
interactions51. 
Because of the multiple roles of this protein, many of them in common with APE1 
functions, in future it will be interesting to unveil if these two proteins participate 
together in some cellular processes. 
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APE1 role in RNA metabolism and rRNA quality control 
 
APE1 takes part also in rRNA quality control. Studies performed on inducible APE1 
kd HeLa cell line, demonstrated that under genotoxic stress a greater accumulation of 
oxidised RNA species is observed. Moreover, in basal conditions, APE1 down- 
regulated cells showed an impairment of cell growth due to an inefficacy of 
translational machinery and a reduction of the total cellular protein amount65. These 
relevant evidences suggest that APE1 exerts the role of RNA cleansing factor for 
genotoxic stress and that has a role also in controlling the quality of transcribed RNAs 
before their translation. APE1 localizes in nucleoli interacting with NPM1. Seems that 
the interaction APE1-NPM1 inhibits the ribonuclease activity of the protein, and 
actually nothing is known about the hypothetic role of this protein complex during 
normal conditions. When oxidative stress occurs, the protein is released from nucleoli 
to the nucleoplasm where it can exert the DNA damage response15,65. For all these 





APE1 non-canonical role in maintaining genome stability through   the 
 
recognition of abasic or deoxy riboG embedded in DNA 
 
Ribonucleotides triphosphate (rNTPs) cellular amount is much higher compared to 
deoxyribonucleotide triphosphate (dNTPs) one ( ̴ 40-350-fold higher in cycling cells) 
because cells need a greater quantity for transcription67,68. During normal condition 
there is a default frequency of ribonucleotides monosphate rNMPs incorporation into 
DNA that was estimated around ̴ 100milions of residues per cell cycle29. These events 
of incorporation are much more frequent under genotoxic stress because the 
production of reactive oxygen species promotes the oxidation of deoxyribonucleotide 
triphosphate (dNTPs) in rNTPs69. The incorporation of rNMPs in genomic DNA causes 
a topological distortion of the sequence, giving rise to genome stability issues67,70. The 
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enzyme RNase HII is involved in the recognition and removal of rNMPs incorporated 
in DNA through ribonucleotides excision repair (RER) pathway71. Studies demonstrated 
that RNAse HII is not able to remove abasic rNMPs embedded in DNA. Our group 
recently found that APE1 is the only enzyme able to do it, having also a weak activity 
upon oxidised rNMPs embedded in DNA, opening a new scenario about APE1 




APE1: a prognostic marker in different tumors 
 
Due to its pleiotropic activity in controlling genome stability, regulating gene 
expression and controlling RNA quality, APE1 actively intervenes in several cellular 
mechanisms, for this reason its dis-regulation is associated to different pathologies 
such as neurodegenerative and cardiovascular disorders and above all to cancer1,72. 
Numerous are the evidences in literature asserting APE1 overexpression as a 
prognostic factor in many tumor such as prostate cancer, hepatocellular carcinoma, 
lung carcinoma, oral squamous carcinoma, prostate cancer and ovarian 
adenocarcinoma73–80. APE1 overexpression in fact is associated with deregulated 
cancer cell proliferation and with the activation of chemoresistance mechanisms, for 
all of these reasons it is considered as a good target for anticancer therapy1. APE1 
overexpression is a frequent event, which occurs in many neoplastic diseases, probably 
because a dis-regulation of APE1 gene expression occurs during cell transformation1. 
APE1 is a ubiquitous protein, which can show different subcellular distribution 
according to cell types. It is mainly located in nuclei81, particularly into nucleoli 
together with its interactor NPM1, where probably can perform the rRNA quality 
control. During oxidative stress, as explained before, it comes out from nucleoli and it 
is distributed into nucleoplasm, where it can exert the DNA repair activity65. But there 
are also evidences about APE1 cytoplasm localization and this distribution has been 
found in cells having high metabolic and proliferative rate. Even if there is no still 
explanation about APE1 role in cytosol, it is supposed that probably could contribute 
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in DNA repair into the mitochondrial compartment82, and also could be responsible 
for ROS reduction in endoplasmic reticulum through Rac Family Small GTPase1 (Rac1) 
inhibition31,83. Noteworthy, in many kind of cancer like breast, ovarian, lung and 
hepatocellular carcinoma, its overexpression and its cytosol localization are markers 
of poor prognosis and shorter overall survival84. In hepatocellular carcinoma for 
instance, these features could be associated to an adaptive response to chronic 
oxidative stress, that could support hepato-carcinogenesis and also tumor 
progression75,84. Further studies need to be performed to comprehend APE1 role in 









As already mentioned, APE1 subcellular localization is a dynamic finely regulated 
event1,65. An overexpression and a dis-localization of the enzyme is registered in many 
tumor as explained before, like breast cancer and hepatocellular carcinoma and it is 
also considered a prognostic factor. For Acute myeloid leukemia (AML) instead, a kind 
of blood tumor in which APE1 is expressed at normal extents, what is interesting is a 
frequent genetic mutation of NPM1 gene, that causes both APE1 and NPM1 
dislocation. This mutation was found in OCI-AML3 cells, which show abnormal APE1 
cellular distribution, due to a frameshift mutation in C-term (CTD) of NPM1. This 
common dominant genetic alteration causes conformational changes in the third helix 
of NPM1-CTD, that gives rise to a greater aggregation propensity and also confers a 
modest toxicity of the protein85. Due to this mutation, NPM1 is dislocated into cytosol 
(NPM1c+). Because NPM1 is indispensable to held APE1 into nucleus, as a 
consequence of this mutation also APE1 is dislocated into cytosol. In this kind of tumor 
the impairment of APE1 correct localization, causes deficit in DNA repair, and   OCI- 
28  
AML3 for this reason are more sensitive to chemotherapy treatment, compared OCI- 





APE1 in hepatocellular carcinoma (HCC) 
 
Hepatocellular carcinoma is the second cause of cancer lethality over the world. The 
incidence of this disease is constantly growing and 40.710 it has been the estimation of 
new cases in 201786. Moreover, many studies for comprehending the biology and the 
prevention for this kind of tumor are still needed. HCC onset can be determined by an 
inflammatory status triggered by many possible causes, for instance viral infections 
such as chronic hepatitis B (HBV) and C (HCV), chronic alcohol consumption, cirrhosis, 
non-alcoholic steatohepatitis (NASH), some genomic alterations and neoplastic 
dysplasia87,88. Chronic inflammation causes cirrhotic tissue formation, which trigger to 
dysplasia focus formation that can acquire malignancy features, and becoming cancer. 
Different grade of this disease have been identified. From a low-grade dysplastic nodules 
(LGDN), the transformation can proceed in an intermediated status call high grade 
dysplastic nodule (HGDN) which culminates in the advanced stage defined HCC. Due 
to the severity of the disease and to its high incidence, the individuation of HCC 
biomarkers for its prognosis, are needed. For this purpose, transcriptomic studies on 
different tumor stage specimens87, and also on circulating miRNAs and protein 
biomarkers have been performed89–91. In HCC APE1 is upregulated in terms of protein 
and transcript levels. APE1 amount is higher in low differentiated tumors compared 
to the high differentiated ones and it seems to have a protective role against oxidative 
stress, safeguarding cells for triggering apoptosis process through BAX inhibition75. 
Besides APE1 upregulation, cytosolic localization is also considered as a prognostic 
marker for HCC. This is a peculiar feature of cancer cells since normal cells retain APE1 
in nucleus compartment. Moreover,  higher  level of  cytosolic APE1  were found    in 
poorly differentiated tumors, compared to the well differentiated ones, and   patients 
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having high cytosolic APE1 levels showed lower overall survival. For all of these 
reasons APE1 can be considered as a prognostic biomarker for HCC84. Information 
about the possible function of cytosolic APE1 in this kind of cancer are still missing 
and our laboratory is making efforts for better characterize and comprehend this 






APE1, as already explained, is a negative prognostic factor in many tumor, due to its 
capability to promote cell proliferation and also chemoresistance mechanisms for 
instance through the induction of the drug efflux transporter protein MDR1 
expression92. The first evidences about APE1 presence in serum samples came out in 
2011, when autoantibodies for the protein were detected in sera of Lupus 
erythematosus patients93. Because of its predictive role in cancer, and of the necessity 
to find new tumor prognostic biomarkers, the Dong Wang group together with his 
collaborators, started to look APE1 in sera samples and surprisingly they found higher 
APE1 levels in sera of not small cell lung cancer NSCLC patients compared to controls94. 
They also noticed that APE1 could be defined as a predictive biomarker for the 
patient’s response to platinum-based chemotherapy95, because its higher levels in 
tissue and sera are responsible for a decreased sensitivity to treatments. The obtained 
evidences studying NSCLC regarding APE1 as a serological biomarker for the disease 
are also confirmed in other tumor types for instance in bladder cancer96. It would be 
now useful to unveil the extracellular APE1 function. Regarding this point recent 
studies suggested that APE1 could participate in inflammatory response because its 
secretion is induced in monocyte after inflammatory stimuli, and its role could be 
connected to the inflammatory response induction through NFκB activation, which is 
responsible for IL-6 gene transcription97,98. Would be not the first time in which a DNA 
repair protein can act as a senescence-associated secretory phenotype (SASP) factor. SASP 
are immune-modulatory factors such as IL-6 and IL-8, but also growth factors, survival 
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molecules that can act as autocrine proteins strengthening the senescence phenotype 
and also as paracrine factors stimulating epithelial to mesenchymal transition (EMT) and 
tumor progression99. 
Another evidence suggested also that secreted hyper-acetylated APE1 can induce the 
initiation of apoptotic process via receptor for advanced glycation end product (RAGE) 
activation in triple negative breast cancer cells (TNBC)100. The authors in this case 
excluded the possibility of a downstream NFκB pathway activation via RAGE. Further 
investigation will be useful for comprehending extracellular APE1 role, which could 
be connected to tumor progression. 
 
 




In the last 6 years, literature offered some interesting indications regarding APE1 
extracellular release. Before then, a software called Secretome 2.0101, which offers a 
prediction of the secreted proteins plethora, individuated APE1 as an un-canonical 
secreted protein. 
APE1 is a protein which shuttling from cytoplasm to nuclei was observed in response 
to oxidative and nitrosative stress102. Its localization is regulated by the N-term of the 
protein, where acetylation events mediated by p300 histone acetyl transferase (HAT) can 
occur103. Many are the proteins which secretion is mediated by acetylation occurrence, 
on example is the high mobility group-1 protein (HMGB1)104. In 2013 the same release 
mechanism it has been proposed for APE1, whose extracellular release seems to be 
based on the occurrence of N-terminal K6 and K7 lysine residues acetylation105. In this 
work the authors demonstrated that an inhibition of histone deacetylases (HDAC) 
mediated by trichostatin A (TSA) promotes APE1 secretion. The same group offered 
the first indication about APE1 presence in plasma sample of lipopolysaccharide- 
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induced endotoxemic rats106, offering a first explanation about the extracellular APE1 
role and defining the protein as a serological biomarker for endotoxemia. 
The acetylation upon N-terminal domain is a modification having important relevance 
not only for APE1 secretion but also for cancer progression. It was recently 
demonstrated how acetylation events are correlated in sustaining cell proliferation in 
NSCLC103. Acetylation occurrence in the N-terminal domain of the protein in fact, not 
only protects the protein from cleavage, but it is also indispensable for promoting 
APE1 role in the regulation of gene expression for supporting cancer cell proliferation. 
In tumor tissues indeed, this post translational modification seems to arise with higher 
efficiency compared to normal tissues in which APE1 proteolysis greatly occurs107. 
These evidences suggest a mechanism by which APE1 is a promoter of cell 






Exosomes are nanovesicles, whose dimension range is approximately from 20 to 
100nm. They originate from the fusion of endosomal multivesicular bodies (MVBs) with 
the plasma membrane and the consequent release of new generated particles in to the 
extracellular compartment. Deeper information about exosomes characterization and 
function are still needed. There are already some indications about the potentiality of 
these microvesicles to act as a carrier of proteins and nucleic acids, that are later 




Exosomes biogenesis and characterisation 
 
MVBs are constituted of many intraluminal vesicles (ILVs), originated by MVB 
membrane invaginations. The ILVs formations can occurs through different 
mechanisms and information about the regulation of these different processes and the 
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possible differences between the cargo selection promoted is still missing110. The first 
mechanism proposed involves lipid rafts in MVBs membrane, which can promote the 
ILVs formations. The lipid rafts are constituted by ceramide, that is generated by the 
protein neutral sphingomyelinase 2 (nSMase2). nSMase2 hydrolyses sphingomyelin in 
ceramide, which confers negative MVBs membrane folding and the consequent ILVs 
formation and inclusion into MVB111. 
The ILVs formation could be also promoted by the Endosomal Sorting Complex Required 
for Transport (ESCRT), which manages a cargo selection. ESCRT complex is constituted 
by five complexes ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III and Vps4112 (Figure 9). 
ESCRT-0 recognizes ubiquitinated proteins, which are later recruited by ESCRT-I and 
ESCRT-II complexes, generating a dense zone of cargo proteins, in the meantime the 
invagination of MVB membrane occurs. ESCRT-III is required for the assembly of the 
ILVs content through the de-ubiquitination of the cargo, and thanks to its spiral shape 
it restricts the ILVs neck and it concludes the formation of the ILVs, where the proteins 
are seized. Once the ILVs is generated, the protein cargo is sorted inside the new 
vesicles and the ATPase Vps4 complex fulfils the disassembly of the ESCRT-III 
complex and the release of the ILV inside MVB occurs112. Once formed MVBs can be 
fused together with lysosomes or can be released such as exosomes outside the cell 
through the plasma membrane. Actually there are no indications about the regulation 
of the MVBs shunting and the possible differences of protein content between 
“degradative” MVBs and “secretory” MVBs 113–115. The secretory MVBs are transported 
in proximity of plasma membrane along microtubules by kinesin. Different RAB 
proteins, according to different cellular types (normal or tumor cells), are responsible 
for MVBs docking to the plasma membrane116–118. Subsequently, soluble N- 
ethylmaleimide-sensitive component attachment protein receptor (SNARE) proteins 






Figure 9: ESCRT-mediated ILV formation. Ubiquitinated cargo is recognised by ESCRT-0. ESCRT-I and ESCRT-II 
are recruited and dense protein cargo is formed followed by membrane invagination. Subsequently ESCRT-III de- 
ubiquitinates the protein cargo, which is now sequestered and it restricts the neck of the new formed vesicles. Vsp4- 




Recently has been observed that syndecan heparan sulfate proteoglycans are 
important for exosomes formation via ESCRT complex. Syndecan interacts with the 
adaptor protein syntenin, which makes a bridge between proteoglycan components 
and ESCRT complex, interacting with Alix protein, which is a protein associated with 
ESCRT-III complex121. There is a specific guide for EVs characterization (Figure 10). 
Exosomes in fact, possess proteins which participate together with ESCRT complex for 
the assembly of the vesicles such as the aforementioned syntenin, Alix, TSG101, and 
they also possess the tetraspanins such as CD63, CD9, CD81, scaffold membrane 
proteins, important for the recruitment of cargo proteins. To fully define the 
extracellular vesicles as exosomes, is necessary to detect at least three indispensable 










Exosomes can be directly received by the neighbouring cells or travel into bio-fluids 
such serum, saliva, blood, breast milk125 and act very distantly110, distributing their 
molecular content. Exosomes contain lipids such as sphingomyelin, cholesterol, 
phosphatidylserine125, proteins, small RNAs, and also mitochondrial DNA (mtDNA) 
and fragmented genomic DNA (gDNA)110,126. 
The majority of the protein content identified in exosomes until now seems to be 
necessary for the formation of the vesicles, but there are some evidences about the 
presence of oncoproteins in exosomes derived from tumor cells, or molecules that can 
modulate immune response of receiving cells, involved in tumor propagation, such as 
the receptor for tyrosine kinase MET and Hsp72127–129. Further investigations about 
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exosomes protein contents will be helpful to understand exosome function in cellular 
communication. 
As already mentioned, exosomes contain many RNA molecules such as mRNAs, long 
non coding RNAs (lncRNAs) and miRNAs. mRNAs loading into exosomes could 
depend on a specific sequence, “zipcode”-like, (CUGCC), which is present in the 
3’UTR of exosomal mRNAs130. Noteworthy, among RNA molecules present in 
exosomes, microRNAs are the most abundant110. Some ribonucleoproteins have an 
important role in the sorting of specific miRNAs into exosomes131, one example is the 
already described APE1 protein partner hnRNPA2B1, which is deputy for recognizing 
and loading miRNAs, having a specific EXO motif (GGAG) sequence56. Also gDNA, 
no more longer than 10kb, has been found in exosome particles, even if it is impossible 
to exclude in this case contamination with apoptotic bodies and EVs membrane 
fragments, due to the ultra-centrifugation methods used for the exosomes extraction126. 
Usually, gDNA can be released in the cytosol after DNA damage occurrence, and 
induces the activation of DNA sensor proteins which promote the beginning of 
senescence or apoptotic pathways132. The release of gDNA through exosomes, may 
prevent the activation of cytosol DNA sensor factor and may protect damaged cells 
from senescence mechanisms activation promoting cellular homeostasis. This 
mechanism would explain why cancer cells are much more prone to exosomes 
release133. 
Exosomes and cancer 
 
It seems that under un-physiological conditions, especially under stress conditions 
such as hypoxia and cancer, the exosomes release is increased but, the specific 
mechanism of the regulation of this process is still unknown108,134,135. As the healthy 
cells secreted less exosomes compared to the tumor cells, studying exosome functions 
at basal condition is very difficult, easier instead it is acquire information about 
exosomes contribution in tumor progression and metastasis125, due to a greater 
concentration of exosomes released by tumor cells, such as ovarian, pancreatic, and 
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breast cancer 125,136,137. Through the analysis of circulating exosome content some 
markers specific for certain kind of tumors can be used for diagnosis, reinforcing the 
relevant role of these EVs. 
There are many indications about the powerful action of exosomes to induce certain 
behaviours in receiving cells, especially through oncogenic miRNAs delivery110 and 
many are the microRNAs that have been individuated with a great potential in the 
tumor features propagation, because they are able to affect the whole transcriptome of 
the receiving cells 125. Some miRNAs may also be considered as good target for the 
diagnosis of a specific tumor and are also predictive biomarkers, because they are 
indicative of the stage of the disease. One example could be miR-21, which is highly 
expressed in serum of patient with oesophageal squamous carcinoma, and it is 
indicative of an advanced stage of the tumor138. Another example is miR-141, which 
expression in serum of patients with prostate cancer is indicative of metastatic process 
establishment and for this reason it is considered a poor prognostic factor139. Recent 
evidences suggest also that miRNAs derived from metastatic cells are able to induce a 
malignant transformation in receiving cells, demonstrating the important role of 
exosomal miRNAs in tumor propagation140. 
Exosomes and cancer therapy 
 
Exosomes contribute to tumor spread, proliferation and metastasis. They are able to 
activate chemoresistance and radio-therapy resistance in the recipient cells141, and 
affect chemotherapy treatment efficacy, because they are responsible for exocytosis of 
chemotherapeutic drugs such as cisplatin and doxorubicin from tumor cells142,143. 
These evidences suggest that exosomes could be considered as a good target for cancer 
treatment. Affecting exosome production and release in fact could be possible abolish 
oncogenic miRNAs transferring to hamper metastatic propagation144. Future and 
deeper investigations about exosomes composition, cargo selection, and functions 
need to be done to comprehend this new emergent cell-cell conditioning system and 
its important relevance in cancer progression. 
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Aims of the study 
 
Nowadays, new evidences are emerging about active secretion of APE1 by cancer cells 
and its involvement as a biomarker for different kind of tumors. It seems that 
extracellular APE1 is involved in regulation of apoptotic or inflammatory processes, 
even if no clear evidences about its biological impact in tumor biology has been 
elucidated, yet. Moreover, indication about extracellular APE1 and its contribution in 
chemoresistance have been recently provided. Our hypothesis is that APE1 might 
operate as a damage associated molecular pattern (DAMP) factor in tumor 
microenvironment, triggering the inflammatory response. Exosomes are released EVs 
that deliver proteins, RNA and DNA molecules. Their production and secretion is 
higher in tumor cells compared to the healthy ones, for this reason EVs become 
vehicles of tumor effector factors and significantly participate in the progression of the 
disease. 
In this work we wanted to explore the extracellular APE1 role in the progression of 
HCC, by measuring the sAPE1 amount in sera of affected patients in comparison with 
healthy controls. We wanted also to study the sAPE1 secretion process and its 
biological contribution to tumor progression, focusing our attention on the activity of 
APE1 in triggering inflammation responses. 
We wanted also to unveil the APE1 contribution in HCC tumor progression and 
chemoresistance, by investigating its role in the regulation of miRNA 
processing/decay. For this purpose, we carried out Nanostring analysis in JHH-6 APE1 
silenced cells, to detect miRNAs, whose expression is affected by APE1 in HCC. 
To understand the APE1 role in miRNA processing regulation, we wanted to 
characterize its interaction with the ribonucleoprotein hnRNPA2B1, which 
participates in RNA splicing, miRNA processing and miRNA EVs sorting, performing 
CoIP and PLA analyses. Further investigations need to be performed to analyse the 
hypothetic  role  of  this  protein  complex  in  the  circulating  miRNAs  world.   Data 
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obtained clearly pointed to the relevance of studying the extracellular roles of this 





























Serum APE1 (sAPE1) a prognostic biomarker in HCC 
 
Serum APE1 is considered as a negative prognostic biomarker in NSCLC and bladder 
cancer94,96. To understand if also in HCC sAPE1 could be considered as a prognostic 
biomarker, its detection in serum samples of 99 HCC, 50 cirrhotic and 100 healthy 
patients, was carried out, through the Human APEX1 ELISA kit, as already reported 
in95. The case-control study was performed in patients referring to the Liver Center of 
the University Hospital of Trieste and the aetiology of HCC samples analysed, derived 
from alcohol or metabolic syndrome. Serum APE1 levels were obtained by using a 
standard linear regression curve fitting by NCSS 11 Statistical Software (2016). For the 
specificity of the test, 62.5 and 31.25 pg/ml of rAPE1 protein were spiked into blood 
donor’s sera. It was used a curve-fitting model, built on OD vs sAPE1 concentration 
(pg/ml) for the evaluation of the two spiked samples (data not shown). 
As reported in Figure 11, the levels of APE1 protein, obtained by ELISA and expressed 
as median (95% CI), are significantly higher in serum of HCC patients (median= 75.8 
pg/ml), compared to the healthy donors (median= 10.8 pg/ml). Intermediate 
concentration values have been found for cirrhotic patients (median= 29.8 pg/ml), 
indicating that with the evolution of the disease a progressive increase of sAPE1 is 
observed. These experiments were executed in collaboration with Fondazione Fegato 








In order to evaluate if the observed trend was coherent to APE1 tissue expression in 
terms of mRNA and protein levels, qPCR and western blot analysis were performed. 
APE1 mRNA expression levels resulted increased in HCC tissue samples compared to 
the healthy control (CTRL), moreover intermediated mRNA levels were registered in 
surrounding liver cirrhosis (SLC) and peri-HCC tissues. Data were normalized for 18S 
RNA and ACTB expression levels (Figure 12). Western blot for APE1 protein levels 
were carried out analysing the protein content of a pool of HCC tissue sample lysates, 
compared with that one of SLC. We observed higher APE1 protein levels in HCC tissue 
compared to SLC. Moreover, two bands for APE1 protein, the first one of 37 kDa 
correspondent to the full length, and the second one shorter correspondent to the 
truncated APE1NΔ33 form, were detected (Figure 13, left panel). The densitometry 
analysis of APE1 immune-reactive bands normalized for actin in both HCC and SLC 
was reported in the histogram (Figure 13, right panel). These data demonstrated a 
correspondence between serum and tissue APE1 levels. 
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These observations were also confirmed through immunohistochemistry analysis in 
HCC, SLC and CTRL. Interestingly HCC tissue was characterized by having higher 
level of APE1, but also an altered cellular distribution of the protein (Figure 14). APE1 
in fact, was localized non only in the nuclei of HCC cells, but also in the cytoplasm, 
while in SLC only an overexpression of the protein was observed, without showing 
any alteration of its distribution. Control cells instead, displayed normal protein 
expression levels and localization. These data indicated that in HCC tumor biology 
APE1 overexpression can be followed by its displacement. Unfortunately, we could 






Figure 12: APE1 mRNA expression levels in HCC, peri-HCC, surrounding liver cirrhosis (SLC) and CTR tissues. 




Figure 13: Western blot analysis carried out in lysates of SLC and HCC tissue samples. Actin was used as a loading 
control. Histogram shows the densitometric analysis of APE1 protein content normalised for actin. Bar graph 







Figure 14: Immunohistochemistry carried out on SLC, HCC and CTR tissues. Red arrows indicate nuclear APE1 




In order to unveil serum APE1 biological role, we tested if exogenously added 
recombinant purified APE1 protein (rAPE), could trigger an inflammatory response 
activating interleukins expression, as already demonstrated for human monocytes 
cells97.  For this  purpose,  JHH-6 hepatocellular  carcinoma  cells  were  treated  for 24 
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hours with “non-tagged” rAPE1WT and also with rAPE1K4pleA, an APE1 mutant form 
where lysine residues (K27, K31, K33 and K35) of the N-terminal domain are replaced 
by arginine, mimicking a constitutive acetylation status of the protein, that, as it 
already demonstrated, has a relevance in tumor proliferation107. We proved that 
exogenously added rAPE1 was able to promote IL-6 and IL-8 mRNA expression and 
that the mutated form rAPE1K4pleA induced a greater extent of activation compared to 
the rAPE1WT (Figure 15A). TNF-α treatment performed for 3 hours at the concentration 
of 2000U/ml was performed as a positive control for IL-6 and IL-8 activation (Figure 
15B). According to these data, serum APE1 could be defined as a prognostic biomarker 
in HCC and exogenous APE1 could participate to the HCC progression contributing 










Figure 15: A) APE1, IL-6 and IL-8 expression levels in JHH-6 cell line treated for 24 hours with rAPE1WT and 
rAPE1K4pleA proteins at the concentration of 1/2μg/ml. Serum starved cells for 24 hours were used as a control. B) 
APE1, IL-6 and IL-8 mRNA expression levels of JHH-6 cells treated for 3 hours with TNF-α at the concentration of 
2000U/ml. Untreated cells were used as a control (CTR). Data represent means ±SD of three independent 




Study of extracellular APE1 role in tumor biology 
 
Once it was demonstrated that sAPE1 could be considered as a biomarker in HCC, an 




Extracellular vesicles characterization from JHH-6 cell line 
 
In order to set up the conditions to analyze extracellular vesicles (EVs), we isolated them, 
by Total exosome isolation kit, from the media of JHH-6 hepatocellular carcinoma cell 
line and characterized the quality of the preparations (see Material and Methods). 
Particles were analysed by dynamic light scattering using the NanoSight instrument 
for nanoparticle tracking analysis (NTA). The distribution of the obtained vesicles and 
the measured range of size, that showed an average of 237nm with a mode of 149.5 
nm, indicating the expected dimensions of small vesicles, were shown in (Figure 16A). 
Regarding the EVs shape and size characterization, vesicles obtained from serum 
depleted medium of JHH-6 cells were validated by TEM (Figure 16B). The image 
shows vesicles having a round shape with a mean diameter below 100 nm, 
corroborating the NTA analysis. Therefore, this characterization confirmed that the 













Figure 16: JHH-6 exosome vesicles characterization. A) NTA analysis of JHH-6 exosomes. The picture shows the 
quantification spectre of exosomes extracted from JHH-6. The prominent vesicles size range registered is from 50 
to 150nm, correspondent to exosome range dimensions. B) TEM analysis of exosomes extracted from JHH-6 
medium after 48 hours. The picture shows spheroid exosome particles. The diameter of exosome particles 





APE1 protein is present in EVs of different cell lines 
 
Some recent preliminary evidences showed the presence of APE1 in the extracellular 
environment. However, limited information is available regarding the mechanism of 
this secretion as well as if it may be associated with EVs release97. For these reasons, 
we were interested in understanding if APE1 could be secreted in EVs. To test this 
hypothesis, JHH-6 cells were kept in culture for 48h under serum starvation conditions 
and, later, EVs were extracted from the serum-free medium. The EVs extract (EXE) 
prepared, was analysed for the presence of APE1 protein. As positive control for 
proper EVs isolation, enriched in exosomes, Syntenin and Alix proteins were analysed. 
In addition, Golgi apparatus protein (GM130) was assayed as an EXE negative marker145. 
Moreover, JHH-6 whole cell extract (WCE) was used as a reference control for protein 
expression. As shown in (Figure 17), JHH-6 EXE were positive for the presence of APE1 
full length, indicated as (APE1 p37), but were also positive for the truncated form of 




Figure 17: APE1 detection and quantification analysis in exosome extract. Western blot analysis performed in 
whole cell extracts (WCE) and exosome extract (EXE) of JHH-6 cells. APE1 detection was observed in JHH-6 EXE. 
WCE were used as a reference control for APE1 expression (panel below). Cellular and exosome markers were also 
tested for EXE characterization. Golgi apparatus protein GM130 was assayed as a EXE negative marker (panel above), 
Alix and Syntenin were assayed as a EXE positive markers (middle panels). 
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Notably, by using an antibody specific for the N-terminal part pf APE1 we were able 
to demonstrate that this truncated form corresponded to the N∆33 form (Figure 18), 
which lost the first 33 amino acid residues as a consequence of proteolysis, already 







Figure 18: Western blot analysis of APE1 p37 and p33 forms in WCE and EXE of AML2 and AML3 cell lines. Alix 
detection was performed as a loading control (panel above). Two different APE1 antibodies were used. In the middle 
panel antibody against APE1 N-terminal region detects only full length APE1, the detection of both isoforms is 




We also tested the presence of other base-excision repair (BER) enzymes in exosomal 
fractions and we demonstrated the presence of XRCC1 protein. Interestingly, the 
absence of Polδ, OGG1, and of the highly abundant intra-nuclear Polβ protein, was 
indicative of the fact that APE1 release is a specific process and is not associated with 





Figure 19: BER enzymes analysis in JHH-6 EXE. JHH-6 EXE were assessed by western blot for the detection of 
XRCC1, Polβ, Polδ and OGG1 BER enzymes. JHH-6 nuclear cell extracts (NCE) were also examined as reference 




In order to prove that secretion of the p33 and p37 forms in EVs is a general feature of 
mammalian cells, we also performed EXE analysis in lymphocytes mouse isogenic cell 
lines, i.e. the CH12F3Δ++ and CH12F3ΔΔΔ cell lines, expressing and or not APE1, 
respectively146. The latter is an APE1-KO cell line, while the CH12F3Δ++ represented the 
isogenic control expressing the APE1 protein. Using these two cell lines, we 
demonstrated that APE1 was indeed only present in the EVs from the CH12F3Δ++ 
expressing cells (Figure 20). Moreover, these data suggested that the release of APE1 
in EVs was not exclusively found from JHH6 cells. In order to demonstrate whether 
the presence of APE1 in exosomal vesicles was a general phenomenon of cancer cells 
from different origin, we used the A549, lung tumor cell line and the HCT116p53+/+ and 
HCT116p53-/- colon carcinoma isogenic cell lines. We observed that APE1 presence in 
EVs of different tumor cell lines is a general phenomenon, being common to all tested 
cell lines. Interestingly, the amount of p33 form was variable between the different 
tested cell lines. These data clearly demonstrated that both p37 and p33 forms of APE1 
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protein may be released in EVs of different cancer cell lines and that, among the tested 







Figure 20: APE1 secretion through ESCRT is a general process that occurs in different cell lines: EXE from JHH-6, 
A549, HCT116 p53+/+, HCT116 p53-/- were analysed by western blot for the presence of APE1 protein. Alix detection 




Based on the observation of the consistent presence of the p33 APE1 form in EXE of 
cancer cells and on our previous characterization of this protein form in cancer cells 
from hematopoietic origin, i.e. Acute Myeloid Leukemia15, we tested the distribution 
of APE1 in EXE of these cancer cells. For these experiments, we used the OCI-AML3 
(expressing mutated NPM1c+ protein) and the OCI-AML2 control cells147. These two 
cell lines represent a suitable model for this analysis. In fact, OCI-AML2 cells show 
normal subcellular expression and nuclear distribution of APE1 protein and do not 
have any significant accumulation of APE1 p33 form. Interestingly, the OCI-AML3 cell 
line harbours a driver mutation of NPM1 protein, a known APE1 protein interacting 
partner148 called NPM1c+, which causes APE1 cytoplasmic localisation and consequent 
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BER impairment15. In OCI-AML3 cells in fact, APE1 protein is re-localized within the 
cytoplasm where it is subjected to proteolytic degradation of the first 33 amino acids 
at the N-terminal sequence15. For this reasons, OCI-AML3 possesses significant levels 
of APE1 p33 form, as shown in Western blot analysis of WCE, (Figure 21, left panel). 
When examining APE1 p37 and p33 proteins content in EXE obtained from OCI-AML2 
and OCI-AML3 cells, we surprisingly observed that both forms are indeed released by 
the two different cell lines, as shown in (Figure 21, right panel). In particular, in OCI- 
AML2 cells, the amount of total secreted APE1 (comprising both p37 and p33 APE1 
forms) was higher than that secreted by OCI-AML3 cells. Interestingly, the ratio 
between p37 and p33 APE1 forms was comparable between EXE of both cell lines 
(Figure 21, histogram below). These evidences suggest that while OCI-AML2 cells, 
differently from the OCI-AML3 cells, did not show any truncated protein in WCE, as 
previously observed15, the truncated form was present in the EXE extracts of both cell 
lines at comparable levels. These data would denote that an additional proteolytic 






Figure 21: APE1 isoforms analysis in WCE and EXE derived from OCI-AML2 and OCI-AML3 cell lines. β-Tubulin 
and Alix detections were performed as loading controls. APE1 p37 and APE1 p33 are indicated by arrows. The 
histogram below shows the percentage of exosomal APE1 p37 and p33 isoforms. Data were obtained through 




Unpublished data from our Laboratory clearly demonstrated that the truncation of 
APE1-N-terminal region giving rise to the p33 form of the protein is, at least in part, 
contributed by cytoplasmic proteasome complex (Lirussi et al., in preparation). In 
order to evaluate whether the proteasomal pathway can be also involved in the 
observed accumulation of the p33 form in EVs, we blocked proteosomal degradation 
by the specific MG-132 inhibitor. The treatment was performed at the concentration of 
0.25μM for 48hours149. EXE analysis (Figure 22A) clearly demonstrated a significant 
reduction of the only p33 form upon MG-132 treatment, as represented in the 
histogram (Figure 22A, right panel), demonstrating that the truncated form of APE1 
accumulated in the EVs might be contributed, at least in part, by a proteosomal 
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degradation-pathway. Moreover, WCE were analysed and not significant difference 
of the amount of the two isoforms was registered in MG132 treated cells compared to 
control, probably because the low concentration used for treatment was not enough to 
appreciate significant APE1 intracellular isoforms pool variations (Figure 22B, left 
panel), for this reason IκB-α accumulation was also tested as positive control for MG132 


















Figure 22: A) APE1 p37 and p33 detection in EXE of JHH-6 [MG132] treated cells (left panels). Alix detection was 
performed as a loading control. The histogram shows the percentage of exosomal APE1 p37 and p33 in JHH-6 CTR 
and MG132 treated samples (right panel). The percentages of APE1 p37 and p33, were obtained through 
densitometry analysis and have been normalised for Alix. B) APE1 p37 and p33 detection in WCE of JHH-6 
[MG132] treated cells, Alix detection was performed as a loading control (left panel). IκB-α detection in WCE as a 
positive control for MG132 treatment. β-Tubulin detection was carried out as a loading control (right panel). 
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Proteosomal components can be actively secreted in EVs150. We therefore tested 
whether EVs isolated from JHH-6 cells could contribute to APE1 N-terminal cleavage. 
For this purpose, JHH-6 EXE (0.1μg) proteolytic activity was tested in rGST APE1WT 
protein (0.2μg). The reaction was carried out for 15, 30 minutes, 1, 2, 4 hours at 37°C. 
rGST and rGST APE1WT were used as control to check eventual protein degradation. 
After reaction the proteins were denatured loaded in 12% acrylamide/bis-acrylamide 
gel and resolved in SDS page. JHH-6 EXE exerts cleavage activity upon rGST APE1WT 
protein in a time dependent manner (Figure 23) and seems that proteases are able to 
remove the GST tag to the rGST APE1WT because the obtained products showed the 






Figure 23: JHH-6 EXE proteolytic activity upon rGST APE1WT. EXE (0.1μg) proteolytic activity was tested in rGST 
APE1WT (0.2 μg). The reaction was performed at 37°C for 15, 30 minutes, 1, 2, 4 hours. rGST and rGST APE1WT were 
used as control for protein degradation. The reaction was loaded in 12% acrylamide/bis-acrylamide gel and 
resolved in SDS page. Western blot analysis was later performed for APE1 and GST protein detection. The 




APE1 can be efficiently detected in NBI-isolated vesicles 
 
In order to confirm the presence of APE1 in secreted EVs by quantitative approaches, 
we subjected the media of JHH-6 cells to nickel-based isolation (NBI) and detected the 
intra-vesicular  APE1  using  an  amplified  luminescence  proximity  homogeneous    assay 
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(alpha)151. These experiments were executed thanks to the kind collaboration of CIBIO 
Trento. We used purified GST APE1WT protein (Figure 24). We performed a 
quantification analysis by western blot, using known amount of recombinant APE1 
protein as a reference and also a known amount of JHH-6 whole cell extract (WCE) as 
control for APE1 detection (Figure 25A). We titrated the recombinant protein as a 
reference substrate in the alpha assay using Glutathione-Donor beads and Protein G- 
Acceptor beads recognizing the anti-APE1 antibody. In this setting, we sensitively and 
specifically detected APE1-GST in the low nanomolar range compared with GST alone 
as further control (Figure 25B). In (Figure 25B), 100 nM of APE-GST represents the 
hook point. Subsequently, we isolated vesicles from JHH-6 by NBI, which prevents 
aggregation of the EVs in solution, and applied the alpha assay using a range of 102 to 
105 vesicles as determined by qNANO with a NP250 nanopore (the applied stretch 
gave a size window of approximately 80-800 nm). We only detected specific signals 
using EVs exposed to 90°C for 5 min before using them in the assay (Figure 25C), 
indicating that the APE1 is enclosed within vesicles. According to the standard curve 
obtained using the purified APE1-GST, we calculated the remarkable amount of 1.27 




















Figure 25: A) APE1 detection in A549 and JHH-6 EVs obtained by NBI. β-Tubulin detection was performed as a 
loading control. APE1_p37 and APE1_p33 are evident in both cell lines. B) setting of the reference substrate for the 
alpha assay trough a titration curve of rGST APEWT by alpha technology. rGST APEWT detection resulted in low 
nanomolar range compared to rGST alone. C) Alpha assay executed for APE1 detection, performed on a range of 
102-105  EVs derived from JHH-6 cells. 
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EVs APE1 protein is enzymatically active 
 
We then tested whether APE1 was enzymatically active on different kind of DNA 
substrates29. For this purpose, we used increasing amount of EXE to check its capability 
to exert a specific endonuclease activity. First of all, we checked exosomal APE1 
activity on canonical abasic deoxyribonucleotides in dsDNA (ds_dF:dC) shown in (Figure 
26A). Representative denaturing polyacrylamide gel (Figure 26B) showed the EXE 
endonuclease activity upon the described oligonucleotide. Substrate (S) and the 
relative product (P) of reaction are indicated. With this experiment, we were able to 
demonstrate that exosomal APE1 was competent to process a canonical substrate in a 
dose-dependent manner. Then, in order to check whether the enzymatic activity of 
EXE was exclusively ascribed to APE1, an endonuclease assay was performed after 
treating EXE with different doses of compound #3152, a specific inhibitor of APE1 
endonuclease activity (Figure 26C). This experiment confirmed that in EXE the only 















Figure 26: A) Schematic representation of double strand (ds) DNA 25-mer substrate (ds_dF:dC), generated by 
annealing of IRDye fluorophore labelled single strand (ss) oligonucleotide (5’– 
GGATCCGGTAGTGTTAGGCCTGAAC-3’), in which the 13th position G, indicated in light purple, is modified in 
deoxy-tetrahydrofuran (dF) with a ss_dC complementary oligonucleotide (5’- 
GTTCAGGCCTAACACTACCGGATCC-3’). Moreover, the 5′ and 3′ ends of each DNA strand are indicated. The 
name of the modified dsDNA oligonucleotide is indicated below the sequence. B) JHH-6 EXE-containing APE1 
possesses endonuclease activity on the canonical abasic dsDNA substrate. Representative denaturing 
polyacrylamide gel of EXE incision on ds_dF:dC oligonucleotide. The volume of EXE used, expressed in μl, is 
shown on the top of the figure. The reaction was performed for 15 minutes. C) Representative denaturing 
polyacrylamide gel showing the incision on ds_dF:dC executed by EXE (0.5 μl), pre-treated for 15 minutes with 
different concentrations (μM) of APE1 inhibitor #3. The reaction was performed for 15 minutes and different 




Then, we tested whether APE1 was able to process abasic ribonucleotide embedded in 
dsDNA (ds_rF:dC), shown in (Figure 27A) in a dose dependent manner, similarly to 
what we recently found for nuclear APE129. Enzymatic assays clearly showed that 
exosomal APE1 was indeed able to process this substrate, showing an activity even 










Figure 27: A) Schematic representation of double strand (ds) DNA 25-mer substrate (ds_rF:dC), generated by 
annealing of IRDye fluorophore labelled single strand (ss) oligonucleotide (5’– 
GGATCCGGTAGTGTTAGGCCTGAAC-3’), in which the 13th position G, indicated in blue, is modified in ribo- 
tetrahydrofuran (rF) with a ss_dC complementary oligonucleotide (5’-GTTCAGGCCTAACACTACCGGATCC-3’). 
Moreover, the 5′ and 3′ ends of each DNA strand are indicated. The name of the modified dsDNA oligonucleotide 
is indicated below the sequence. B) JHH-6 EXE-containing APE1 possesses endonuclease activity on abasic 
ribonucleotides embedded in dsDNA. Representative denaturing polyacrylamide gel of EXE incision on ds_rF:dC 
oligonucleotide. The volume of EXE used, expressed in μl, is shown on the top of the figure. The reaction was 
performed for 15 minutes. ds_dF:dC oligonucleotide was used as positive control, (lower panel). Graph illustrating 
the comparison of EXE activity on ds_dF:dC and ds_rF:dC oligonucleotides. Data are expressed as mean + SD of 




Then, we tested the EXE activity on a non-canonical substrate, containing an oxidized 
ribonucleotide embedded in dsDNA (ds_r8oxoG:dC), shown in (Figure 28A), as we 
recently proved29. We observed that APE1 was able to process and generate a peculiar 
cutting pattern upon this dsDNA substrate. In fact, APE1 exerted not only a 5’ 
endonuclease activity on ds_r8oxoG:dC, that gave rise to a 12nt long product, but also 
a 3’ exonuclease activity, that gave rise to a 11nt shorter product, in agreement with 
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recent findings29. As positive controls of incision on this substrate, we used rAPE1, to 
have a simultaneous evaluation of the expected products, and also E. coli rRNase HII, 











Figure 28: A) Schematic representation of double strand (ds) DNA 25-mer substrate (ds_r8oxoG:dC), generated by 
annealing of IRDye fluorophore labelled single strand (ss) oligonucleotide (5’– 
GGATCCGGTAGTGTTAGGCCTGAAC-3’), in which the 13th position G, indicated in pink, is modified in oxidized 
ribo- guanosine (r8oxoG) with a ss_dC complementary oligonucleotide (5’- 
GTTCAGGCCTAACACTACCGGATCC-3’). Moreover, the 5′ and 3′ ends of each DNA strand are indicated. The 
name of the modified dsDNA oligonucleotide is indicated below the sequence. B) JHH-6 EXE-containing APE1 
possesses a weak endo- and exo- nuclease activity on oxidized ribo- G embedded in dsDNA. Representative 
denaturing polyacrylamide gel of EXE incision on ds_r8oxoG:dC oligonucleotide. The volume of EXE used, 
expressed in μl, is shown on the top of the figure. The EXE-containing APE1 activity was compared to the 
recombinant APE1 (rAPE1) activity on the same substrate at the indicated dose. The reaction was performed for 30 
minutes. 
Overall, these experiments proved that also in the EVs APE1 is able to fully perform 
its enzymatic activities on different canonical (abasic sites containing DNA) and non- 
canonical (r8oxoG containing DNA) substrates. 
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Given its intra-vesicular-secreted active form and its nucleic acid-binding activity, we 
exploited a quantitative approach to interrogate the abundance of RNA (detectable in 
the heterogeneous sub-micrometer-sized EVs) enclosed in vesicles released from 
CH12F3 cells expressing or not APE1 (CH12F3Δ++ and CH12F3ΔΔΔ, respectively) (Figure 
29). We subjected the media exposed for 24 hours to these cells to NBI for EV isolation, 
then, after characterization of the prep by TRPS, we extracted and analyzed the total 
RNA from the same amount of vesicles. Albeit the EVs recovered from the two cell 
lines showed an equivalent size-distribution and abundance (Figure 30A), the RNA 
electrophoresis clearly showed that the presence of APE1 is responsible for a more 
than 3-fold enrichment (~45%) of transcripts spanning 30 to 4000 nt in length, with 
major peaks around 150-200 nt typically profiling the small/fragmented EV-RNA 
(Figure 30B). Interestingly, the profile of the total RNA isolated from the two cell lines 
showed a similar trend, in which the absence of APE1 caused a 30% reduction in the 






Figure 29: Western blot analysis for APE1 detection was carried out in murine positive for APE1 expression 
















Figure 30: A) Analysis of CH12F3∆++ and CH12F3∆ΔΔ EVs distribution. The figure shows the concentration and the 
size-distribution spectre of EVs obtained from CH12F3∆++ and CH12F3∆ΔΔ media. B) Graphical representation of EVs 
RNA size distribution obtained from media exposed to CH12F3∆++ and CH12F3∆ΔΔ cells C) Graphical representation 
of CH12F3∆++ and CH12F3∆ΔΔ intracellular RNA size distribution. 
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Analogously, the EV-RNA profile obtained from A549 cell line transiently transfected 
for 72 hours with control (SCR) or APE1-targeting (siAPE) siRNAs (Figure 31A), 
showed a reduction of ~30% in the recovered RNA from EVs of APE1-silenced cells, 
while considering an average fluctuation of 6% in the SCR condition versus non- 










Figure 31: A) Western blot analysis for APE1 detection executed in A549 siAPE1 silenced for 72 hours and the 
respective SCR control. β- Tubulin detection was carried out as loading control. B) Graphical representation of EVs 
RNA size distribution obtained from media exposed to A549 not transfected cells (NT), A549 siSCR and A549 
siAPE1 transfected cells. 
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Interestingly, a HeLa cell clone selected for a stable knock-down of APE1 (HeLa Cl3) 
(Figure 32A), consistently showing a reduction of near 50% in the EV-RNA in 
comparison to those from SCR cells, secreted EVs with a partial recover of RNA in case 
of concomitant expression of APE1WT (15%). This partial rescue was not observed in 
case of transfection with mutated APE1K4pleA or APE1NΔ33 APE-encoding plasmids 
(Figure 32B). 













Figure 32: A) Western blot analysis for APE1 protein was carried out in HeLa inducible knock down cell lines. HeLa 
SCR indicates cell line which expresses endogenous APE1 protein levels. HeLa Cl3 indicates cell line in which only 
downregulation of endogenous APE1 was carried out. The respective reconstituted APE1WT, APE1K4pleA, APE1NΔ33 
clones are also indicated. Western blot for β-Tubulin was executed as loading control. B) Graphical representation 
of EVs RNA size distribution obtained from media exposed to HeLa SCR, CL3 and reconstituted WT, K4pleA and 
N∆33 clones. 
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These analyses indicate that APE1 has a remarkable impact on the global intracellular 
RNA processing/stability and intravesicular RNA sorting, further influencing the 
metabolism of recipient cells. 
 
 
Secretion of APE1 p33 form is stimulated by doxorubicin treatment   in 
 
JHH-6 cell line and by CDDP treatment in A549 cells 
 
To evaluate if APE1 release could be affected by induced genotoxic treatment, we 
evaluated APE1 secretion upon doxorubicin treatment. First, we determined the 
proper treatment conditions, represented by sub-lethal drug doses, in order to 
correlate the effect of the treatment on exosomal APE1 composition with the viability 
of JHH-6 cells. As shown in (Figure 33), a treatment with doxorubicin at the dose of 
0.25 μM was considered ideal because of low toxicity at 24hours of treatment and a 




Figure 33: Analysis of Cell viability upon JHH-6 cell line after Doxorubicin treatment. MTS assay was performed 
upon JHH-6 cells after 24, 48, 72 hours of treatments with the indicated concentrations of Doxorubicin. The viability 
of untreated cells at the previously indicated time points was evaluated as a control. Data are expressed as mean ± 
S.D. 
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Then, JHH-6 cells were treated for 24, 48, 72 hours with Doxorubicin at the 
concentration of 0.25 μM and exosomes isolation was performed as indicated before. 
In parallel, the cell pellets of control- and Doxorubicin-treated cells were processed in 
order to evaluate the expression of APE1 and the other protein markers in WCE. 
Western blot analyses of WCE clearly demonstrated that Doxorubicin treatment did 
not affect neither the expression of APE1 nor that of Alix proteins. When analysing the 
content of APE1 in EXE as a function of time, we clearly observed a higher 
accumulation of APE1 total protein under Doxorubicin treatment condition compared 
to the untreated control. Interestingly, when we compared the expression of APE1, as 
a function of Doxorubicin treatment, we clearly noticed that the accumulation of the 
p33 form was significantly increased in Doxo-treated cells with respect to controls 








Figure 34: A) Analysis of APE1 content in JHH-6 WCE and EXE after 24, 48, 72 hours of Doxorubicin treatments. 
JHH-6 cells were treated with 0.25μM of doxorubicin for 24, 48 and 72 hours. Cells and media were collected and 
processed for the production respectively of WCE and EXE. WCE and EXE were also obtained from JHH-6 
untreated cells at the three previously indicated time points. APE1 p37 and APE1 p33 isoforms were later analysed 
in WCE and EXE by western blot. Alix and β-Tubulin were detected as loading controls for both extracts. B) The 
accumulation of APE1 content in EVs, obtained from media of CTR and Doxorubicin treated cells and the 




In order to check if this trend was only related to a specific effect of doxorubicin upon 
exosomal APE1 or it was common to other genotoxic treatments, JHH-6 cells were 
treated with Cisplatin (CDDP). According to the cell viability analysis (Figure 35), we 
chose a CDDP concentration of 6.25 μM because of low toxicity at 24hours of treatment 
and a toxicity of 50% at 48 and 72 hours, similarly to previous doxorubicin treatment. 
The treatment with CDDP at the concentration of 6.25 μM was performed for 24,   48, 
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72 hours and EXE were isolated as indicated before. As shown in (Figure 36A), also in 
EXE obtained from CDDP-treated JHH-6 cells, an accumulation of APE1 protein 
compared to the JHH-6 EXE of the untreated control was clearly apparent. In addition, 
we observed that, especially at 24 and 48 hours of CDDP-treatment, the relative 
amount of APE1 p33 form quantified was higher compared to that of the p37 form, as 








Figure 35: Analysis of cell viability upon JHH-6 cell line after CDDP treatment. MTS assay was performed upon 
JHH-6 cells after 24, 48, 72 hours of treatments with the indicated concentrations of CDDP. The viability of untreated 
cells at the previously indicated time points was evaluated as a control. Data are expressed as mean ± S.D of three 









Figure 36: A) Analysis of APE1 content in JHH-6 WCE and EXE after 24, 48, 72 hours of CDDP treatments. JHH-6 
cells were treated with 6.25μM of CDDP for 24, 48 and 72 hours. Cells and media were collected and processed for 
the production respectively of WCE and EXE. WCE and EXE were also obtained from JHH-6 cells untreated cells 
at the three previously indicated time points. APE1 p37 and APE1 p33 isoforms were later analysed in WCE and 
EXE by western blot. Alix was detected as loading control for both extracts. B) The percentage of exosomal APE1 





This result confirms that different genotoxic agents could promote an increase of APE1 
exosomal release and also that genotoxic agents may promote the release of higher 
amount of APE1 p33 form compared to the p37 one, corroborating our hypothesis 
about the possible different functions absolved respectively by p33 and p37 forms in 
EXE released in the microenvironment of cancer cells. To check if the effect observed 
in JHH-6 cells was a general effect reproducible in different cell lines, we repeated the 
experiment of CDDP-treatment in A549 lung cancer cell line. Therefore, in agreement 
with the previous approach on JHH6 cells, we performed viability analysis on    A549 
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cells treated with different doses of CDDP. Also for this cell line, we choose the 
concentration of 6.25 μM, as shown in (Figure 37), because CDDP-treatment at this 
concentration caused low toxicity at 24 hours and a toxicity of about 50% upon 48 and 
72 hours of treatment, similarly to what we observed in the case of JHH-6 cells. Then, 
we performed EXE isolation from A549-conditioned media after 24, 48, 72 hours of 
CDDP-treatment, and we analysed the amount of APE1 p33 and p37 forms in EXE. As 
shown in (Figure 38A), similarly to JHH6 cells, we observed an accumulation of the 
total APE1 in EXE also in CDDP-treated A549 cells, and an increase of the relative 






Figure 37: Analysis of cell viability upon A549 cell line after CDDP treatment. MTS assay was performed upon 
A549 cells after 24, 48, 72 hours of treatments with the indicated concentrations of CDDP. The viability of untreated 
cells at the previously indicated time points was evaluated as a control. Data are expressed as mean ± S.D of three 









Figure 38: A) Analysis of APE1 content in A549 WCE and EXE after 24, 48, 72 hours of CDDP treatments. A549 cells 
were treated with 6.25μM of CDDP for 24, 48 and 72 hours. Cells and media were collected and processed for the 
production respectively of WCE and EXE. WCE and EXE were also obtained from A549 untreated cells at the three 
previously indicated time points. APE1_p37 and APE1_p33 isoforms were later analysed in WCE and EXE by 
western blot. Alix was detected as loading control for both extracts. B) The percentage of exosomal APE1 fractions 




Altogether, these results confirmed that the increase of APE1 exosomal release upon 
genotoxic stress is a general process, observed in different cancer cell lines and upon 
different genotoxic stresses and that chemotherapeutic drugs induce an accumulation 
of APE1 p33 form compared to the p37 protein. 
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We also wanted to test if the proteolytic activity of EXE derived from JHH-6 genotoxic 
treated cells could show different cleavage efficiency profiles. For this purpose, EVs 
proteolytic activity onto 0.2μg of rMAT APE1WT was evaluated, using different amount 
of EVs (0.1, 0.5, 1 μg), derived from JHH-6 untreated and doxorubicin treated cells. A 
higher proteolytic activity mediated by EVs derived from doxorubicin treated cells 
was clearly observed, compared to that one mediated by EVs of untreated cells (Figure 
39). We need to repeat the same experiment decreasing the time of reaction to better 
appreciate the differences. This experiment was performed using rMAT APE1WT, 
another rAPEWT, MAT tagged. In this experiment is possible to appreciate the different 







Figure 39: JHH-6 EXE derived from doxorubicin treated cells and untreated cells proteolytic activity upon rMAT 
APE1WT. Different doses of EXE derived from JHH-6 doxorubicin treated cells and untreated cells were tested for 
their proteolytic activity upon rMAT APE1WT (0.2 μg). The reaction was performed at 37°C for 4 hours. The reaction 
was loaded in 12% acrylamide/bis-acrylamide gel and resolved in SDS page. Western blot analysis was later 
performed for APE1 protein detection. The formation of APE1 cleaved product is higher in EXE derived from 
doxorubicin treated cells. 
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Soluble rAPE1 triggers SASPs factors expression 
 
SASPs factors expression is emerging as important paracrine mechanisms to promote 
inter-cellular communication of DDR responses being involved in triggering cancer 
cell-senescence phenotypes99. In order to evaluate a possible role for secreted soluble 
APE1 in cancer cells, we tested whether exogenous addition of recombinant purified 
APE1 may trigger SASPs factors expression in JHH-6 cell line (Figure 40 panel above)97. 
Recombinant proteins used here were GST-tagged APE1 proteins expressed in E. coli 
and purified to the homogeneity by FPLC-chromatography11,154,155 (Figure 24). To this 
aim, in addition to the wild-type protein (rAPE1WT) and the 33N-terminal deletion 
mutant (rAPE1N∆33), we also used an acetylated-mimicking mutant on residues 27, 31, 
32, 35 (rAPE1K4pleA). In this mutant, the Lys residues have been replaced by Ala, (as 
described previously) and whose relevance in cancer have been recently 
demonstrated56. 
As a negative control, we used purified GST protein that constitutes the tag of each of 
the above mentioned proteins. As a positive control of IL-6 and IL-8 inductions, we 
treated the cells with rTNF-α (Figure 40 panel below). As previously described, cells 
were treated for 24 hours with two doses of recombinant purified proteins, and the 
expression of IL-6 and IL-8 genes was assayed by qPCR. As can be observed (Figure 
40, panel above), while GST alone did not exert any major effect, treatment with soluble 
rAPE1 proteins induced an upregulation of both cytokines in the treated cells, showing 
a more pronounced effect on IL-8, rather than on IL-6, gene expression. Interestingly, 
treatments with either rAPE1NΔ33 or the rAPE1K4pleA proteins promoted a higher increase 






Figure 40: Exogenously added recombinant APE1_GST proteins are able to induce the mRNA expression of IL-6 
and IL-8 genes: IL-6 and IL-8 mRNA expression levels analysis upon JHH-6 cells treated for 24 hours with 1μg/ml 
or 2μg/ml of rGST APE1 proteins. JHH-6 untreated cells and treated for 24 hours with 1μg/ml or 2μg/ml of rGST 
protein where used as a negative controls. After treatments, total RNAs were extracted, cDNAs were obtained and 
quantitative Real Time PCR was executed. Data show that while rGST APE1WT is slightly able to induce IL-6 and 
IL-8 mRNA expression, the mutated forms rGST APE1K4pleA and rGST APE1NΔ33 more efficiently have the capability 
to induce the activation of IL-6 and IL-8 mRNA expression (panel above). IL-6 and IL-8 mRNA expression analysis 
upon JHH-6 cells treated for 3 hours with TNF-α as a positive control for interleukins induction (panel below). Data 
represent means ±SD of three independent experiments. Statistical analysis was achieved by applying Two-way 
ANOVA test. ****P<0.0001. 
78  
In order to exclude that the observed stimulatory effect could be due to possible 
contaminants, deriving from the E. coli as hosting vector used to express recombinant 
APE1 proteins or from the use of the GST-tag, we also performed similar experiments, 
by testing the effect on IL-8 gene expression, using recombinant Flag-tagged APE1 
proteins expressed in JHH-6 cells and immune-purified using an anti-Flag M2 affinity 
chromatography (see materials and methods). Also in this case, treatments of JHH-6 cells 
for 24h with 1μg/ml immune-purified Flag-APE1WT, Flag-APE1K4pleA, Flag-APE1NΔ33 
proteins were performed. As negative control, immune-purified material of extract 
from JHH-6 transfected with pCMV5.1-empty vector was used. As shown in (Figure 
41), the induction of IL-8 mRNA expression, even though to a lower extent than in the 
previous case, was confirmed by qPCR also performing the treatment with immune- 
purified APE1 proteins, corroborating the data previously obtained with APE1 






Figure 41: JHH-6 cells were treated for 24h with 1μg/ml of immune-purified Flag APE1WT, Flag APE1K4pleA and Flag 
APE1NΔ33 proteins. Treatment with 1μg/ml of immune-purified extracts derived from cells transfected with 
pCMV5.1_empty vector was executed as a negative control. After treatments, total RNAs were extracted, cDNAs 
were obtained and quantitative Real Time PCR was executed. Data show that immune-purified APE1 proteins are 
able to induce the mRNA expression of IL-8 gene. 
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In order to generalize our findings with a different cell model, we performed the same 
experiments described in (Figure 40) using the A549 cell line. Data shown in (Figure 
42), clearly demonstrated that the stimulatory effect on endogenous IL-6 and IL-8 
expression by treatment with the recombinant proteins was clearly obtained also in 
the A549 cell line, even to different extent relative to the JHH-6 cell model, with a more 
pronounced effect on IL-6 rather than IL-8. Altogether, these data suggest a role of 
secreted APE1 as a paracrine pro-inflammatory molecule, which may modulate the 




Figure 42: IL-6 and IL-8 mRNA expression levels analysis in A549 cells treated for 24h with rGST APE1 proteins. 
A549 untreated cells were used as control. After treatments, total RNAs were extracted, cDNAs were obtained and 
quantitative Real Time PCR was executed. 
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Soluble rAPE1 promotes the activation of IL-8 promoter through NF-κB 
transcription factor 
 
APE1 is known to be an activator of IL-8 expression though NF-kB transcription factor 
activation12,98. Thus, we tested whether the APE1 paracrine effect on IL-8 expression 
was due to a transcriptional activation process on IL-8 promoter. For this purpose, 
Luciferase Reporter assay was performed on JHH-6 cells, previously transfected with 
IL-8_promoter or IL-8_ΔNF-κB_promoter, the last one characterized by the deletion of 
NF-κB binding sites, as already described in Cesaratto et al., 201398 (Figure 43A). It was 
evaluated the ability of exogenously added recombinant APE1 to promote the 
activation of IL-8 gene expression. JHH6 cells transfected with the indicated 
promoters, were treated for 24 hours with 1μg/ml of rGST-APE1WT, rGST-APE1K4pleA 
and rGST-APE1 N∆33. As a negative control, treatment with rGST alone was performed. 
As a positive control for IL-8 promoter activation, TNF-α treatment [2000U/ml] was 
executed. Then, Luciferase activity was measured. Data obtained, clearly showed that 
recombinant exogenously added APE1 protein was able to activate IL-8 promoter 
through NF-κB pathway, being abolished in the IL-8 ΔNF-kB promoter (Figure 43B). 
Interestingly, the activation of IL-8 promoter was more effective when treating the cells 
with GST-APE1K4pleA or with GST-APE1N∆33 mutant forms, in agreement with the 
endogenous gene expression, data shown in (Figure 40A), while no activation of IL-8 
promoter was induced when treating with the rGST protein alone (Figure 43B). As a 
positive control, activation of IL-8 promoter, mediated by TNF-α was also measured. 
These data clearly suggest that stimulation of IL-8 expression by exogenously added 
recombinant APE1 proteins requires a transcriptional activation process involving NF- 












Figure 43: Exogenously added rGST APE1 proteins are able to promote the activation of the IL-8 promoter: A) 
Schematic representation of -1498/+44 hIL-8/Luc (IL-8 promoter) and -162/+44 hIL-8 Luc ∆NF-κB (IL-8 ∆NF-κB) 
promoters; B) Gene reporter assay upon JHH-6 respectively transfected with IL-8 and IL-8 ∆NF-κB promoters. The 
day after transfection cells were treated for 24h with 1μg/ml rGST APE1 proteins in serum starvation and the 
activity of IL-8 and IL-8 ∆NF-κB promoters was measured. As a negative control for the activation of the IL-8 
promoter, a treatment for 24h with rGST protein at the concentration of 1μg/ml was performed. As a positive 
control a TNF-α treatment for 3 hours at the concentration of 2000U/ml was executed. Data represent means ±SD 
of two independent experiments. Statistical analysis was achieved by applying Two-way ANOVA test. ****P<0.0001 
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Activation of IL-8 gene expression induced by soluble rAPE1  depends 
 
on ATM and on the APE1-redox function 
 
It is known that NF-kB activation is regulated during DDR by ATM156. For this 
purpose, ATM inhibitor [KU60019] treatment for 24 hours (2μM) was performed 
coupled to reporter assay, as above156. As shown in (Figure 44), ATM inhibitor 
treatment significantly affected the activation of IL-8 promoter mediated by 
exogenously added recombinant APE1 proteins. Moreover, since it is known that 
activation of NF-kB could be exerted through a redox-based mechanism by 
endogenous APE1157, we wanted to evaluate whether intracellular APE1 redox 
function was essential for the activation of IL-8 promoter via NF-κB, as previously 
reported in Cesaratto et al.,201398, IL-8 promoter reporter assay was performed as 
above, in combination with the inhibition of the APE1 redox function through 
[E3330]158. For this purpose, after 20 hours of treatment with recombinant GST APE1 
proteins, E3330 treatment (125μM), (as reported in Cesaratto et al., 2013)98 was 
performed together with rGST APE1 proteins for the remaining 4 hours. Inhibition of 
APE1 redox function blocked the induction of IL-8 promoter induced by exogenously 
added APE1 recombinant proteins. Overall, these data clearly demonstrate that ATM- 
signalling participates in the NF-κB induction of IL-8 gene expression by exogenously 







Figure 44: Gene reporter assay upon JHH-6 transfected with IL-8 promoter. The day after transfection cells were 
treated for 24h with 1μg/ml rGST APE1 proteins together with 2μM of the ATM inhibitor KU60019. Cells were also 
treated firstly for 20 hours with 1μg/ml rGST APE1 proteins followed by E3330 [125μM] in combination with rGST 




Characterization of APE1-hnRNPA2B1 interaction 
 
In order to unveil non-canonical APE1 role in EVs and its contribution in the regulation 
of extracellular miRNA, we decide to validate the interaction between APE1 and 
hnRNPA2B1. hnRNPA2B1 is a ribonucleoprotein that exerts different functions such 
as participates in splicing events53, takes part in RNA decay55, interestingly regulates 
miRNAs processing62, and miRNA sorting in EVs56. Because also APE1 participates in 
many of these processes and according to the recent indication, obtained through 
APE1 interactome analysis3, about the possible direct interaction between APE1 and 
hnRNPA2B1, we decide to properly validate the existence of this complex in JHH-6 
cells. For this purpose, we first carried out a Co-immunoprecipitation (Co-IP) experiment 
(see material and method) in JHH-6 cells overexpressing Flag APE1WT, while co- 
immunoprecipitation in JHH-6 transfected with an empty vector (Empty) was carried 
out as a negative control. The obtained IPs and the respective INPUTs, were resolved 
in SDS page and western blot using anti hnRNPA2B1 antibody was executed. In 
parallel western blot with anti Flag antibody was performed to check if the IPs had 
been opportunely normalized. To better characterize the interaction, and understand 
if is direct or if is mediated by nucleic acids, Co-IP were also performed in cell lysates 
treated with RNaseA or with DNaseI (for treatment see material and methods). As shown 
in (Figure 45), APE1 clearly interacts together with hnRNPA2B1 and this interaction is 





Figure 45: APE1-hnRNPA2B1 interaction analysis. Co-IP experiment carried out in JHH-6 cells overexpressing Flag 
APE1WT and in JHH-6 cells transfected with an empty vector (Empty) as a negative control. INPUT and IP are 
indicated. Western blot was performed using anti hnRNPA2B1 antibody. Western blot using anti-Flag antibody 




To prove the specificity of the interaction, it was performed a Proximity ligation assay 
(PLA) in JHH-6 knock down for APE1 protein. The knock down was obtained 
transfecting the cells with siRNA against APE1 (siAPE1) and a transfection with a 
siRNA scramble (siSCR) was performed in parallel as a control. PLA positive signal, 
indicative of the interaction between the two proteins, was represented by red spots 
present in siSCR condition (Figure 46) (higher middle panel), confirming the interaction 
observed before with Co-IP analysis. The PLA signal was missing in siAPE1 condition, 
proving the specificity of the signal. In the panels on the left are shown 
immunofluorescence carried out using APE1 antibody to observe APE1 cellular 
amount and distribution. In siAPE1 condition a weaker APE1 signal compared to the 
signal of siSCR is shown, indicating the downregulation of the protein. The merge of 
the  two  acquisition  is  shown  on  the  right  panels.  A  negative  control,     realized 
performing PLA in JHH-6 cells not incubated with anti hnRNPA2B1 antibody was also 
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realized and the relative APE1 cellular distribution and PLA signals were shown in 






Figure 46: Validation of APE1-hnRNPA2B1 interaction. PLA was performed using anti APE1 and anti 
hnRNPA2B1 antibodies in JHH-6 cells silenced for APE1 protein (siAPE1), and JHH-6 silenced with siRNA 
scramble (siSCR) as a control. In the lower panels PLA was carried out in JHH-6 not-transfected cells omitting 




To further evaluate the APE1 function involved in the interaction with hnRNPA2B1, 
CoIP experiments were carried out overexpressing the functional Flag APE1 mutants 
C65S, E96A and NΔ33. APE1C65S is a mutant that displays a substitution of cysteine 65 
with a serine residue, this mutation cause the removal of the thiol group involved in 
APE1 redox activity22, abolishing this function. APE1E96A  is a mutant which displays a 
substitution of glutamic acid with alanine residue, which impairs the endonuclease 
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activity of the protein3. APE1NΔ33 is the APE1 truncated form lacking of the first 33 
amino-acids of the N-terminal region that are used to be involved in RNA-protein 
interaction and protein-protein interaction15,85. Immunoprecipitation with empty 
vector and APEWT were carried out respectively for negative and positive control. The 
(Figure 47) shows that the interaction between APE1 and hnRNPA2B1 is not 
dependent by APE1 redox or endonuclease activity, the N-terminal region of the 






Figure 47: APE1-hnRNPA2B1 interaction analysis. Co-IP experiment carried out in JHH-6 cells overexpressing Flag 
APE1WT, Flag APE1NΔ33, Flag APE1C65S, Flag APE1E96A proteins and in JHH-6 cells transfected with an empty vector 
(Empty) as a negative control. INPUT and IP are indicated. Western blot was performed using anti hnRNPA2B1 




Figure 48 APE1-hnRNPA2B1 interaction analysis. Co-IP experiment carried out in JHH-6 cells overexpressing Flag 
APE1WT, Flag APE1K4pleA, Flag APE1K4pleQ, Flag APE1K4pleR, proteins and in JHH-6 cells transfected with an empty 
vector (Empty) as a negative control. INPUT and IP are indicated. Western blot was performed using anti 





Once we demonstrated that APE1 interacts together with hnRNPA2B1 through its N- 
terminal domain and considering that usually APE1 interacts with several proteins 
through the lysine residues located to the same region11, we wanted to evaluate if also 
this interaction occurred through the same mode. CoIP experiments were carried out 
overexpressing the lysine Flag APE1 mutants K4pleA, K4pleQ and K4pleR. APE1K4pleA, 
is characterized by having the substitution of K27, K31, K32, K35 lysine residues with 
alanine. These substitutions neutralize the positive charges of lysines and simulates a 
constitutive acetylation status of the protein11,19. APE1K4pleQ, is characterized by the 
substitution of the K27, K31, K32, K35 residues with glutamine. Also this mutant 
displays a constitutive acetylated APE1 form. APE1 K4pleR instead    is characterized by 
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having the substitution of the four K residues with arginine. This mutation confers a 
not-acetylable status to APE1 protein159. As shown in (Figure 48), APE1 lysine residues 
located at the N-terminal region of the protein are essential for the interaction with 
hnRNPA2B1 protein, and their acetylation status regulates this interaction. 
Considering that APE1 and hnRNPA2B1 are both negative prognostic factor in several 
tumors1,60, we wanted to check the correlation between these two factors in cancer. For 
this purpose, correlation analysis was performed consulting The Cancer Genome Atlas 
(TCGA) datasets. As shown in (Figure 49) there is a strong positive correlation between 
the expression levels of APE1 and hnRNPA2B1 in many tumors. The levels of 
correlation are reported in the (Table 1) below. This bioinformatics analysis supports 
the hypothesis that this complex could have an important role in tumor biology. 
Due to the APE1 contribution in miRNA processing3 and to the hypothetic role of 
extracellular APE1 in EVs miRNA sorting, considering also that hnRNPA2B1 
contributes in the same biological events, further investigation need to be executed to 




Figure 49: APE1 hnRNPA2B1 correlation analysis was performed consulting 30 TCGA datasets. In the graph is 





Table 1: The chart shows all the analyzed TCGA data sets. Positive correlation data are indicated in green, negative 








APE1 participates in tumor progression regulating miRNA processing in cancer cells3. 
In order to explore APE1 contribution to miRNA processing/decay, based on our 
recent findings correlating APE1 protein expression levels to miRNA sorting in EVs, 
we wanted to identify miRNAs that a) participates in the progression of HCC, b) 
whose expression is affected by the APE1 protein, for comprehending APE1 role in 
HCC tumor biology and c) can have a prognostic value. For this purpose, Nanostring 
analysis in JHH-6 depleted for APE1 protein was carried out. APE1 depletion was 
realized through custom APE1 siRNA transfection (Figure 50). In parallel, siRNA 
transfection with a SCR pool (siSCR) was performed as a control (see material and 
methods). Once obtained these JHH-6 cells, miRNA extraction was executed and 
NanoString analysis was carried out to estimate differentially expressed miRNAs (DE- 
miRNAs) in HCC upon APE1 depletion. Through this analysis we could identify 7 DE- 
miRNAs (see table 2). Five of them are up-regulated and two are downregulated in 
APE1 depletion condition. We did not obtain a higher number of significantly DE- 
miRNAs because the silencing efficiency in this specific cell line was around 50%. 
Using the database TarBase v7.0, queried through the DIANA-MirPath v.3 web-server, 
we defined the experimentally validated target genes for each identified miRNA. It 
was used DIANA-MirPath also to perform the functional enrichment analysis for Gene 
Ontology-Biological Process terms. Through this analysis, we obtained a Heat-map 
showing the significantly enriched functional terms associated with DE-miRNAs 
validated targets (Figure 51). We also represented the most informative enriched GO 
terms through a treemap, summarizing the output with REVIGO tool (Figure 52A). 
This kind of representation allow to identify the different biological pathways, whose 
regulation  could  be  indirectly  mediated  by  the  identified  DE-miRNAs.        Many 
pathways are associated with biosynthesis, regulation and metabolism of RNA, as well 
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as the regulation of gene expression, reinforcing our previous collected evidences 
about APE1 participation in tumor biology through the regulation of these cellular 
processes. 
To further study the interconnections between the identified pathways, we also 
performed a functional enrichment analysis using the KEGG database, summarizing 
the output with the KEGG-PathwayConnector web tool. From this analysis we 
obtained a network of the top 15 enriched KEGG functional terms associated with the 
validated DE-miRNAs (Figure 52B). 11 major clusters were defined, including Hippo 
pathway160, Wnt signaling161, p53 pathway162 and FoxO. Interestingly the RNA 
transport pathway was also observed among the significantly enriched terms. These 
results strengthen APE1 contribution in controlling processes related to tumorigenesis, 




Figure 50: western blot analysis for APE1 detection executed in siAPE1 JHH-6 cells silenced for 48 hours and the 




Table 2: DE miRNAs obtained by the Nanostring analysis carried out upon JHH-6 cells silenced for 48 hours with 







Figure 51: Functional enrichment analysis of DE-miRNAs validated targets. Heatmap showing the significantly 
enriched functional terms (adj pvalue≤0.05) associated with DE-miRNAs validated targets, according to DIANA- 









Figure 52: Functional enrichment analysis of DE-miRNAs validated targets. A) Gorilla/REVIGO TreeMap 
representation summarizing the most informative enriched GO terms (pvalue≤0.001). B) Network of the top15 
enriched KEGG functional terms (pvalue≤0.05) associated with DE-miRNAs validated targets, according to the 


























Cancer cells are able to counteract cell death through the activation of DDR in response 
to chemotherapeutic treatment, by triggering chemoresistance phenomena and 
maintaining their proliferative rate163,164. BER enzymes, that are mainly involved in 
DDR but are also able to induce the regulation of gene expression, are considered as a 
good target for cancer treatment26,165. Chemoresistance process causes a modulation of 
immune response166. Many secreted factors, which act in autocrine and paracrine 
manner, are also able to modulate inflammatory response in tumor 
microenvironment165 and the study of tumor microenvironment appears to become 
relevant for comprehending the mechanisms activated by cancer cells in order to 
support tumor maintenance and proliferation. Damage associated molecular patterns 
(DAMP), are secreted factors, which contribute in tumor progression. Some DNA 
repair protein are also DAMP factors, and when secreted, they may act as a 
chemokines and cytokines, contributing in cell signalling and inflammation. APE1 is a 
multifunctional protein that participates in DNA repair and in the regulation of gene 
expression. Elevated levels of APE1 protein in sera of different tumors like bladder 
and NSCLC have been registered, and extracellular APE1 contribution in promoting 
chemoresistance, by affecting cell sensitivity to chemotherapy it was proved95,96, 
suggesting that APE1 could be considered as a prognostic biomarker in cancer. 
Moreover, it seems that APE1 extracellular release could be mediated by acetylation 
upon N-terminal region of the protein100, but no clear evidences about the extracellular 
APE1 biological function have been elucidated, yet. A recent work, in fact, suggested 
that extracellular APE1 could be involved in triggering apoptosis in TNBC cells 
through its binding to RAGE receptors100. Other evidences claim that extracellular 
APE1 can control TNF-α induced inflammatory response, modulating the activation 
status of TNFR receptor through its redox activity167, other data instead sustain that 
exogenous APE1 can participates in the early phases of inflammation process, 
inducing the activation of IL-6 gene expression through NF-κB97. For all of this reasons 
it is possible to hypothesize that APE1 could act as a novel unsuspected DAMP factor. 
98  
In the present thesis, the extracellular role of APE1 and its relevance in HCC tumor 
progression was analysed. It was proved that APE1 is present in HCC serum samples 
and that serum APE1 levels parallel the cellular protein amounts in tumor tissues. 
APE1 paracrine function was characterized, demonstrating that exogenously added 
APE1 and its mutant forms APE1K4pleA and APE1NΔ33 may trigger endogenous IL-6 and 
IL-8 expression in a paracrine way, using both rGST APE1 from E. coli and IP-purified 
proteins from HeLa cells. In particular, we observed that rAPE1k4pleA and rAPE1NΔ33 
were more efficient in inducing IL-6 and IL-8 expression than rAPEWT. IL-6 and IL-8 
are SASP factors but also important players in triggering immune-response in cancer 
microenvironment. Considering these data, we can hypothesize that APE1 may 
contribute to HCC tumor maintenance and progression possibly through the 
activation of cytokines that support cells senescence and also tumor cell invasiveness 
through triggering the inflammatory response. 
APE1 protein lacks of the classical secretory signal in its sequence even if its secretion 
was observed in different works105,106. We were able to demonstrate that APE1 is 
released by means of EVs, and that is the only BER enzyme that takes part to EVs 
protein composition, together with the scaffold protein XRCC1, that possibly 
contributes in stabilizing a complex between APE1 and nucleic acids. We found, in 
fact, that APE1 is enzymatically active in EVs, because is able to exert its endonuclease 
activity upon 8oxoy-riboG and also in abasic ribo- embedded in DNA. APE1 EVs 
secretion process is a general mechanism carried out by all tumor cell lines we 
analysed, and its accumulation in EVs is increased upon different genotoxic stresses, 
specifically doxorubicin and cisplatin. Moreover, we found that APE1 truncated form 
increases in EVs upon oxidative stresses. 
Few publications elucidate how EVs could contain different kind of proteases, some 
of them are exposed to EVs membrane and contribute to the remodeling of 
extracellular matrix promoting tumor invasiveness and sustaining inflammation 
processes150,168. We observed that APE1 can undergo proteolytic cleavage inside    EVs 
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and that proteases activity increased under genotoxic stress conditions, but we still 
need to properly identify the protease(s) responsible for APE1 cleavage and also to 
characterize APE1 function in EVs according to its nature. It could be speculated that 
the full length protein function is related to the RNA/DNA processing on the 
encapsulated nucleic acid, while the paracrine function could be exerted by both full 
length and APE1NΔ33 forms, according to the evidences that we collected regarding 
rAPE1 role in the activation of IL-8 promoter. These data demonstrated that the IL-8 
gene expression is promoted by a transcriptional regulatory mechanism, exerted by 
exogenous APE1 through its redox function. We think in fact that extracellular APE1 
could act in a paracrine manner modulating the activity of not yet identified receptors 
exposed by the recipient cells, which are responsible for the activation of signaling 
cascades, that culminate with the IL-8 gene transcription initiation. The inhibition of 
APE1 redox function in fact, represses the activation of IL-8 promoter. The proposed 
mechanism is similar to that one exerted by the DAMP factor High mobility group box 1 
(HMGB1) protein169,170. HMGB1 is an early DDR factor which rapidly accumulates in 
loci were oxidative stress occurs171. It is also like a sort of BER cofactor because is able 
to stimulate BER enzyme activities such as the APE1 endonuclease and also FEN1 flap 
cleavage activity169 when DNA damage occurs. Studies demonstrated that HMGB1 
cellular localization is altered by oxidative stress, which causes the translocation and 
later the secretion of the protein. HMGB1 cysteine residues are important for the 
regulation of its extracellular biological activity. In particular, three are the cysteine 
residues involved in its reversible regulation Cys23, Cys45 and Cys106. When all the 
cysteine residues are in the thiol state, HMGB1 exerts its chemotactic activity, forming 
a complex with CXCL12, which binds CXCR4 to trigger the process. In an intermediate 
oxidation status, a disulphide bound between Cys23 and Cys45 residues occurs and 
the protein becomes able to interact with MD-2 and TLR4, acquiring the pro- 
inflammatory cytokine behaviour. In the condition in which all the cysteine residues 
are oxidised into sulfonates HMGB1 is not able to act as chemokine or cytokine. 
Moreover,  other  post-translational  modifications  are  indispensable  for   switching 
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HMGB1 protein functions and also for promoting its secretion. Acetylation occurring 
in the NLS sequence of the protein makes for instance HMGB1 able to promote 
inflammation and when it is hyper-acetylated, the protein can shuttle from nucleus to 
cytoplasm, where it can be later secreted and participate in inflammation and 
immunity response172. 
As a secreted factor, HMGB1 is enrolled to act as a pro-inflammatory molecule173,174. 
The evidences about the role of secreted HMGB1 in tumor progression, are presently 
contradictory. Some studies, in fact, demonstrated that its secretion is promoted by 
chemotherapeutic treatment, and its function is related to the stimulation of 
chemokine CXCL11, taking part to antitumor immune response166,175. Conversely, 
other evidences suggested that secreted HMGB1 could have a role in supporting 
cancer progression, as demonstrated for oesophageal squamous cell carcinoma (ESCC)165. 
These indications suggest that some DNA repair proteins, like HMGB1 can be also 
molecules that acting as autocrine or paracrine factors could have an important role in 
supporting cancer progression, and in the activation of inflammatory status in tumor 
microenvironment. It is conceivable that APE1 could act similarly to HMGB1, because 
of a similar redox domain that is responsible for the modulation of APE1 function. 
APE1 participates in the processing of some oncogenic miRNAs under genotoxic 
stress3. In this thesis, it was proved that the protein significantly contributes to the 
regulation of miRNAs expression/processing and to their sorting into EVs, considering 
that EVs from APE1 murine KO cells (CH12F3) and also from HeLa and A549 APE1 
depleted cells, displayed a strongly reduced content of miRNAs. Moreover, the 
intracellular levels of mature miRNAs are lower in APE1 KO cell lines suggesting that 
APE1 could have a strong impact also in miRNAs production. 
For better comprehending APE1 contribution in this field, a preliminary 
characterization of APE1-hnRNPA2B1 interaction was performed. hnRNPA2B1 is an 
APE1  protein  partner  identified  through  the  interactome  analysis  and     resulted 
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interesting to study for its implications in miRNA processing and also in EVs miRNA 
sorting3,56,62. 
It was proved that this interaction occurs through APE1 N-terminal region and that is 
mediated by RNA. Furthermore, APE1 N-terminal acetylation impairs this interaction. 
It will be interesting, in the future, to characterize the role of this complex. We 
hypothesized that these two proteins could be involved, together, in the regulation of 
extracellular miRNAs, starting from their expression/processing up to their sorting. 
In order to understand the APE1 role in the regulation of miRNAs processing in HCC, 
a Nanostring analysis in JHH-6 depleted for the protein was performed. 
Unfortunately, due to the low efficiency of silencing, in this specific cell line, we could 
not provide many DE-miRNAs, but we could notice that the identified ones participate 
in the regulation of important cellular pathways such as Wnt, FoxO and p53. 
Surprisingly, we also noticed that some of them are implicated in the regulation of 
proteoglycan synthesis in cancer, sphingolipids biosynthesis and RNA transport. All 
of these processes are possibly related to EVs formation and sorting of 
macromolecules, strengthening the concept of APE1 involvement in biogenesis and 
transport of miRNA in EVs. 
In the future, further investigation will be necessary to characterize these phenomena. 
In the meantime, a representative model illustrating the hypothetic extracellular APE1 
role as DAMP factor and its implication in the regulation/sorting of miRNAs in tumor 




Figure 53: Representative model of APE1 as miRNA expression/processing/sorting regulator and as DAMP factor, 




Some major aspects that came out from the work of this Thesis need further specific 
studies. 
We observed that exogenously added rAPE1 can acts as a DAMP factor, because it is 
able to induce IL-6 and IL-8 mRNA expression in the receiving cells. We also 
demonstrated APE1 secretion through EVs. Further investigations will be carried out 
to shed light on the hypothesis of these two different secretion mechanisms, involving 
or not vesicular bodies, and their contribution in tumor biology. 
Moreover, we need to characterize the molecular mechanism by which APE1 may act 
in a paracrine manner, inducing the inflammatory response in the receiving cells. For 
this purpose, we will try to understand if the mechanism could occur via any not yet 
identified receptor and if the APE1 redox domain could be involved in this process, as 
it was demonstrated for HMGB1 protein. For this purpose, treatment using rAPE1 
redox mutants will be performed. 
It was proved that APE1 can undergo proteolytic cleavage inside EVs, therefore we 
need to identify the protease(s) responsible for this event, to understand APE1 
function in EVs according to its nature. 
To comprehend the APE1 role in controlling miRNAs processing and sorting, 
Nanostring analyses will be performed in HeLa inducible APE1 knock down cells and 
in HeLa SCR as a control, in order to identify those EXE miRNAs regulated by APE1. 
Moreover, further investigation about the function of the complex hnRNPA2B1-APE1 

























Material and methods: 
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Cell culture and treatments 
 
JHH-6, an undifferentiated HCC cell line, was grown in William’s medium E (Sigma- 
Aldrich), supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml 
streptomycin (Euroclone, Milan, Italy). A549, human epithelial lung cell line, was 
grown in RPMI 1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 
100μg/ml streptomycin (Euroclone, Milan, Italy). Hct116 +/+p53 and Hct116 -/-p53, human 
epithelial colon cancer cell lines, were grown in Dulbecco’s Modified medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml 
streptomycin (Euroclone, Milan, Italy). Acute myeloid leukemia cell lines OCI-AML2, 
and OCI-AML3, the last one characterized by having a mutation on the third helix of 
the C-Term domain (h3 mutA and H3 mutE) of NPM1 protein85, were grown in α- 
MEM with ribonucleosides, 20% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml 
streptomycin (Euroclone, Milan, Italy). CH12F3∆++, murine B cell line, biallelic for Ape1 
gene, and CH12F3∆∆Δ murine B cell line, allelic null for Ape1, were grown in RPMI 1640 
medium supplemented with 10% fetal bovine serum, Non Essential Aminoacids, 1mM 
Sodium Pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin (Euroclone, Milan, 
Italy). HeLa inducible cell clones expressing ectopic Flag APE1 proteins were grown 





JHH-6 or A549 were seeded at the density of 4*10^3 cells in 96well plates. The day after 
seeding, cells were treated for 24, 48 and 72 hours with the following genotoxic agents: 
Doxorubicin hydrochloride (Sigma Aldrich, Milan Italy), dissolved in UltraPure™ 
DNase/RNase-Free Distilled Water (Invitrogen™, Thermo Fisher Scientific, Waltham, 
Massachusetts, United States) or with cis-Diammineplatinum(II) dichloride (CDDP), 
(Sigma Aldrich, Milan Italy), dissolved in dimethylformamide (DMF), at the indicated 
concentrations (see results section). The cellular viability was assayed by using CellTiter 
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96® AQueous One Solution Cell Proliferation Assay (Promega, Milan, Italy). 
Absorbance at 490nm, indicative of cellular metabolic activity, was measured with 
EnSpire 2300 Multilabel reader, (Perkin Elmer, Waltham, Massachusetts United 
States). Each treatment was performed in three biological replicas, and for every single 
experiment a four technical replicas were executed. Each absorbance value registered 





Extracellular vesicles (EVs) isolation 
 
Exosomes were isolated from medium supplemented with 10% Fetal Bovine Serum, 
exosome-depleted (ThermoFisher Scientific, Waltham, Massachusetts United States), 
100 U/ml penicillin, 100 μg/ml streptomycin (Euroclone, Milan, Italy), using Total 
exosome Isolation kit (Thermo Fisher Scientific Waltham, Massachusetts United 
States), according to the manufacturer instructions. Polydisperse EVs in the range of 
80-800 nm were obtained by nickel-based isolation (NBI)151. Briefly, nickel-charged 
beads were added to the media to capture EVs during 30 min incubation at RT in 
shaking, Then EVs from recovered beads were eluted using a pH 7.4 elution buffer 
containing EDTA and sodium citrate as chelating agents. 
 
 
Exosome quantification and characterization 
 
Exosomes range size analysis and quantification was assayed performing the 
nanoparticle tracking analysis (NTA) with the Nano-Sight instrument, version   NTA 
3.2 Dev Build 3.2.16. Exosomes vesicles were characterized by transmission electron 
microscopy (TEM). EVs isolated by NBI were characterized by Tunable Resistive Pulse 
Sensing (TRPS)  technology, using  qNANO  instrument (iZON Science)  and   NP250 
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nanopores. Stretch conditions and quality of acquisitions were assessed based on 




Exosome extracts preparation (EXE) 
 
Once the EVs have been obtained, laemmly buffer (SDS 2%, Glycerol 10%, Tris-HCl 
pH 6.8 0.5M, β-mercaptoethanol 3.5%, bromophenol blue) was added to shatter the 
vesicles and to denature their protein content. The samples were later boiled for 5 
minutes at 95°C and kept on ice until use. 
 
 
Whole cell extracts preparation (WCE) 
 
Cells were harvested, centrifuged at 1200 rpm for 3 minutes, washed with PBS, and 
resuspended with lysis buffer (50mM Tris HCl pH 7.5, 150mM NaCl, 1mM EDTA pH 
8.0, 1% Triton X-100). After 20 minutes of incubation on ice, the lysate was centrifuged 





Nuclear cell extracts preparation (NCE) 
 
Cells were washed twice with PBS, harvested in PBS complemented with DTT 0.1mM 
and PMSF 0.5mM and centrifuged at 1000rpm for 10 minutes at 4°C. The cell pellet 
was later resuspended with T1 solution (HEPES pH 7.9, 10mM, KCl 10mM, MgCl2 
0.1mM, EDTA pH 8.0, 0.1mM) and centrifuged at 2400 rpm for 10 minutes at 4°C. The 
supernatant, consisting of cytosolic proteins, was harvested and kept on ice. Nuclear 
pellet was resuspended in T1 solution, centrifuged at 2400 rpm for 10 minutes at 4°C 
for pelleting nuclei again. The supernatant was discarded and nuclear pellet was 
properly resuspended with T2 solution (HEPES pH 7.9, 20mM, NaCl 420mM,  MgCl2 
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1.5mM, EDTA pH 8.0, 0.1mM, Glycerol 5%). After 30 minutes of incubation, the 
sample was centrifuged at 12000rpm for 20 minutes at 4°C and the supernatant 
containing nuclear proteins was harvested and kept on ice. Both cytosolic and nuclear 




Western blot analysis 
 
Protein extracts were suitably quantified with Bradford solution (Bio-rad, California, 
United States), according to the manufacturer’s instructions, resolved in 10%/12% gel 
SureCast™ Acrylamide Solution (40%) (Invitrogen, California, United States) and 
transferred in nitrocellulose membrane, (Amersham, United Kingdom). Western blot 
analyses were executed using the listed primary antibodies: anti APE1 antibody 
(13B8E5C2, Novus), anti β-tubulin antibody (T0198, Sigma-Aldrich), anti DNA 
Polymerase beta antibody (ab26343, Abcam), Anti-DNA Polymerase delta (ab10362 
Abcam), anti OGG1 antibody, supplied by Radicella, anti Alix Antibody (1A12) (SC- 
53540, Santa Cruz), anti GM130 Antibody (B-10) (SC-55591, Santa Cruz), anti Syntenin 
antibody (EPR8102) (ab133267, Abcam), anti GST antibody (ab19256, Abcam), anti 
Flag M2 antibody (F1804, Sigma Aldrich). After incubation with primary antibodies, 
membranes were washed three times with PBS-0.1% Tween-20, (Sigma Aldrich, Milan, 
Italy), incubated for 1 hour at room temperature with the appropriate 
IRDye800/IRDye600 labelled secondary antibodies (diluted to 1:2000). The acquisition 
of the images and the quantifications analyses were achieved using Odyssey CLx 
Infrared Imaging system (LI-COR GmbH, Germany). 
 
 
Comassie brilliant blue staining 
 
Comassie brilliant blue staining was performed for the following GST recombinant 
proteins:  rGST,  rGST  APE1WT,  rGST  APE1k4pleA,  rGST  APE1N∆33.  1.5μg  of        each 
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recombinant protein was loaded in a 10% polyacrylamide gel and SDS PAGE was 
executed. Later Comassie staining was made for 15 minutes and finally the gel was 
incubated for 30 minutes in destaining solution. The acquisition of the image was 
achieved using Odyssey CLx Infrared Imaging system (LI-COR GmbH, Germany). 
 
 
Cell transfection and immuno-purified protein production 
 
Immuno-purified proteins APE1WT-flag, APE1K4pleA-flag, APE1NΔ33-flag were obtained as 
indicated below. On day one 3*10^6 JHH-6 were seeded in 10cm dish, the day after they 
were transfected with 6μg of pCMV5.1_hAPE1WT-flag, pCMV5.1_hAPE1K4pleA-flag, 
pCMV5.1_hAPE1NΔ33-flag, pCMV5.1_empty vectors with Lipofectamine 2000 reagent 
(Invitrogen, California, Unites States), according to the manufacturer’s instructions. 
On day three, immunoprecipitation was carried out using FLAG® magnetic affinity 
resin and the elution for competition was made with Flag peptide, (both supplied by 
Sigma Aldrich, Milan Italy). The immunoprecipitation was performed as indicated 
below. Later, the obtained immune-purified proteins were directly used to treat JHH- 






On day one 3*10^6 JHH-6 cells were seeded in 10 cm dish and the day after were 
transfected with pCMV5.1_hAPE1 constructs, using Lipofectamine 2000 reagent 
(Invitrogen, California United States), according to the manufacturer’s instructions. 
The following day, cells were washed twice with PBS, and 800μl of lysis buffer (Tris 
HCl pH 7.4, 50mM, NaCl 150mM, EDTA 1mM, Triton 1%, protease inhibitor, PMSF, 
NaF, Na3VO4) was directly added to the dish. The lysis was performed in shaker at 4°C 
for 20 minutes. Later cells were scraped, lysates were harvested and centrifuged at 
12000g for 10 minutes at 4°C. Supernatants were collected and 50μl of lysate for  each 
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condition were kept as INPUT and quantified with Bradford solution. In parallel 30μl 
of FLAG® magnetic affinity resin, (Sigma Aldrich, Milan, Italy), for each experimental 
condition was centrifuged at 8000g for 1 minutes at 4°C to remove the storage liquid. 
Later resin was washed three times with TBS solution (Tris HCl pH 7.4, 50mM, NaCl 
150mM) at 8000g for 1 minute at 4°C and an incubation of the lysate with resin for 3 
hours on the rocker at 4°C was performed. After incubation, the resin was centrifuged 
at 8000g for 1 minute, washed three times with TBS and later the elution was 
performed adding to the resin 3μl of peptide FLAG, (Sigma Aldrich, Milan, Italy), 
resuspended in 50μl of TBS complemented with protease inhibitors. The elution was 
performed on the rocker for 30 minutes at 4°C. Subsequently the resin was centrifuged 
and the immuno-precipitated extract (IP) was collected. A comassie staining loading 
just 3μl of IP in a 10% polyacrylamide gel was executed in a way to normalize the 
different IPs. 
The treatment with RNaseA (Sigma Aldrich, Milan Italy) were performed at the 
concentration of 100μg/ml for 30 minutes at 37°C. For treatments with DNaseI RNase 
free (Thermo Fisher Scientific Massachusetts, United States), lysates were prepared 
using the following lysis buffer: DNaseI Reaction buffer, protease inhibitor, NaCl 
25mM, TritonX-100 1%. Once lysates were ready, DNase I was added to the lysate and 
the treatment was performed for 30 minutes at 37°C. The inactivation of DNaseI was 
executed simply adding DTT 1mM to the lysate. No heat inactivation was made to 





2.5*10^6 JHH-6 cells were seeded in 10 cm dishes. The day after, cells were transfected 
with 600 pmol of custom hAPE1 siRNA (see hAPE1 siRNA sequence below). Non- 
targeting siRNA pool (siSCR) transfection was in parallel performed as a control. Both 
siRNAs were supplied by GE Healthcare Dharmacon, (Colorado, Unites States).   The 
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transfection was executed with DharmaFECT transfection reagent (Thermo Fisher 
Scientific, Massachusetts, United States), according to the manufacturer’s instructions. 
After 6 hours of transfections, fresh medium was added to the complexes for reducing 
cytotoxicity. The day after transfection cells were washed twice with PBS, fresh media 
was added and after 48 hours from transfection cells were collected, washed twice with 
PBS, centrifuged and later miRNAs extraction was performed using miRNeasy Mini 
Kit (QIAGEN, Hilden, Germany), according to the manufacturer’s instructions. 
 
 
Custom hAPE1 siRNA sequence: 
 
Sense: 5' U.A.C.U.C.C.A.G.U.C.G.U.A.C.C.A.G.A.C.C.U.U.U 3' 
 
Antisense: 5' A.G.G.U.C.U.G.G.U.A.C.G.A.C.U.G.G.A.G.U.A.U.U 3' 
 
siSCR used is a pool of selected siRNAs, for this reason no sequences were provided 




Gene expression analysis 
 
For the analysis of gene expression profiles, cells were collected and total RNAs were 
extracted with NucleoSpin ® RNA, (Macherey Nagel, Germany), according to the 
manufacturer’s instructions. The obtained RNA was later retro-transcribed using 
SensiFAST™ cDNA Synthesis Kit, (Bioline, Ohio, United States), and cDNA were 
tested for IL-6 and IL-8 gene expression. The housekeeping genes GAPDH, HPRT, 18S 
RNA and ACTB were used for normalization. qRT-PCR was executed using 
SensiFAST™ SYBR® No-ROX Kit, (Bioline, Ohio, United States), according to the 
manufacturer’s instruction. Reaction were run on CFX96 Real-Time System, (Bio-Rad, 
California, United States), applying the following cycling parameters: denaturation at 
95° C for 10 seconds and annealing/extension at 60° C for 30 seconds repeated for   40 
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times. The analysis was executed performing three biological replicas. Data were 






Description of modified DNA and RNA substrates used in this study 
 
The 25-mer oligonucleotide containing a deoxy- and a ribo- tetrahydrofuran, called 
ss_dF and ss_rF respectively, and its reverse complementary sequence, ss_dC, were 
synthesized from Metabion International AG (Steinkirchen, Germany), purified 
through RP-HPLC, checked in Mass Check and re-suspended in RNase- and DNase- 
free water. Then, the modified oligonucleotides were labelled with either IRDye800 
and IRDye700 fluorophores, respectively. Synthesis of oligonucleotide containing an 
internal ribose 8-oxo-guanosine (r8oxoG) and an IRDye700 fluorophore at 5’ end was 
in-house carried out as explained in Malfatti et al., 201729. 
All oligonucleotides used in the present study were re-suspended in RNase- and 
DNase- free water at 100 µM. In order to favorite the double strand annealing, 100 
pmol of each oligonucleotide was annealed with an excess of 150 pmol of its 
complementary DNA oligonucleotide in 10 mM TrisHCl pH 7.4 and 10 mM MgCl2, 


















Human recombinant GST APE1 proteins (rGST APE1) were produced as explained in 
Fantini et al.,11 and in Erzberger and Wilson177. E. coli RNase HII and RNase A from 
bovine pancreas were respectively purchased from New England BioLabs® Inc (Milan, 
Italy) and from Sigma Aldrich (Milan, Italy). 
 
 
Serum APE1 quantification 
 
Serum APE1 protein level was determined using Human APEX1 ELISA kit (Cusabio, 
Houston, USA). The detection of the optical density (OD) at 450nm, with a correction 
set at 540 nm, was executed with EnSpire microplate reader (Perkin Elmer, Waltham, 
USA). sAPE1 levels were later calculated through a standard linear regression curve 
fitting by NCSS 11 Statistical software (2016) (NCSS, LLC Kaysville, USA). 
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Amplified luminescent proximity homogeneous assay (alpha) 
 
Glutathione-Donor beads (Perkin Elmer, #6765300) and Protein G-Acceptor beads 
(Perkin Elmer, #AL102C) were used in saturation binding experiments to detect and 
quantify the secreted, recombinant APE1 protein. Briefly, a mix of Donor and Acceptor 
beads, at final concentration of 10 mg/ml each, was added to 3 nM of APE1 antibody 
(13B8E5C2, Novus) pre-incubated with increasing concentration of rGST APE1 or 
rGST to reach hooking point. In case of EV experiments, aliquots of vesicles were 
denatured or not at 90°C for 5 min and equilibrated at RT before adding the alpha mix 
of beads plus antibody. All the reactions were performed in 20μl as final volume in 
384-Optiplates (Perkin Elmer, Massachusetts, United States) and incubated for 1 hour 
at RT before acquiring the results with an Enspire Plate Reader (Perkin Elmer, 





Enzymatic activity assays 
 
To measure enzymatic activity of EXE on different modified DNA substrates (25 nM), 
each reaction was prepared following different volumes of the extract, expressed in µl, 
as specified in the legend of each panel. Reactions were performed in a buffer 
containing 20 mM Tris-HCl, 25 mM KCl, 4 mM MgCl2, 0.1% BSA, 0.01% Tween20, pH 
7.4 for the indicated time at 37°C. Final volume for each reaction was 10 µl. At the end 
of all reactions, samples were blocked with a stop solution, containing 99.5% v/v 
Formamide (Sigma Aldrich, Milan, Italy) supplemented with 10X Orange Loading 
Dye (LI-COR Biosciences, Milan, Italy) and heated at 95°C for 5 minutes. Then, all 
samples were loaded onto a 7 M denaturing 20% polyacrylamide gel in TBE buffer pH 
8.0 and run at 4°C at 300V for 1 hour. Later, the gel was of the non-incised substrate 
(S) and the incision product (P) bands were quantified using Image Studio software 
(LI-COR GmbH, Germany). 
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Study of IL-8 promoter activity 
 
1*10^4 JHH-6 cells were seeded in 96well plate. 24 hours after seeding, cells were 
transfected with 200ng of IL-8_promoter or IL-8_ΔNf-κB_promoter, together with 4ng 
pRL-CMV Renilla Luciferase construct, using Lipofectamine 2000 reagent (Invitrogen, 
California, United States), as indicated from the manufacturer’s instructions. The day 
after transfection, cells were treated for 24 hours in medium without serum, with 
1μg/ml GST APE1 recombinant proteins and the activity of the IL-8 or IL-8_ ΔNf-κB 
promoters was assayed by Dual-Glo Luciferase Assay System, (Promega, Madison, 
Wisconsin, United States), according to the manufacturer’s instructions. As a positive 
control for the induction of the IL-8 promoter activity, a treatment in serum starvation 
for 3 hours with 2000U/ml of TNF-α (Peprotech Inc., New Jersey, United States) was 
performed, as already reported in Cesaratto et al., 201398. 
The ATM inhibitor KU60019 (Sigma Aldrich, Milan, Italy) was dissolved in DMSO and 
treatments for 24 hours at the concentration of 2μM were performed as shown in 
Ivanov, Oncotarget 2019156. 
The redox APE1 inhibitor E3330 (Sigma Aldrich, Milan, Italy) was dissolved in DMSO 
and treatments at the concentration of 175μM for 4 hours were performed as indicated 




Extracellular vesicle proteolytic activity 
 
Extracellular vesicles suspension was diluted in a solution with PBS-Triton X-100 
(Sigma Aldrich, Milan, Italy) at the final concentration of 0.1% and quantified with 
Bradford solution (Bio-rad California, United States). Different concentrations of 
extracellular vesicles (0.1, 0.5, 1μg) were incubated with 200ng of GST APE1WT, GST 
APE1K4pleA or rMAT APE1WT recombinant proteins and the reactions were performed 
at 37°C for 4 hours. The reactions were stopped adding Laemmly sample buffer 4x 
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(SDS, Glycerol, Tris-HCl 0.5M pH 6.8, β-mercaptoethanol, Bromophenol blue) and 
denaturing the samples for 5 minutes at 95°C. Each reaction was later loaded in 10% 





Proximity ligation assay 
 
For the experiment 2*10^4 JHH-6 cells were seeded on top of slides disposed inside a 
12-well plate. The following day cells were fixed for 20 minutes with 4% 
paraformaldehyde in PBS, and permeabilized for 5 minutes with 0.25% Triton X-100 
in PBS. After permeabilization, blocking for 1 hour with FBS 10% in PBS was 
performed. Later an incubation for 3 hours at 37°C with anti APE1 primary antibody 
(13B8E5C2, Novus), diluted 1 to 22 was executed. After incubation with anti APE1 
antibody, an O/N incubation at 4°C with hnRNPA2B1 antibody (PA5-34939, Thermo 
Fisher Scientific, Massachusetts, United States) diluted 1to 500 was made. The 
following day in situ Proximity Ligation assay technology (Duolink Sigma Aldrich, 
Milan Italy) was performed according to the manufacturer’s instructions. Images were 




miRNA targets functional enrichment analysis 
 
DE-miRNAs human validated targets were retrieved through the DIANA-MirPath v.3 
web-server178. Functional enrichment analysis was performed querying the Gene 
Ontology – Biological Process databases (p≤0.05), applying the “genes union” and 
“pathways union” methods. To reduce output redundancy and provide an easier 
visualization of the results, a graphical representation of raw data was obtained using 
GOrilla/REVIGO179,180  (default settings) and KEGG-PathwayConnector181  (Select score 
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to sort: Adjusted pvalue; Select sort order: Ascending Order; Select number of EnrichR 






Statistical analyses were achieved performing Two-way ANOVA test using GraphPad 
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ABSTRACT 
Late diagnosis for Hepatocellular Carcinoma (HCC) remains one of the leading 
causes for the high mortality rate. The apurinic/apyrimidinic endonuclease 1 (APE1), 
an essential member of the base excision DNA repair (BER) pathway, contributes to 
cell response to oxidative stress and has other non-repair activities. In this study,  
we evaluate the role of serum APE1 (sAPE1) as a new diagnostic biomarker and we 
investigate the biological role for extracellular APE1 in HCC. sAPE1 level was quantified 
in 99 HCC patients, 50 non-HCC cirrhotic and 100 healthy controls. The expression level 
was significantly high in HCC (75.8 [67.3–87.9] pg/mL) compared to cirrhosis (29.8 
[18.3–36.5] pg/mL] and controls (10.8 [7.5–13.2] pg/mL) (p < 0.001). The sAPE1 
level corresponded with its protein expression in HCC tissue. sAPE1 had high diagnostic 
accuracy to differentiate HCC from cirrhotic (AUC = 0.87, sensitivity 88%, specificity 
71%, cut-off of 36.3 pg/mL) and healthy subjects (AUC 0.98, sensibility 98% and 
specificity 83%, cut-off of 19.0 pg/mL). Recombinant APE1, exogenously added to JHH6 
cells, significantly promotes IL-6 and IL-8 expression, suggesting a role of sAPE1 as a 
paracrine pro-inflammatory molecule, which may modulate the inflammatory status in 
cancer microenvironment. We described herein, for the first time to our knowledge, that 




Hepatocellular  carcinoma  (HCC)   ranks   sixth   
as the most frequent cancer worldwide [1] with more  
than 800,000 new  cases  diagnosed  every  year.  The  
late diagnosis still remains one  of  the  leading  causes 
for the high mortality rate [1]. The recent molecular 
characterization of the disease [2] provided new insights 
into the cellular networks involved in hepatocarcinogenesis 
becoming a source of potential new therapeutic targets as 
well as new biomarker to use in a clinical setting. 
DNA repair pathways play a  significant  role  in 
the cellular and organismal response to environmental 
exposure by maintaining the genome integrity and thus 
helping to prevent the onset of disease, aging phenotypes, 
and cancer development. Tumor cells can develop drug 
resistance via repair mechanisms that counteract the DNA 
damage from chemotherapy or radiation therapy, and DNA 
repair enzymes are emerging targets for novel anticancer 
strategies [3, 4]. 
The base excision DNA repair (BER) pathway 
handles simple alkylation and oxidative lesions    arising 
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from both endogenous and exogenous sources, including 
cancer therapy agents [5]. The essential BER enzyme, 
the apurinic/apyrimidinic endonuclease 1 (APE1), 
contributes to the regulation of oxidative stress responses 
and has other non-repair activities, such as regulating   
the expression  of  chemoresistance  genes  through  
direct and indirect mechanisms [6, 7]. By using APE1 
knock-down models, we and others have demonstrated 
the pleiotropic ability of this protein to regulate the 
expression of hundreds of genes, involved in different 
biological processes, which are associated with cancer 
cell proliferation, invasion and drug resistance [8–11]. 
Interestingly, accumulating evidences indicate that APE1 
may control gene expression via unsuspected functions in 
RNA metabolism [5, 12, 13] including miRNA expression 
[10], thus enhancing APE1 critical functions in tumor 
progression. 
Well-known features linking APE1 and tumor 
development are its over-expression in many tumors and 
the correlation with the onset of chemoresistance in HCC 
and Non-Small Cell Lung Cancer (NSCLC), as well as 
neurologic, ovarian and breast tumors [11, 14]. Notably, 
its inhibition or down-regulation sensitizes cancer cells  
to DNA-damaging chemotherapeutic drugs and ionizing 
radiation [15]. Interestingly, a recent pioneering study 
found that plasmatic APE1 may represent a biomarker  
for predicting prognosis and therapeutic efficacy in 
NSCLC [16]. In fact, the chemotherapy-naïve serum 
APE1 level, which correlates with its tissue level, is 
inversely associated with progression-free survival of 
platinum-containing doublet chemotherapy; whereas post- 
treatment serum APE1 level is inversely associated with 
overall survival [16]. Interestingly, increasing evidences 
support the finding that extracellular APE1 secretion is    
a common feature of cancer cells, while the biological 
meaning remains to be elucidated but could be associated 
to triggering the inflammatory response of cancer 
microenvironment [17–19]. 
Despite several findings that associated APE1 to 
chemo- and radio resistance in tumors [16], marginal 
information exists in HCC. From our previous studies 
performed in cancer tissue biopsies, we defined a 
prognostic role for APE1 expression in HCC [20, 21]; 
however, nobody still evaluated the expression of APE1 
in serum (sAPE1) of HCC patients. 
Considering all these observations, we checked 
whether sAPE1 may serve as a biomarker for HCC. This 
work was undertaken to answer this issue and could 
represent a further step in biomarker discovery associated 
to patient’s prognosis, helpful to ameliorate therapy 
efficacy. Also, we show here that extracellular APE1 may 
contribute to triggering a pro-inflammatory state being 
able to promote IL-8 expression in a hepatic cancer cell 
line. Our novel findings open new perspectives in HCC 






The demographic features of the groups are shown 
in Table 1. The participants were predominantly male 
(78%, 62%, and 71%) with a median age of 72, 67, and 
56 years, respectively (p < 0.001). The etiology of chronic 
liver disease was alcohol abuse and/or metabolic in the 
majority of HCC and cirrhotic patients (55% and 40%, 
respectively), while viral hepatitis was in 23% and 16%. 
As of cirrhosis severity, most of the patients were 
CTP score A for 74% and 80%, whereas it was B or C in 
23% and 20% for HCC and cirrhosis group, respectively. No 
significant difference was noticed between the two groups. 
In HCC group BCLC 0, A, B, C/D scores were recorded 
in 7%, 59%, 26%, and 7% of patients, respectively. 
Regarding the prognosis scores, GRETCH score was 
intermediate in most patients (68%), low in 15%, and 
high in only 1%. CLIP score distribution appears to be 
more homogeneous, with a score 0 in 27% of the 
patients, score 1 in 32%, score 2 in 16%, and score 3/4 
in 9%. As regards ITA.LI.CA Prognostic, score 2 was in 
44%, score 3 in 21%, score 4 in 12%, and score >5 in 7%. 
ECOG score was 0 in the vast majority of HCC patients 
(85%), score 1 in 7%, and score 2/3 in 5% of the study 
group. No statistical differences exist among all groups. 
In HCC group, tumor mass, number of lesions, and the 
level of alpha-fetoprotein (AFP) were recorded. With respect 
to tumor mass and number of lesions, 15% subjects showed 
a single nodule smaller or equal to 2 cm in diameter, 47% 
had either a single nodule ranging 2 to 5 cm, or 2–3 nodules 
up to 3 cm each, while 37% had single nodule larger than   
5 cm in diameter or multifocal. As for AFP level, 53% had 
AFP level lower than 20 ng/mL, 13% between 20 ng/mL 
and 400 ng/mL, and 12% with AFP level above 400 ng/mL. 
 
Serum APE1 level significantly distinguishes 
HCC from cirrhotic patients and healthy subjects 
The level of sAPE1 was measured by ELISA and 
expressed as median (95% CI), as previously described 
[16]. As a validation of the specificity of the ELISA assays 
used, we included a pool of blood donors’ sera spiked with 
different concentrations of recombinant purified APE1 
protein (data not shown). 
The highest concentration of sAPE1 was found in 
HCC, with median concentration of 75.8 (67.3–87.9) pg/ 
mL with a minimum and maximum value of 15.2 and 
881.4 pg/mL, respectively, and it was significantly higher 
(p < 0.001) compared to median concentration in either 
cirrhosis (29.8; 18.3–36.5 pg/mL) or healthy blood donors 
of (10.8; 7.5–13.2) (Figure 1A). sAPE1 was undetectable 
in 36 (36%) of healthy and in 10 (20%) of cirrhotic 
samples. A significant difference was observed also in 
cirrhosis compared to healthy control (p < 0.001). 
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Table 1: Demographic characteristics of the study populations 
 HCC Cirrhosis Healthy P value 
Patients characteristics     
Age (mean, 95%CI) 71 (68.8–72.1) 66 (63.6–68.3) 56 (55.1–56.6) <0.001 
Sex (M/F) 77/22 31/19 71/29 ns 
Etiology    ns 
Alcohol metabolic 54 20   
Alcohol metabolic viral 18 17   
Viral 23 8   
Other* 4 5   
Disease scores     
CTP A/B/C 73/20/3 40/7/3  ns 
BCLC 0/A/B/C–D 7/58/26/6    
ECOG 0/1/2–3 84/7/5    
GRETCH Low/Intermediate/High 15/67/1    
CLIP 0/1/2/3–4 27/32/16/9    
ITA.LI.CA Prognostic 2/3/4/5–8 44/21/12/7    
Tumor parameters     
Number of lesions     
Single <2 cm 15    
Single or 3 <3 cm 46    
Large-single or multi 37    
Alpha fetoprotein     
<20 ng/mL 52    
20–400 ng/mL 13    
>400 ng/mL 12    
*autoimmune, hemochromatosis, cryptogenic, usually in combination with other. 
 
Circulating sAPE1 as diagnostic biomarker for HCC 
 
When considering the diagnostic value of sAPE1, 
the area under the curve (AUC) of the receiver operator 
characteristic (ROC) curve was  0.87  (0.78–0.92)  
(Figure 1B). Using a cut-off of 36.3 pg/mL, sAPE1 can 
distinguish HCC patients from cirrhotic subjects with 
sensitivity and specificity of 88% and 71%, respectively. 
When considering the predictive value of sAPE1 in 
distinguishing HCC patients from healthy subjects, the 
AUC score improves to 0.98 (0.96–0.99) (Figure 1C). At 
a cut-off determined at 19.0 pg/mL, the sensibility and 
specificity increased to 98% and 83%, respectively. 
 
sAPE1 level in HCC is associated with viral 
infection but not with other clinical parameters 
sAPE1 levels were significantly higher when 
comparing HCC-related viral infection to other non-viral 
etiologies (p < 0.001). In patients with either viral hepatitis 
C or B infection, the median sAPE1 was 98.8 (85.4–141.1). 
However, highest sAPE1 level was observed in patients 
with multiple etiologies (viral, metabolic, and alcohol) 
with median concentration of 132.37 (84.3–208.2). 
The association of sAPE1 level and clinical and 
pathological characteristics  of  HCC  patients  was  shown  
in Table 2. With respect to HCC staging and prognostic 
scores, there was a significant correlation between sAPE1 
and GRETCH score, but not with any other HCC scores.   
No correlation with other clinical parameters, such as AFP, 
transaminases, transferrin, albumin, and insulin was observed. 
 
APE1 expression is higher in HCC compared to 
its surrounding and normal tissue 
In order to determine whether high sAPE1 levels 
found in HCC tumor samples correlate with an overall 
overexpression of APE1 both at protein and mRNA 
levels, Western blot analysis and qPCR were performed  
in non-tumor and tumor tissue of liver cancer. APE1 
mRNA expression was analyzed in 59 tissues from 24 
HCC patients, and 4 normal liver (CTRL). As shown    in 
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Figure 2A, an increase of APE1 mRNA was observed in 
HCC as compared either to the SLC and peri-HCC or also 
to normal liver (CTRL). When the mRNA expression was 
compared in paired samples of HCC to its corresponding 
SLC and peri-HCC, the ratio of mRNA up-regulation 
between HCC/SLC and HCC/peri-HCC was 4.9 ± 6.9 and 
5.8 ± 11.3-fold, respectively. 
APE1 protein levels were quantified in tissues  
from patients with high sAPE1 levels. Analysis were 
performed either within single patients (Figure 2B and 
Supplementary  Figure  1)  and  pooled  samples  (Figure 
2C). APE1 protein expression levels were determined by 
densitometric scanning of the immunoreactive bands and 
normalized against actin loading control. Besides the full- 
length protein band, a truncated form of the protein was 
detectable (Figure 2C), corresponding to a proteolytic form 
called NΔ33 (Supplementary Figure 2) [22]. A significant 
increase of APE1 total protein was observed in tumor 
samples, particularly in the full-length form (Figure 2C). 
These results were confirmed by immunohistochemistry 
staining (Figure 2D), where APE1 protein resulted highly 




Figure 1: sAPE1 level in circulation. (A) circulating sAPE levels in healthy blood donors, cirrhosis and HCC groups. ***P < 0.001 
among groups. (B) ROC curve for HCC diagnostic from cirrhosis with AUC score of 0.87 (0.78–0.92, 95%CI) with 36.3 pg/mL as a cut-off. 
(C) ROC curve for HCC diagnostic from healthy blood donors with AUC score of 0.98 (0.96–0.99, 95%CI) with 19.0 pg/mL as a cut-off. 
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 Count Median (95% CI) p value 
Age   ns 
<72 52 74.2 (60.5–96.4)  
>72 47 78.8 (66.2–103.7)  
Sex   ns 
Male 77 73.9 (63.2–87.2)  
Female 22 97.1 (65.0–122.9)  
Etiology   <0.001 
Alcohol metabolic 54 62.6 (48.6–73.9)  
Alcohol metabolic viral 18 132.37 (84.3–208.2)  
Viral 23 98.8 (85.4–141.1)  
Other* 4 63.2  
CTP   ns 
A 73 78.8 (65.0–96.4)  
B/C 23 70.76 (44.5–128.6)  
BCLC   ns 
0-A 65 77.3 (60.5–96.4)  
B-C-D 32 74.5 (48.6–101.3)  
GRETCH   <0.05 
Low 15 60.5 (33.0–101.3)  
Intermediate-high 68 83.2 (68.1–91.1)  
CLIP   ns 
0–1 59 78.7 (67.3–97.7)  
2–3–4 25 71.6 (56.1–114.7)  
ITA.LI.CA prognostic   ns 
2 44 87.1 (69.7–107.8)  
3 21 74.6 (56.1–108.7)  
4 12 53.5 (32.3–159.2)  
5–8 7 71.6 (40.3–138.3)  
Number of lesions   ns 
Single <2 cm 15 86.9 (43.8–120.4)  
Single or 3 <3 cm 46 74.6 (60.5–117.9)  
Large-single or multi 37 74.5 (61.2–89.5)  
AFP   ns 
<20 ng/mL 52 76.7 (65–87.2)  
20–400 ng/mL 13 138.3 (37.1–179.9)  
>400 ng/mL 12 80.5 (43.8–122.9)  
 
 
while it was not noticed in normal liver. In SLC, the positivity 
of APE1 was mostly noticed in the nucleus, while in HCC 
tissues, both strong nuclear and cytoplasmic expressions were 
detected. To  check whether the sAPE1 might be    correlated 
 
with its expression in HCC nodule,  the  level  of  sAPE1  
and hepatic APE1 protein were compared within the same 
patients. As shown in Figure 2E, the high sAPE1 expression 
corresponded with that found in HCC nodules. 
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Recombinant exogenously added APE1 protein 
promotes the expression of IL-6 and IL-8 genes 
in JHH-6 cell line 
In order to evaluate a possible role for secreted 
APE1 in HCC, we tested whether exogenous addition of 
recombinant purified APE1 (rAPE1) may trigger a pro- 
inflammatory status in JHH-6 HCC cell line, as   recently 
demonstrated in human monocytes cell lines [19]. In 
addition to the wild-type  protein  (rAPE1WT),  we  used 
an acetylated-mimicking mutant  on  residues  27,  31,  
32, 35 (rAPE1K4pleA), in which Lys residues have been 
replaced by Ala, as described before [23, 24] and whose 
relevance in cancer have been recently demonstrated [22] 
(Supplementary Figure 3). As previously described, cells 




Figure 2: APE1 expression in HCC tissues. (A) qPCR of tumor (HCC), peri-HCC, and surrounding liver cirrhosis (SLC), and 
normal liver (CTRL) (left panel). Ratio between HCC and SLC and HCC and peri-HCC within the same patients (right panel). APE1 
mRNA quantification was normalized to two reference genes 18srRNA and Actin. Bar graphs indicate mean and SEM. (B) APE1 protein 
quantification in HCC and SLC tissue lysates from HCC cancer patients. Graphs indicate the different distributions of the fold of protein 
expression for each sample as the ratio between APE1 and actin. (see Supplementary Figure 1). *P < 0.05. (C) Western  blot analysis      
of HCC and SLC tissue lysates patients performed on pooled samples from HCC cancer. Actin was used as loading control and for the 
relative normalization. A representative image of western blot analysis is shown. Data represent the means of ± SD of three independent 
experiments. *P < 0.05. (D) Immunohistochemistry of HCC, SLC, and normal (CTRL) tissue. Red and yellow arrows indicate nuclear and 
cytoplasmic positivity, respectively. (E) Scan of HCC nodules and its corresponding sAPE1 from 3 patients representing for each low, 
median, and high sAPE1. 
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purified proteins, and the expression of IL-6 and IL-8 
genes was assayed by qPCR. APE1 recombinant proteins 
induced an upregulation of both cytokines in treated 
cells; the rAPE1K4pleA promoted a higher increase of IL-
6/IL-8 compared to rAPE1WT (Figure 3A). The cells 
responsiveness to a proinflammatory stimulation was 
verified by treating cells with rTNF-α (Figure 3B). This 
stimulatory activity of rAPE1 was also confirmed, even  
to different extents, in other cancer cell lines, such as: 
A549 from lung cancer, confirming the  generality  of 
this phenomenon that requires further additional careful 
characterization. However, we checked the stimulatory 
activity by rAPE1 using also GST-tagged rAPE1 as well 
as recombinant Glutathione –S-Transferase (a bacterial 
protein) alone obtained from the same E. coli strain. Data 
obtained (not shown) clearly demonstrated that, while 
GST-APE1 exerts the same stimulatory activity of rAPE1, 
the GST alone did not produce any effect on IL-6/-8 
induction, eliminating the possibility of IL-6/-8 induction 
by any contaminating LPS or other proteins. These data 
suggest a role of sAPE1 as a paracrine pro-inflammatory 
molecule, which may modulate the inflammatory status in 
cancer microenvironment. However, in clinical samples 
there were not significant correlation between sAPE1 
with both IL-6 and IL-8 levels in sera and in tissues 




In the present study, we found that sAPE1 protein, 
an essential DNA repair enzyme in the BER pathway, 
could be a promising diagnostic biomarker for HCC 
patients. Interestingly, this previously reported nuclear 
protein has been recently detected in the serum of patients 
of coronary artery disease [25] and bladder cancer patients 
where its level correlated with the level measured in 
cancer tissue [26]. More recently, this unexpected finding 
was confirmed in the plasma of both lipopolysaccharides- 
induced endotoxemic rats [27] and in NSCLC human 
patients [16], opening new perspectives in understanding 
the many functions of this unusual DNA repair protein   
in different conditions associated to oxidative stress and 
cancer development. We report that the sAPE1 levels 
correlate with its level in HCC tissue, in line with previous 
findings in non-small cell lung cancer [16]. 
The secretion of this protein seems to be a regulated 
phenomenon, depending on acetylation occurring on 
specific Lysine residues [17]. The biological relevance  
of secreted APE1 is still a matter of debate. It has been 
demonstrated that acetylated-APE1 may trigger apoptosis 
in TNBC cells by binding to the receptor for advanced 
glycation end products (RAGE) [28]. Other recent data 
demonstrated that the redox-function of APE1 may 
contribute to the control of the inflammatory response by 
inhibiting the TNF-α-induced endothelial inflammation 
via  thiol-disulfide  exchange  in  TNFR  [18]. Moreover, 
very recently, a role for extracellular APE1 in the control 
of early stages of inflammation processes has been 
proposed [19]. Treatment of human THP-1 and RAW264.7 
monocytes with rAPE1 increased the expression and 
secretion of the pro-inflammatory cytokine IL-6, through 
the involvement of NF-κB transcriptional activation, 
eliciting an autocrine/paracrine cellular response in a 
functional feedforward loop between APE1 and IL-6 
regulation.  However,  detailed  information  regarding 
the mechanism responsible of APE1 release is still 
controversial, though it seems plausible that it might occur 
through extracellular vesicles formation via endosomal 
sorting complex [19]. 
Therefore, as a mainly nuclear protein, the source 
of sAPE1, whether it be from normal or cancer cells,      
is currently unknown and it is the focus of ongoing 
investigations. In our present study, we show a direct 
correlation between serum and tissue  APE1  levels  in 
the cohort we analyzed. We already described that the 
cytoplasmic expression of the protein in HCC patients 
correlates with poor prognosis, but we could not provide a 
significant biological role for cytoplasmic APE1 in HCC 
[20]. APE1 is a non-canonical secretory protein lacking   
a classic secretory signal based on protein sequence 
analysis. Intriguingly, several reports showed that APE1 
is secreted under specific stimuli, such as those provided 
by Trichostatin-A [17] and LPS [19, 27]. According to 
these studies, secretion of APE1 was associated with its 
cytoplasmic translocation; however, in the present study, 
we failed to find a positive correlation between sAPE1 
and its cytoplasmic distribution in HCC. Future work is 
warranted to inspect the secretory pathway of APE1 and 
its biological relevance. We believe that a passive release 
of sAPE1 by a necrotic process is unlikely, as its level 
does not correlate with any of the markers of liver damage 
analyzed. Moreover, cultured JHH-6 liver cancer cell lines 
do actively secrete APE1 in the culture media (data not 
shown) supporting the hypothesis that sAPE1 derives 
from an active secretion process involving, for instance, 
an exosomal pathway. Work is ongoing in our lab along 
this line to test this hypothesis. 
Regarding the biological relevance of APE1 
secretion, we found that recombinant exogenously added 
rAPE1 is able to promote IL-6/8 gene expression in JHH- 
6 HCC cell line. Two of the major pro-inflammatory 
cytokines secreted by senescent cells, IL-6 and IL-8, may 
function either to reinforce senescence [29] or to promote 
tumor invasiveness [30]. Thereafter, regulation of the 
inflammatory environment may have a critical role in 
determining the fate of both senescent and proliferating 
tumor cells. Based on the evidence that exogenous rAPE1 
may trigger expression of both IL-6/8 cytokines, we may 
hypothesize that secreted APE1 may act as a paracrine 
molecule in regulating tumor microenvironment cell 
decision fates. These findings provide new insight into 
the  underlying  the  clinical  and  biological  relevance of 
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Figure 3: Recombinant APE1 promotes IL-6 and IL-8 mRNA expression in JHH-6 HCC cell line. (A) JHH-6 cells were 
treated for 24 h in serum free medium with recombinant rAPE1WT and rAPE1K4pleA proteins (1–2 μg/ml concentration). 24 h serum free 
medium JHH-6 cells were used as a control (CTR). Performed qPCR analyses show that rAPE1K4pleA recombinant protein promotes an 
induction of IL-6 and IL-8 mRNA expression levels. (B) IL-6 and IL-8 induction in JHH-6 TNF-α treated cells. JHH-6 cells were treated for 
3 h in serum free medium with TNF-α (2000 U/ml concentration). Performed qPCR analyses show the induction of IL-6 and IL-8 mRNA 
expression mediated by TNF-α. Statistical analyses were achieved by using Two-way ANOVA test. 
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circulating sAPE1, however, future work is needed to 
address these issues, which may have a strong relevance 
in the clinics of HCC prognosis and therapy. 
 




This case-control study was conducted in patients 
referring to the Liver Center of the University Hospital of 
Trieste, Italy. Fasting blood samples were collected in three 
groups: 99 consecutive patients patients observed between 
2008 and 2018 whose HCC was diagnosed according to 
the EASL criteria [31]; 50 consecutive patients with 
cirrhosis confirmed by imaging, elastography, blood 
tests, and/or histological evaluation, without echographic 
evidence of HCC observed between April and June 2018; 
100 consecutive healthy blood donors recruited in 2018 at 
the Transfusion Clinic. 
Cirrhosis and HCC groups were further defined 
according to Child-Turcotte-Pugh score (CTP) and 
etiology (i.e. viral, alcoholic, metabolic, and other 
uncommon etiologies). For HCC group, classifications  
of Barcelona Clinic Liver Cancer (BCLC) [31], Eastern 
Cooperative Oncology Group (ECOG) [32], GRoupe 
d’Etude et de Traitement du Carcinoma Hépatocellulaire 
(GRETCH) [33], Cancer of Liver Italian Program (CLIP) 
[34], and the Italian Liver Cancer (ITA.LI.CA) [35] 
prognostic were defined. HCC samples were collected at 
the time of diagnosis, before any oncological treatment. 
Exclusion criteria for all groups were age lower 
than 18 years old, pregnancy, and other malignancies.  
All the patients provided written informed consent and 
patient anonymity has been preserved. Investigation was 
conducted according to the principles expressed in the 
Declaration of Helsinki. The study was approved by the 
regional ethical committee (Comitato Etico Regionale 
Unico del Friuli Venezia Giulia, Prot. No. 2018 Os-008- 
ASUITS, CINECA no. 2225). 
 
Serum samples collection and sAPE1 quantification 
 
Serum samples were collected in Vacuette® tubes, 
centrifuged at 3500 rpm for 10 min and stored at –80°C 
until use.  Hemolyzed  samples  were  discarded  from  
the analysis. Hemoglobin in serum was assessed with 
Beckman Coulter®DU®730 spectrophotometer using the 
Harboe Direct method [36] with Allen correction [37]. 
The considered cut-off for serum was 0.040 g/L. sAPE1 
levels were determined using Human APEX1 ELISA kit 
(Cusabio, Houston, USA). The optical density (OD) was 
detected with an EnSpire microplate reader (PerkinElmer, 
Waltham, USA), at a wavelength of 450 nm with a 
correction set at 540 nm. sAPE1 levels (pg/mL) were then 
calculated by using a standard linear regression curve 
fitting by NCSS 11  Statistical Software (2016)    (NCSS, 
LLC. Kaysville, USA). To determine the specificity of the 
test we spiked into blood donors’ serum 62.5 and 31.25 
pg/mL of rAPEX1. We use the curve-fitting model built 
on OD vs sAPE1 concentration (pg/mL) to estimate the 
concentration of the two spiked samples (data not shown). 
 
HCC tissues collection and hepatic APE1 mRNA 
and protein expression 
Fresh hepatic tissues were collected from HCC 
patients undergoing liver resection without any prior 
treatments. Samples consisted of HCC nodule, peri-  
HCC and surrounding liver cirrhosis (SLC). Tissues were 
quickly snap-frozen and stored in –80°C. 
 
Real time PCR 
 
Total RNA was extracted using TriReagent (Sigma– 
Aldrich) and reversed transcribed using the iScript cDNA 
synthesis Kit (Bio-Rad Laboratories, Hercules, USA) 
according to the manufactures’ protocols. Reactions were 




Lysates were resolved on 12% SDS-PAGE, 
transferred onto nitrocellulose membranes (Amersham™ 
Protran™, GE Healthcare) and probed with antibodies for 
APE1 (NB 100-116, Novus Biologicals, USA) (1:1000), 
APE1 N-terminal 1-14 aa specific goat polyclonal 
Antibody (NB100-897, Novus Biologicals) (1:2000) and 
actin (A2066, Sigma–Aldrich) (1:2000) as internal control. 
The IR-Dye labelled secondary antibodies (anti-rabbit IgG 
IRDye 680 and anti-mouse IgG IRDye 800) were used. 
Detection and quantification was performed with the 
Odyssey CLx Infrared imaging system (LI-COR GmbH, 
Germany). The membranes were scanned in two different 
channels using an Odyssey IR imager; protein bands were 
quantified using Odyssey software (Image Studio 5.0) and 




Paraffined hepatic slices  were  de-paraffinized  
with xylene and rehydrated with gradual concentration  
of ethanol. Tissues were incubated with APE1 antibody 
(NB100-101, Novus Biologicals, USA) followed by 
incubation with primary universal antibody enhancer and 
HRP polymer (Thermo Fisher Scientific, Cheshire, UK). 
The complex was visualized with the DBA peroxidase 
substrate kit (Vector Laboratories, UK) and nucleus was 
stained with hematoxylin. Slides were scanned by using 
Zenit G Sight 2.0 (A.Menarini Diagnostics, Italy) and 
images were generated using two microscopical systems 
Leica DM2000 (Leica, Wetzlar, Germany) and Zenit G 
Sight 2.0. 
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Cell culture and treatments 
 
JHH-6, an undifferentiated HCC cell line, were 
grown in William’s medium E (Sigma–Aldrich), 
supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, 100 μg/ml streptomycin (Euroclone, Milan, 
Italy). A total of 1.5 × 105 JHH-6 cells were seeded in six- 
well plate for 24 h. For rAPE1 treatment, cells were treated 
for 24 h with rAPE1WT or rAPE1K4pleA with concentrations 
1 μg/mL and 2 μg/mL in serum-free medium. While for 
TNF-α treatment, cells were treated with recombinant 
human TNF-α (Peprotech Inc., Rocky Hill, NJ) in serum- 
free medium using the same condition reported in [38]. 
Total RNA was extracted from JHH-6 treated cells using 
NucleoSpin® RNA kit (Machery Nagel, Düren, Germany) 
according to the manufacturer’s instructions and reverse 
transcribed using SensiFAST cDNA Synthesis Kit (Bioline 
GmbH, Luckenwalde, Germany). qRT-PCR was performed 
with CFX96 Real-Time System, using SensiFAST™ SYBR® 
No-ROX Kit (Bioline GmbH, Luckenwalde, Germany). 
APEX, IL6 and IL8 mRNA expressions  were normalized  
to GAPDH and HPRT expression. The primers used were 
included in Supplementary Table 1. 
 
Recombinant APE1 protein expression and FPLC 
purification 
Expression and purification of rAPE1 proteins from 
E. coli were performed as previously described [24, 39]. 
Briefly, E. coli BL21(DE3) cells were transformed with 
the construct pGex2T-APE1, coding for the glutathione 
S-transferase (GST)-APE1 full-length protein and for the 
APE1 acetylated mutant (K27A, K31A, K32A, K35A) and 
induced for 4 hours with 1.0 mM IPTG (Sigma–Aldrich) 
and collected upon centrifugation. The pellet was lysed 
and sonicated in the presence of protease inhibitor 2.1 mg/ 
mL and Lysozyme 0.3 mg/mL. Samples were centrifuged 
at 23000 g for 20 minutes at 4°C, the supernatants were 
filtered and FPLC purified. 
GST-tagged proteins were purified through a 
GSTrap column (GE Healthcare) and they were eluted   
in an increasing range of GSH concentration following 
the manufacturer’s instructions. The proteins were 
incubated with Factor X (Amersham) to remove the tag 
and separated from the enzyme through a benzamidine 
column (GE Healthcare). A cation exchange purification 
was performed. The fractions were pooled together and 
stored in buffer containing 25 mM Tris pH 7.5, 100 mM 




Serum APE1 differences in a pairwise comparison 
were calculated by Mann–Whitney U. Differences among 
groups were calculated by Kruskal-Wallis test in one way 
ANOVA, with Bonferroni correction. The receiver operating 
characteristic  (ROC)  curves  were  plotted  to estimate the 
diagnostic value of sAPE1. Analyses were performed by 
using NCSS 11 Software (2016) (NCSS, LLC. Kaysville, 




AFP, Alpha-fetoprotein; APE1, Apurinic/ 
apyrimidinic endonuclease 1; AUC, Area under the 
curve; BCLC, Barcelona Clinic Liver Cancer; BER,  
Base excision DNA repair; CLIP, Cancer of Liver Italian 
Program; CTP score, Child-Turcotte-Pugh score; CTRL, 
Control; DDR, DNA damage responses; ECOG, Eastern 
Cooperative Oncology Group; GRETCH, GRoupe 
d’Etude et de Traitement du Carcinoma Hépatocellulaire; 
HCC, Hepatocellular Carcinoma; ITA.LI.CA, Italian 
Liver Cancer; NSCLC, Non-Small Cell Lung Cancer; 
OD, Optical density; rAPE1, recombinant apurinic/ 
apyrimidinic endonuclease 1; rAPE1K4pleA, acetylated- 
mimicking mutant recombinant APE1 on residues 27, 31, 
32, 35; rAPE1WT, recombinant wild-type APE1 protein; 
ROC curves, receiver operating characteristic curves; 
sAPE1, Serum apurinic/apyrimidinic endonuclease 1; 
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Alterations of DNA repair enzymes and consequential triggering of aberrant DNA damage 
response (DDR) pathways are thought to play a pivotal role in genomic instabilities associated with 
cancer development, and are further thought to be important predictive biomarkers for therapy 
using the synthetic lethality paradigm. However, novel unpredicted perspectives are emerging 
from the identification of several non-canonical roles of DNA repair enzymes, particularly in 
gene expression regulation, by different molecular mechanisms, such as (i) non-coding RNA 
regulation of tumour suppressors, (ii) epigenetic and transcriptional regulation of genes involved 
in genotoxic responses and (iii) paracrine effects of secreted DNA repair enzymes triggering the 
cell senescence phenotype. The base excision repair (BER) pathway, canonically involved in the 
repair of non-distorting DNA lesions generated by oxidative stress, ionising radiation, alkylation 
damage and spontaneous or enzymatic deamination of nucleotide bases, represents a paradigm 
for the multifaceted roles of complex DDR in human cells.This review will focus on what is known 
about the canonical and non-canonical functions of BER enzymes related to cancer development, 
highlighting novel opportunities to understand the biology of cancer and representing future 
perspectives for designing new anticancer strategies. We will specifically focus on APE1 as an 




Tumour cells can develop drug resistance via repair mechanisms that 
counteract the DNA damage induced by chemo- and radiotherapies. 
DNA repair enzymes are therefore possible targets for promising 
and novel anticancer strategies (1,2), in which specific DNA repair 
inhibitors are combined with DNA-damaging agents to improve 
current anticancer therapies. In parallel, some cancer cells show a 
reduced repertoire of DNA damage responses (DDRs), which pro- 
vide other therapeutic possibilities, relying on the synthetic lethality 
paradigm. Indeed, many polymorphic variants of DDR  enzymes  
have been described in the whole population, but their causal link 
with genome instability, associated with tumour development, is still 
controversial. Emerging evidence in tumour biology has shown that 
RNA processing pathways participate in DDR, and that defects in 
these regulatory connections are associated with genomic instability 
in cancers (3,4). Indeed, many DNA repair proteins interact with 
proteins involved in RNA metabolism, non-coding RNA (ncRNA) 
processing and gene transcriptional regulation (5), indicating a sub- 
stantial role of the deriving interactome network in determining 
their non-canonical functions, thus impacting gene expression in tu- 
mour cells. Moreover, recent studies have shown several interactions 
among DDR  components  and  microRNAs  (miRNAs)  and,  notably, 
a dysregulation of the miRNA biogenesis process has been linked 
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to cancer development (2). Importantly, the molecular mechanisms 
of miRNA processing and/or decay during genotoxic stress are still 
largely unknown, but it is possible that enzymes of the DNA repair 
pathways may be protagonists. We have recently reported that en- 
zymes of the base excision DNA repair (BER) pathway play a crucial 
role in these molecular processes (6,7). Due to its function in the 
maintenance of genome stability under conditions of oxidative stress 
as well as exposure to DNA damaging agents used in chemotherapy, 
and its central involvement in transcriptional regulatory circuits, the 
BER pathway represents an unexpected and intriguing opportunity 
to identify novel cancer biomarkers and design new anticancer strat- 
egies. These findings prompted us to study the role of BER proteins 
in a different way, to understand their real contribution to the onset 
of cancer. These findings will help us to better understand the role of 
these enzymes from benchtop to bedside using a powerful transla- 
tional perspective. This review will focus on what is known of the ca- 
nonical (canonical DNA repair of DNA damage) and non-canonical 
functions (transcriptional, immunological, or repair of RNA-decay/ 
processing) of BER enzymes, to link these functions with the biology 
of cancer. 
 
Focus on the canonical roles of the BER 
pathway in DNA repair and telomere 
maintenance 
Exposure to endogenous (i.e. mitochondrial respiration and inflam- 
matory processes) or exogenous (i.e. ionising radiation, chemotherapy 
treatment by alkylating agents and antimetabolites) damaging ef- 
fectors including deaminating agents, triggers an accumulation of 
non-bulky single base lesions on both nuclear and mitochondrial 
DNA (8,9), which can be efficiently repaired by the BER pathway. 
Thus, this pathway, which is largely conserved from Bacteria to 
Eukaria, preserves genomic integrity (10). The first enzymatic step in 
the BER pathway involves lesion-specific DNA glycosylase activity.  
In mammalian cells, each of the 11 existing N-glycosylase proteins 
differs from the others in its mechanism of action, substrate spe- 
cificity and excision kinetics (11–13). Generally, the recognition of 
specific damaged bases occurs through a flipping out mechanism fol- 
lowed by a sophisticated process involving excision of the damaged 
base (14), thus leaving an abasic (AP) site. DNA glycosylases are 
classified into mono- and bifunctional glycosylases on the basis of  
the type of recognised damaged site and on the mechanism of action. 
Monofunctional DNA glycosylases, e.g. uracil DNA glycosylases 
(UDG), including the mitochondrial uracil N-glycosylase (UNG1), 
nuclear UNG2 and a single strand selective monofunctional uracil 
DNA  glycosylase  (SMUG1),  process  uracil,  thymine  and  alkyl- 
ated bases, to cleave the C1-N-glycosidic bond, leaving an AP  site 
and liberating a nucleobase.  Bifunctional  glycosylases,  including  
the  8-oxo-7,8-dihydroguanine  DNA  glycosylase  (OGG1),  NTH1  
and  the  Nei-like  DNA  glycosylase  (NEIL)  family,  cleave  oxida-  
tive lesions and display, in addition to their glycosylase activity, an 
extra AP-lyase  activity  (15). As  already  demonstrated  by  Hill et al. 
(16) and by our recent work  (7), OGG1  activity  is  stimulated  by 
the presence of APE1 endonuclease, an enzyme that acts following 
OGG1 during the BER pathway. After the recognition of damage, 
bifunctional glycosylases use an amine nucleophile, such as a lysine 
side chain, to cleave the N-glycosidic bond, generating a Schiff base 
(imine) intermediate (17). Subsequently, through their AP-lyase ac- 
tivity, they cleave the DNA phosphodiester backbone on the 3′ side  
of the lesion, through a β-elimination resulting in a single-strand 
break. Moreover, some  of  them  perform  a  second  cleavage  on the 
DNA phosphodiester backbone on the 5′ side of the lesion through    
a δ-elimination process (18). Although the importance of the BER 
pathway has been clearly demonstrated using BER gene knock-out 
models, resulting in embryonic or early postnatal lethality (19), it 
has been reported that a high variety of glycosylases in mamma-   
lian cells causes a significant redundancy in their damage selectivity, 
which would explain why a single knock-out of one of the multiple 
DNA glycosylases is not always lethal   (14). 
After the hydrolysis of the N-glycosidic bond by DNA 
glycosylases, the newly generated AP site must be processed by a 
specific apurinic/apyrimidinic endonuclease (20). Furthermore, a 
spontaneous depurination of DNA also occurs very frequently. It has 
been estimated that, considering only spontaneous hydrolysis of the 
N-glycosidic bond, up to 10 000 abasic sites are formed per day/cell 
in higher eukaryotes (21,22). Unrepaired abasic sites are mutagenic 
and lethal for the cell, so it is clear that their repair is imperative (23). 
In this context, the apurinic/apyrimidinic endonuclease 1 (APE1) is 
the only enzyme having a role in DNA repair (24,25). Embryonic 
lethality as a consequence of the deletion of the ape1 gene high- 
lights the importance of APE1, which is not only restricted to the  
BER pathway, but is also related to all its physiological cellular 
functions (26). APE1 is a monomeric protein, structured in a α/β- 
sandwich globular fold coupled to a 48-amino acid, unstructured 
part in the N-terminal portion (27). Through its C-terminal globular 
region (residues 61–318), mainly responsible for endonuclease ac- 
tivity (28), APE1 specifies the presence of abasic sites among any 
normal nucleoside, principally distorting the  DNA  backbone  with 
an 35°-angled extrahelical distortion (29). When the APE1–DNA 
complex is formed, an additional rearrangement is needed to allow 
the efficient execution of the hydrolytic reaction. The presence of 
Mg2+ (or Mn2+) ions, positioned in the active site of APE1 and prin- 
cipally coordinated by the E96 residue, is necessary to promote this 
rearrangement and to allow for cleavage of the AP site (30). The 
excision of the phosphodiester bond, at the 5′ side of the AP-site,  
also requires a water molecule acting as a nucleophile (31). The ac- 
tive site of the endonuclease is defined by several residues including 
His-309,  Glu-96, Asp-283, Thr-265, Tyr-171,  Asn-68, Asp-210,   Asp- 
70 and Asn-212, which are mostly involved in hydrogen bonding 
(31–33). Through this pocket site, APE1 is also active on damaged 
single-stranded DNA (ssDNA), suggesting a possible role in tran- 
scription, replication and/or recombination (34). Furthermore, in 
vitro studies have demonstrated the capability of APE1 to act as a    
3′ DNA phosphatase and 3′→5′ DNA exonuclease on mismatched 
deoxyribonucleotides located at the 3′-end of nicked or  gapped  
DNA (35–37). Recently, great importance has also been ascribed to 
the APE1 N-terminal region (1–127 residues), which is responsible 
for protein–protein interactions, RNA interactions (residues 1–33) 
and redox-dependent activities (38). Among all the well-known 
interactions of APE1 (39), nucleophosmin (NPM1) is a paradig- 
matic example of how APE1 functions may be modulated by protein 
interacting partners, thus impacting tumour biology (40). As dem- 
onstrated in acute myeloid leukemia (AML), cells expressing a nu- 
cleolar deficient form of the NPM1 protein (i.e. NPM1c+) have an 
altered APE1–NPM1 functional interaction with consequential BER 
impairment (40,41). This finding supports the hypothesis that an al- 
teration of APE1 interactions may be causally involved in cancer de- 
velopment and chemoresistance. Moreover, the N-terminal region of 
APE1 is also subjected to different post-translational modifications 
(PTMs) (42). Although its functional relevance is still controversial, 
the most well-known PTM of APE1 is the cleavage of the first 33 
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signal sequence, leading to the accumulation of protein within the 
cytoplasmic compartment, and impairing the ability of the protein   
to interact with its canonical protein partners, including NPM1. 
Moreover, it has been clearly shown how the removal of the first     
33 amino acids does not affect the APE1 binding affinity for the 
abasic site, but, in contrast, increases the enzymatic catalysis when 
compared with the full-length protein (38,43,44). Up to now, the 
protease responsible for the cleavage is still unknown, even though 
it has been suggested that a Granzyme-like factor could play a role 
(45). Beyond the N-terminal cleavage, a well-known in vitro and in 
vivo PTM of APE1 is represented by acetylation. Different lysine 
residues, including the lysine 27–35 (K27–K35) cluster could be sub- 
jected to acetylation (46). In acetylated (acAPE1), the positive charge 
of the N-tail of APE1 is neutralised, triggering a conformational 
change of the whole protein. Thus, acAPE1 is more prone to asso- 
ciate with chromatin, and less prone to interact with NPM1. A de- 
crease of the APE1–NPM1 interaction, as a consequence of APE1 
acetylation, determines inhibition of the APE1 accumulation within 
nucleoli (44,47) and an enhancement of its AP endonuclease activity 
due to an increase of the speed of product release upon cleavage 
(38,46,48). The observed effects of the PTMs occurring on the N-tail 
of APE1 highlight how the N-terminal region may indirectly influ- 
ence the BER activity of APE1. Currently, the acetylation of APE1 is 
the main PTM of APE1 detected in vivo, as described in the subse- 
quent paragraphs. 
Upon AP cleavage promoted by APE1, a single-strand break 
bearing a free hydroxyl (OH) group at the 3′ end and a deoxyribose 
phosphate (dRP) at the 5′ end is generated. In this phase, BER could 
follow two alternative sub-pathways. In the classical mechanism, 
also called ‘short patch’ (SP-BER), polymerase β (Pol β) replaces the 
single missing nucleotide, adding the correct one at the 3′ end of    
the nick. Then, DNA ligase I (Lig I) or a XRCC1-Lig III complex, 
complete the repair (49). Another sub-pathway of BER exists, called 
‘long patch’ (LP-BER), in which Pol β, coordinated with polymerase  
δ (Pol δ), polymerase ε (Pol ε), and the sliding clamp proliferating 
cell nuclear antigen, synthetise a 2–12 nucleotides strand. The re- 
maining flap is excised by flap endonuclease 1 (FEN1), while the nick 
is sealed by Lig I (50). Due to its elevated complexity, including the 
high number of BER factors involved as generated DNA intermedi- 
ates, different hypothesis have been proposed to explain how the 
BER pathway steps may proceed in a coordinated way. Specifically,  
in the ‘passing the baton’ mechanism proposed by Tainer et al. (33),  
a coordination among all the BER factors in the passage of the DNA 
intermediates (BER baton) has been suggested. This model would 
explain how the cell works to preserve cellular stability, and protect 
it from the presence of potentially mutagenic DNA intermediates 
(51). In contrast, in the “BERosome” model, proposed in different 
studies (52,53), a fine regulation exists among all BER enzymes to 
coordinate every step of DNA repair. This coordination depends on 
several PTMs that regulate protein–protein interactions, including 
pathway cascade signaling, cellular localisation, conformational 
changes and protein stability (52,54). In this scenario, several other 
proteins, including p53 and NPM1, act as BER modulators (55,56). 
The efficiency of BER is also due to the coordinated use of additional 
scaffold proteins. Among them, the poly (ADP-ribose) polymerase 1 
assumes an important role in the regulation of BER enzymes. Recent 
reports have shown the AP lyase activity of poly(ADP-ribose) poly- 
merase 1 (PARP1) (57), and the stimulating activity of PARP1 on 
APE1 endonuclease activity (58). 
Since knock-out of DNA glycosylases does not increase sensitivity 
to oxidative stress or ionising radiations (59–61), the existence of   a 
 
 
backup mechanism acting on damaged bases, typically recognised by 
BER proteins, has been suggested. In this context, a pathway known 
as nucleotide incision repair (NIR), acts directly on the 5′ side of    
the oxidised base by the direct action of APE1, thus ensuring the 
correct removal of the oxidised bases (62–67), which bypasses the 
action of glycosylases (Figure 1). The 3′ OH terminals, thus gener- 
ated, are processed by FEN1 (68,69) and DNA polymerases. Several 
studies have reported this non-canonical APE1 activity operating in 
NIR, pointing to substrates that are efficiently processed, which in- 
clude 5,6-dihydro-2′-deoxyuridine (DHU), 5,6-dihydrothymidine, 5-
hydroxy-2′-deoxyuridine (62,70), 5-hydroxy-2′-deoxycitidine 
(5OHC) (62,66,70) and alpha-2′-deoxynucleosides (αdA, αdT and 
αdC) (62,71). Notably, the majority of these damages are generated 
as a consequence of DNA exposure to ionising radiation (72–75). 
APE1 NIR activity is stimulated under significantly different experi- 
mental conditions, in terms of salts, pH and structural requirements 
(62), compared with the classical BER  activity.  Notably,  although 
the N-terminal region of APE1 is indirectly involved in the regula- 
tion of BER endonuclease activity, it is essential for the NIR process 
(62). Timofeyeva et al. (63) have reported how the lysine residue at 
position 98 (K98) significantly contributes to the 5′ phosphodiester 
bond hydrolysis of the DNA substrate, but not to the dissociation of 
the enzyme from the product complex. Furthermore, an amino acid 
substitution of K98 influences the NIR activity more than the BER 
activity, demonstrating how the catalytic site active in BER and NIR 
is the same, although different conformations of APE1 are respon- 
sible for the incision of unrelated lesions such as AP sites and DHU, 
which are substrates of BER and NIR, respectively   (63). 
A good and well-characterised example of canonical activity of 
BER in the maintenance of genomic stability is represented by its ac- 
tivity at telomeres. Telomeres are composed of a repetitive non-coding 
DNA sequence that avoids the loss of genetic information, as the 
DNA polymerase is generally able to replicate the template DNA 
until its end, but only on the leading strand (76). In humans, the telo- 
meric sequence is represented by repetitive “TTAGGG” hexameric 
blocks (77). Human telomeres are bound by the shelterin complex, 
which is composed of several protein partners that ensure stability 
and protection to the chromosome ends (78). The shelterin complex 
also functions to guarantee the acquisition and maintenance of G4 
folding (79). This secondary structure is preserved by the establish- 
ment of Hoogsten hydrogen bonds between the G4 guanines (80). 
Because guanine is the base with the lowest redox potential, telomeres 
are hotspots for oxidative modifications with the consequential gener- 
ation of 8-oxo-2′-deoxyguanosine (8-oxo-dG) (81), efficiently handled 
by the BER pathway to be removed and replaced. G4-8-oxo-dG sites 
are specifically recognised by the NEIL1 and NEIL3 glycosylases (82), 
which are able to cleave the oxidised base, leaving an abasic site that 
is then nicked by APE1 (83) (Figure 1). It has been shown that NEIL1 
and NEIL3 process 8-oxo-dG located in G4 structures formed in the 
promoter region of VEGF and c-Myc (83). Regarding 8-oxo-dG gen- 
erated in G4 structures at telomeric regions, only NEIL3 seems to be 
able to efficiently cleave it and subsequently recruits the LP-BER ma- 
chinery to favor repair (84). Moreover, NEIL3 also interacts with the 
TRF1 shelterin complex, and seems to play an essential role in coord- 
inating the repair of oxidation damages, as demonstrated by telomere 
dysfunction observed in the absence of this glycosylase (84). Wallace 
et al. hypothesised the possible involvement of NEIL glycosylases 
in both telomere maintenance and gene regulation (84). The abasic 
site generated by glycosylase is later handled by APE1 endonuclease, 
which is able to bind and process different types of G4, through the 





























































































































Figure 1. BER pathway and the ‘Deathly Allows’. Representational cartoon of canonical and non-canonical functions of enzymes belonging to the BER pathway. In 
the middle, canonical BER is represented as starting by the action of several glycosylases on non-bulky lesions (8-oxo-dG). When the abasic site (F) is generated, 
APE1 cleaves it, generating a single-strand break that can be processed by a short- (SP-BER) and long- (LP-BER) patch. Several BER enzymes are also involved 
in other important cellular pathways regarding DNA processing (left blue side), including a NIR pathway, telomere maintenance and transcriptional regulation. 
Recently, new discoveries regarding a role of BER enzymes in RNA processing (right red side) are emerging, including mRNA and miRNA processing and/or 
decay. Moreover, BER enzymes are also involved in the processing of DNA:RNA hybrids, including 8-oxo-G and ribose monophosphate abasic site embedded in 
DNA (top). Finally, their extracellular secretion has been also recently hypothesised (bottom). See the text for further information. Figure available in colour online. 
 
(Figure 1). The localisation of the abasic site in the quadruplex and the 
electrostatic interactions that mediate the contact of nucleic acids with 
APE1 then influence its activity on the lesion (48). The N-terminal 
region of APE1, and more specifically the lysine residues located in  
this region, are important for the regulation of the endonuclease ac- 
tivity on G4-containing abasic sites (56). Specifically, APE1 mutants, 
which mimic the acetylation of lysine residues, display increased endo- 
nuclease activity in vitro. The acetylation may therefore represent a 
dynamic mechanism to fine tune the activity of the protein at telo- 
meric sites (48) (Figure 1). Cells depleted in APE1 showed reduced 
telomere length and the knock-out of APE1, in postnatal mice, re- 
sulted in compromised development and growth, and increased senes- 
cence (85). APE1 can also interact with the TRF2 and POT1 sheltering 
proteins, and its presence at telomeric sites is important in stabilising 
these regions (86). Moreover, the depletion of APE1 results in telo- 
mere dysfunction and segregation defects in cells that employ alter- 
native lengthening of telomere pathways or telomerase re-expression 
to elongate telomeres (86). These results suggest an interdependence 
between the BER machinery and telomere homeostasis. 
 
Non-canonical roles of the BER pathway in the 
immunological response 
The BER pathway, besides being the main mechanism for coping 
with  DNA  lesions  described  above,  plays  an  essential  role  in the 
immunological response. It has been clearly shown that BER en- 
zymes regulate the genomic rearrangement that induces the antigen- 
stimulated somatic hypermutation (SHM) process, responsible for 
the diversification of the variable genomic regions of the heavy and 
light chains of immunoglobulins, and plays a central function in the 
process of class switch recombination (CSR) responsible for diversi- 
fication of the heavy chain constant region (87). These two antibody 
maturation mechanisms are dependent on the activation-induced 
cytidine deaminase (AID), which converts cytosine to uracil in the 
variable (V) and switch (S) regions of the immunoglobulin gene. 
APE1, through its AP-endonuclease activity, is responsible for the 
introduction of DNA nicks when AID-dependent deaminated cyti- 
dine is removed by the glycosylase, UNG2-dependent BER. Despite 
several uracil glycosylases being present in mammals, APE1 is the 
only AP-endonuclease, although a weak endonuclease activity has 
been recently identified for APE2 (88–90). Besides APE1 and UNG2, 
all the other BER enzymes have been found to participate in the 
uracil removal process (91). Their role in SHM and CSR strongly de- 
pends on crosstalk between each protein partner, and is finely tuned 
by the expression levels of each partner and by specific regulated 
posttranslational modifications, such as phosphorylation  of  Ser38 
in the AID protein (92,93). In particular, while APE1 endonuclease 
activity is important for CSR, it has been shown to be dispensable  
for SHM- and AID-induced DNA breaks. In fact, APE1 does not 
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rather, it may function as a DNA end-processing enzyme to facilitate 
the joining of broken ends during CSR (94,95). APE1 endonuclease 
activity is likely to remove 3′-tyrosyl residues from the DNA end 
after topoisomerase 1 (Top1) cleavage and Top1-cc degradation, 
which is essential to efficient recombination of broken S regions. 
Additionally, S regions are subjected to a high rate of transcription 
driven by cytokine-inducible promoters, which regulate the CSR 
process. Moreover, because APE1 is dispensable for AID activity, 
understanding the mechanism by which AID is targeted to its sub- 
strates is of great interest, given the potentially deleterious conse- 
quences of AID’s mutagenic activity (96). While the endonuclease 
activity of APE1 in the CSR process is well-established, its contri- 
bution as a transcriptional coactivator has been only hypothesised. 
In fact, the remaining CSR activity observed in APE1-endonuclease 
activity deficient cells (88) could be explained by the ability of APE1 
to stimulate the DNA-binding activity of several transcription fac- 
tors, including nuclear factor kappa B (NF-κB) and a few others, 
involved in inflammation and immunological responses (6,97,98). 
Very recently, using different APE1 inhibitors and APE1 DNA-repair 
and redox-defective mutants, we provided more evidence in support 
of this hypothesis, demonstrating that APE1 redox function also 
plays an important role in regulating CSR through the IL-6 signaling 
pathway and proper IgA expression  (99). 
 
The role of the BER pathway in trascriptional 
regulation 
A growing list of BER proteins, that were initially thought to exclu- 
sively function in DNA repair, are emerging as important in tran- 
scription (100). It is perhaps not surprising that these two processes 
are often coupled, when considering the mutagenic potential of the 
transcriptional process. DNA lesion repair, in transcriptionally active 
genes, must be kept under strict control to maintain transcriptional 
fidelity and genome stability. However, it does not simply involve a 
preferential repair of the transcribed DNA strand but, as suggested 
by several findings, a more physically and functionally intertwined 
crosstalk between the two processes must exist. Importantly, re- 
cent studies have generated a substantial body of evidence pointing 
to a direct function of DNA repair enzymes as coactivators of 
transcription. 
APE1 represents a paradigmatic example of a DNA repair en- 
zyme with a peculiar function as a transcriptional regulator. Indeed, 
APE1 plays a role in the regulation of expression of human genes in 
response to oxidative stress conditions by stimulating the DNA 
binding activity of several transcription factors, such as nuclear 
factor kappa B (NF-κB), Egr-1, Hif-1α, Nrf1 and STAT3, thus 
influencing the onset of inflammatory and metastatic processes (97) 
(Figure 1). Recently, a direct role of APE1 has also been character- 
ised in the transcription of sirtuin 1 (SIRT1) gene, by binding to 
negative calcium responsive element (nCaRE) sequences present on 
its promoter demonstrating that BER-mediated DNA repair pro- 
motes the initiation of transcription of the SIRT1 gene upon oxida- 
tive DNA damage (98) (Figure 1). Paradoxically, it has been shown 
that programmed DNA single or double strand breaks, with con- 
comitant activation of the DNA damage response, can induce tran- 
scription at gene promoters (101,102). Conventionally, DNA 
modifications (especially oxidation) are widely thought to be 
harmful for cell stability (103). The only described exceptions, rela- 
tive to DNA modifications with important regulatory roles, are 5-
methylcytosine and uracil, which are enzymatically generated in 
DNA    under    controlled    conditions    to    fulfil    crucial regulatory 
 
 
functions as epigenetic marks, or to be involved in antibody diversi- 
fication (104). The existence of modifications with potential regula- 
tory functions on other bases remains to be investigated. Oxidative 
DNA modification, as a consequence of the exposure to reactive 
oxygen species, is very frequent and guanine is the most susceptible 
targeted base, with 8-oxo-dG as the most common product (105). 
The distribution of 8-oxo-dG sites is not random throughout the 
genome, but occurs more frequently at the promoter region of active 
genes, thus contributing to transcriptional regulation (106). If not 
repaired, 8-oxo-dG is moderately mutagenic, causing a G to T 
transversion mutation that is thought to be responsible for initiating 
and driving carcinogenesis and neurodegenerative diseases, such as 
Alzheimer’s and Parkinson’s diseases (107–109). Recent evidence 
has highlighted how the repair of 8-oxo-dG by OGG1 is involved in 
the regulation of transcription, through the action of specific tran- 
scription factors, and also in signal transduction. Numerous reports 
have reported an interplay between DNA repair of 8-oxo-dG and 
transcription activation, mostly when this modification is found in 
promoter regions (98,101,110). These studies proposed that the 
8-oxo-dG BER-mediated repair may serve as a modulator for tran- 
scription efficiency, supporting a growing body of evidence regarding 
the role of 8-oxo-dG as an epigenetic-like DNA modification 
(102,111). The long-standing view has been that 8-oxo-dG is muta- 
genic and can negatively impact cellular processes such as transcrip- 
tion. When 8-oxo-dG is present in the template strand, it can slightly 
inhibit the advancement of RNA polymerase II (112), and the initi- 
ation of 8-oxo-dG repair may cause polymerases to stop (113); fur- 
thermore, the presence of 8-oxo-dG in transcription binding sites 
can negatively affect the transcription factor binding activity (114– 
116). For all these reasons, it is thought that 8-oxo-dG may act as a 
negative signal for transcription. However, there are a few notable 
findings showing that 8-oxo-dG, when recognised by OGG1, pro- 
vides a platform for the coordination of the initial steps of the BER 
pathway repair coupled with the assembly of the transcriptional ma- 
chinery to prompt the expression of redox-regulated genes. In par- 
ticular, the presence of 8-oxo-dG in promoters can increase gene 
transcription via the BER pathway; these are well-documented cases 
of the BCL2 apoptosis regulator (B-cell lymphoma 2) (117), SIRT1 
(98), vascular endothelial growth factor (VEGF) (118,119) and tu- 
mour necrosis factor-alpha (TNFα) (110) gene expression. We previ- 
ously proposed that BER-mediated repair of an oxidised guanines at 
nCaRE sequences is a key event for SIRT1 transcription (98). We 
hypothesised that the nick, introduced by APE1 during DNA repair, 
might favor local topological relaxation, facilitating the recruitment 
of RNA polymerase for gene transcriptional activation. A similar 
mechanism of transcriptional activation was described later by 
Pastukh et al. (118), in the context of the VEGF gene, and by 
Boldogh et al., who demonstrated OGG1 recruitment and 
upregulation of proinflammatory genes upon TNFα-induced oxida- 
tion of G in NF-κB consensus sequences (110,120). Of note, this re- 
ported role of 8-oxo-dG and OGG1 in the activation of inflammatory 
genes could explain the documented immune deficiencies observed 
in OGG1−/− mice (121,122). Furthermore, using 8-oxo-dG site- 
specifically synthesised reporters of the VEGF regulatory sequence, 
Burrows and co-workers have further characterised the mechanism 
of coupling BER and transcriptional activation. In particular, they 
suggested that the presence of 8-oxo-dG in DNA could provide a 
gene for up/down regulation depending on the strand context. 
Specifically, they demonstrated that the activation of VEGF tran- 
scription depended on the oxidation of Gs present in the guanine- 



























































































































model proposed that when 8-oxo-dG is present in the coding strand 
of the VEGF PSQ promoter, the produced AP site favors the pro- 
longed stalling of APE1, leading to its inability to cleave in the G4 
context but allowing the recruitment of the transcriptional activating 
machinery for gene induction. In contrast, the presence of 8-oxo-dG 
on the template strand activates the transcription-coupled nucleotide 
excision repair pathway, which attenuates transcription (101,119). 
Very recently, the same group reported a similar mechanism of ac- 
tion for the G-rich potential Z-DNA forming sequences (PZS) (123). 
This concept has also been shown for other promoters such as that 
of the endonuclease III-like protein 1 (NTHL1) (101), RAD17 (124), 
proliferating cell nuclear antigen (PCNA) (125) and NEIL3 (126), 
which expanded the generalisation of this model mechanism and 
emphasised the importance of G4-fold oxidation as a critical driver 
for gene activation. Secondary structures are key elements in the 
regulation of transcription, because the frequency of potential G4 
forming sequences within gene promoters is 1.8-fold higher if com- 
pared with other randomly considered regions (127). In addition, the 
GC-content positively correlates with transcriptional activity of 
genes (128), further supporting the possibility that oxidation of G 
and BER activities have the potential to trigger gene expression. 
However, the selective induction of 8-oxo-dG in promoter sequences, 
described in the abovementioned studies, appears difficult to explain 
as a consequence of general oxidative stress. Perillo et al. (117) sug- 
gested an intriguing hypothesis involving a possible alternative ex- 
planation for the generation of oxidised bases localised in promoter 
regions. They showed that lysine specific histone demethylase (LSD1) 
accounted for the generation of 8-oxo-dG in the estrogen-responsive 
promoter region of the bcl-2 gene. By an oxidative process that re- 
leases H O , LSD1 promotes the demethylation of histone H3 at ly- 
pharmacologically modulate OGG1 and APE1 activity to prevent 
degenerative diseases associated with oxidative stress, which can be 
derived by an inaccurate action of the two proteins at oxidised 
guanines. 
 
The roles of the BER pathway in RNA 
processing 
In the past few years, a clear picture of the involvement of DNA 
repair enzymes in specific aspects of RNA metabolism has emerged. 
In particular, a large cohort of BER enzymes has been implicated      
in RNA processes, especially linked with quality control towards 
damaged (i.e. abasic and oxidised) RNA molecules (131–133). BER 
enzymes typically cope with oxidative modifications occurring on 
DNA, but increasing evidence has suggested the involvement of the 
BER pathway as the mechanism of surveillance needed to remove 
damaged RNA molecules to ensure  cell  viability  (133). Currently, 
an unequivocal description of how cells may deal with  oxidised  
RNA is still missing. Notably, no known enzyme seems to be de- 
voted to the recognition and removal of abasic or oxidised RNA. 
However, a quality control mechanism should exist to protect from 
the negative consequences of unrepaired RNA damage, which could 
lead to an impairment of protein synthesis and noncoding RNA 
expression, with deleterious effects on the fate of cells. Therefore,      
a productive crosstalk between DNA repair enzymes and proteins 
associated with the RNA processing machinery seems more than 
reasonable. In this context, among the BER components, APE1 has 
been the particular focus of attention. Increasing evidence has re- 
inforced the view, suggested by our studies of a role of APE1 as a 
‘cleansing’  factor  for  damaged  oxidised/abasic  RNA,  and  possibly 
2      2 
sine 9, which, in turn, modifies the surrounding DNA and determines 
the recruitment of OGG1 and topoisomerase IIb to remove damaged 
DNA bases (129). Finally, another mechanism postulates a specific 
role for the excision of 8-oxo-dG. Boldogh et al. (130) showed that 
a stoichiometric complex of OGG1 with its excised substrate modi- 
fication had a high binding affinity for small GTPases, such as Ras, 
Rac1 and Rho, and that this binding acted as a guanine exchange 
factor (GEF), consequently activating downstream cellular signaling. 
Together, these interesting results highlight an intertwined role be- 
tween DNA repair and gene transcription, which is a phenomenon 
gaining more interest. Furthermore, coupling BER with transcrip- 
tional activation leads to the hypothesis that oxidative modification 
of G to 8-oxo-dG may have regulatory and possibly epigenetic-like 
features in cells. G4-forming sequences can especially sense oxidative 
stress and lead to repression or enhancement of transcription. 
However, whether 8-oxo-dG is an epigenetic modification is not 
clear and needs further discussion. Typically, epigenetic marks com- 
prise DNA methylation, histone modification and nucleosome local- 
isation, all of which are products of the activity of specific enzymes 
that modulate the access of transcription machinery. Conversely, 
DNA oxidation is efficiently repaired by BER and therefore has 
never been considered epigenetic, especially because it lacks the her- 
itability from mother to daughter as established for the epigenetic 
definition. Furthermore, the toxic aspect of 8-oxo-dG cannot be ig- 
nored. Therefore, further studies are needed to establish whether this 
modification can be considered helpful, by facilitating gene expres- 
sion, or as a process leading to mutagenic potential. It can probably 
be argued that deviations from the proper response to oxidative 
stress may be due to the impaired action of BER at oxidised guanines, 
which in turn might be the etiological link of 8-oxo-dG to several 
pathologies.  This  consideration  also  opens  new  scenarios     to 
highlighted its unsuspected function in RNA metabolism, thus af- 
fecting gene expression (5,133,134) (Figure 1). Initially, the poten- 
tial involvement of APE1 in RNA biology was mainly based on in 
vitro findings. In particular, we and others reported that APE1 bound 
structured RNA molecules (135), cleaved abasic single-stranded 
RNA (ssRNA), and was involved in RNA-decay, with 3′-RNA 
phosphatase and 3′-exoribonuclease activities (136). In parallel 
studies, as the interactome of APE1 has been shown, APE1 inter- 
action with components of the RNA metabolism machinery defini- 
tively proved the significance of APE1’s role in RNA metabolism in 
vivo (6,39). Proteomic analyses from our studies showed that the 
APE1 interactome was mostly comprised of proteins involved in 
ribosome assembly, regulation of mRNA stability (e.g. HNRNPK, YB-
1,   NPM1   and   PABPC1),   RNA   splicing   (e.g.   PRPF19,  SNRPB 
and SRPK1) and ribonucleoprotein complex biogenesis (e.g. RPL11, 
DDX6 and RPS14) (6). In support of these observations, we recently 
also showed that APE1 may represent a new hub in RNA-processing, 
including effects on ncRNAs such as miRNAs (6) (Figure 1). This is 
consistent with recent studies showing that the cellular response to 
damage requires not only protein-coding genes, but also a subset of 
ncRNAs (14,137,138). In fact, activation of  DNA  damage  induces 
the expression of multiple kinds of ncRNAs, such as miRNAs and    
the recently discovered DROSHA- and Dicer-dependent RNA, the 
DSB-induced small RNAs and the long intragenic non-coding RNAs 
(lncRNAs), which contribute to the fine tuning of damage repair to 
ensure DNA integrity (4). Numerous studies reported that ncRNAs, 
in particular miRNAs, were able to regulate the DDR by acting on 
several sensors of damage (e.g. γ-H2AX), as well as on crucial signal 
transducers (e.g. ATM, ATR and DNA-PKcs.) and effectors  (CHK1, 
p53 and p21) (137). However, a bidirectional regulatory pathway 
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few DDR proteins modulate miRNA post-transcriptional processing 
by regulating the essential steps of their processing and maturation 
(6,137). Remarkably, in this context, we recently showed a role for 
APE1 in pri-miRNA processing and stability via association with the 
DROSHA-processing complex during genotoxic stress. We showed 
that APE1 endonuclease activity was required for the processing of 
miR-221/222 in regulating the expression of the tumour suppressor 
phosphatase and tensin homolog (PTEN). These results highlight 
how APE1 regulates gene expression through its direct binding and/ 
or processing of specific miRNAs contributing to cancer progression 
(6). It is still unknown whether this mechanism is also involved in 
chemoresistance in cancer. The majority of studies  on  ncRNAs  in 
the DNA damage field have so far focused on the role of miRNAs, 
although a role for lncRNAs has also been reported. They have been 
described to be induced upon DNA damage and associated with 
ribonucleoproteins and proteins in chromatin by acting in various 
ways, including as signals, as decoys, or as scaffolds for these protein 
complexes leading to the regulation of DDR genes (137,139). At 
present, nothing is known about a possible interaction between 
lncRNAs and BER enzymes; however, because the expression of 
lncRNAs has emerged as a new topic in DNA damage, this relation- 
ship cannot be excluded. Preliminary results from our laboratory 
identified few lncRNAs bound by APE1, which might function to- 
gether with APE1 in DNA repair and safeguarding genome integrity 
(G. Antoniali et al., in preparation). In accordance with a  new  role 
for APE1 in RNA described so far, depletion of this protein in tu- 
mour cells leads to nucleolar defects (140), accumulation of oxidised 
RNA species as well as pri-miRNAs (6,56), alteration of miRNAs 
expression, impaired protein synthesis and reduced cell growth (56). 
All these findings, together with the cytoplasmic accumulation of 
APE1 in several tumour cell types (141), support a major function   
of APE1 in RNA-processing/decay. Taking into account these obser- 
vations, the importance of a better understanding of the role played 
by the BER enzymes in RNA-related processes becomes essential, 
especially when considering that some pathologies, including neuro- 
logical disorders and cancer, are associated with deficiencies to both 
RNA processing and DNA repair (142). Furthermore, these insights 
might also explain the complexity that underlies BER involvement in 
the onset of chemoresistance. In conclusion, further studies unveiling 
the regulatory mechanisms coordinating the interplay between BER 
activity and RNA processing will be necessary to understand the 
complexity of DNA repair programs and, finally, these notions can 
definitively facilitate the development of new anticancer agents. 
 
The BER pathway as a new player in RNA:DNA 
hybrid processing 
RNA:DNA hybrids physiologically occur  during  DNA  replication  
and transcription, telomere elongation, retroviral infection and 
retro-element mobilisation (143). In eukaryotic cells, RNA:DNA 
structures are classified in: (i) a configuration in which ssRNA is 
paired to ssDNA; (ii) a R-loop structure, in which a single DNA 
strand, belonging to the duplex DNA molecule, is hybridised with 
ssRNA and finally (iii) an incorporation of a single, or more, 
ribonucleotide(s) (rNMPs) in genomic DNA (144). Although 
RNA:DNA hybrids are needed for the successful ending of cellular 
processes, their persistent presence can induce harmful consequences 
to genome integrity causing replication fork arrest with replication– 
transcription collision and chromosomal breakage repair (145,146). 
For these reasons, a family of endoribonucleases, called RNase H, 
process the RNA:DNA hybrids to restore regular genomic stability. 
 
 
Currently, in-depth studies regarding the incorporation of rNMPs 
within the DNA have been reported (147). This particular RNA:DNA 
hybrid structure is one of the most common types of DNA damage 
because of its high frequency and abundance in the genome of both 
prokaryotes and eukaryotes (148–151). Different methodologies are 
under development for the detection of ribonucleotides incorporated 
in DNA (152–155), but the development of different sophisticated 
high-throughput sequencing-based approaches (156), including 
ribose-seq (149,157), hydrolytic end-sequencing (HydEn-seq) (158), 
polymerase usage sequencing (PU-seq) (159), embedded ribose- 
sequencing (emRibo-seq) (160) and (trimethylsilyl)diazomethane 
derivatisation followed by liquid chromatography–tandem mass 
spectrometry (154) analyses have facilitated the discovery of distri- 
butions and abundances of rNMPs in genomic DNA. Remarkably, a 
widespread but nonrandom distribution of rNMPs presenting sev- 
eral hotspots and a preference for rCMPs and rGMPs has been dis- 
covered (149). The high frequency (>100 million in mammalian 
cells) of rNMPs included in the nascent DNA molecule found during 
each replication cycle and DNA repair could have different origins. 
An imbalance of the rNTPs:dNTPs ratio, generally in favour  of  
rNTPs in normal conditions (149,161), and an imprecise 
discriminating capacity of DNA polymerases, which can erroneously 
incorporate rNTPs rather than dNTPs, are two aspects playing a role 
in these mechanisms (162–166). Moreover, RNA primers, synthetised 
to allow DNA lagging strand replication (167), could be considered 
an additional cause of the presence of rNMPs in  DNA.  Indeed,  if 
RNA primers are not correctly removed, isolated rNMP(s) can be 
included among consecutive Okazaki fragments, which could then 
permanently persist within genomic DNA (168). The biological rele- 
vance of rNMP incorporation in genomic DNA is emerging from a 
growing body of recent scientific studies. Whatever the cause of the 
rNMP(s) incorporation, the additional 2′-OH group on one or more 
rNMP(s) alters DNA elasticity and structure in a sequence-dependent 
manner, destabilising the DNA backbone, increasing the suscepti- 
bility to DNA hydrolysis, and finally causing strand cleavage and/or 
mutability (148,169–174). The genomic DNA stability, perturbed by 
the rNMP(s) presence, is preserved by the combined action of several 
enzymes orchestrated in a unique pathway called ribonucleotide ex- 
cision repair (RER) (160). One of the most important RER enzymes  
is RNase H2 (175), an endonuclease involved in the cleavage of the 
phosphodiester bond at the 5′ side of a single, or more allocated in 
series, rNMP(s) embedded in DNA. Similar to BER, FEN1 incises the 
3′ side of the partially excised rNMP to definitely release it from the 
genomic DNA, leaving a nick that will be finally repaired by Pol δ,   
Pol ε and Lig I enzymes (175,176). The missing processing of rNMPs 
embedded in DNA results in embryonic lethality in mice (160,177), 
as a consequence of activation of a p53-dependent damage response 
(178), cell cycle arrest and blockage of DNA replication (179,180). 
Moreover, it has been documented how mutations in each of the 
three RNase H2 subunits are correlated with the onset of the Aicardi 
Goutières syndrome (AGS), an inflammatory disorder (181,182) 
whose effects are mainly associated with increased levels of rNMP(s) 
incorporated in genomic DNA, that partially stimulates the activa- 
tion of the innate immune response by IFNγ signaling and DDR 
(160,180,183,184). Notably, a recent work performed on mice, ex- 
pressing different types of AGS-mutated RNase H2, has demon- 
strated the existence of a threshold in rNMPs levels during embryonic 
development. When the level is moderate, an activation of the cGAS– 
Sting DNA sensing innate immune response leading to perinatal le- 
thality was observed. When a high abundance of rNMPs exceeded  



























































































































damage caused early embryonic lethality (185). Importantly, a rela- 
tionship between RNase H2 and rNMPs incorporation with cancer 
is emerging. Screening of a cohort of patients with gastric cancers 
has recently revealed an association between the onset of gastric 
cancer and mutations in gene coding for the subunit B of RNase H2 
(186). In parallel, a recent study has shown that RNase H2 can be 
also considered as a colorectal tumour suppressor gene (187). 
Furthermore, loss of RNase H2, in the murine epidermis, results in 
spontaneous DNA damage and development of squamous cell car- 
cinoma (188). In light of this, it becomes clear how additional inves- 
tigations are needed for clarifying the association between mutated 
RNase H2 and/or rNMP(s) DNA-incorporated and pathology. 
Although the deleterious effects of rNMP(s) incorporations in DNA 
are well-known, a new hypothesis has been suggested involving a 
putative helpful role for rNMP(s). Specifically, it has been shown 
that more rNMPs, consecutively incorporated in yeast genomic 
DNA, may mark the nascent DNA strand, initiating programmed 
mating-type switching (189). Furthermore, a recent study reported 
how the erroneous ability of polymerase µ (Pol µ) to discriminate 
rNMPs during the NHEJ pathway (190–192) could be detrimental, 
as well as advantageous, for the cell. Indeed, by inserting rNMPs 
with a higher base fidelity compared with dNMPs (192), Pol µ might 
stimulate Lig IV in promoting initiation of the NHEJ mechanism 
(193). In parallel, another interesting observation has linked the ac- 
tivity of RNase H2 with the mis-match repair (MMR) pathway 
(164,194). The rNMP cleavage mediated by RNase H2 works as a 
signal for MMR enzymes, which are then stimulated to process the 
mismatched sites located in the surroundings. Finally, although the 
results show that rNMP in DNA induced a decrease of DNA poly- 
merases processivity (195), the choice of which rNMP is embedded 
in the template strand can influence the DNA synthesis (195–197). 
A still unanswered question is whether alternative DNA repair sys- 
tems, other than the RER pathway, may remove rNMPs embedded 
in DNA (147,198,199). Until now, topoisomerase I (Top1) is the 
only enzyme able to cleave rNMPs embedded in DNA, when the 
RER pathway is not working. Top1 is an essential enzyme thought 
to resolve DNA supercoils generated during replication and tran- 
scription (200,201). It has been shown that Top1, cleaving at the 
5′-side of rNMPs (199,202) and generating 5′-OH and 3′-cyclic 2′-3′ 
phosphate as DNA termini, is able to compensate for RNase H2 de- 
ficiency, although it causes high levels of DNA mutations (199,203). 
Later, the cleavage is followed by nick processing by Srs2-Exo1 
(204,205). A recent analysis of yeast has identified a role of Apn2 
(homologous to human APE1) in restoring the genome integrity per- 
turbed by the Top1-catalysed rNMPs cleavage by resolving 3′-end 
blocks generated by Top1 (206). Recently, Zimmermann et al. (207) 
have shown how the cleavage of rNMPs by Top1 results in the for- 
mation of PARP-trapping lesions that impede DNA replication. In 
contrast, studies performed on the MMR and the nucleotide excision 
repair (NER) pathways have shown the inefficiency of these path- 
ways in the processing of this particular lesion (199,208). The NER 
pathway generally excises bulky and non-bulky DNA base adducts 
(209). Because rNMP incorporation distorts the DNA backbone, 
NER enzymes could be good candidates in repairing this type of 
damage. Data obtained from Bacteria showed an involvement of 
NER factors in the removal of rNMPs in the DNA (210,211), in 
contrast to what is observed for human NER factors, which are not 
involved in rNMP repair (208). Evidence about this difference has 
not improved, but may suggest that NER factors might have lost this 
function during evolution. In contrast, data collected in vitro have 
shown  that  the  MMR  mechanism  can  target  mismatches  with 
rNMPs both in Escherichia coli and Saccharomyces cerevisiae gen- 
omic DNA (197). Increasing knowledge in this field represents an 
important goal in the DNA repair and in the pathogenesis associated 
with this type of damage. For this reason, we improved the study of 
DNA repair mechanisms acting on rNMPs embedded in DNA, 
under conditions in which RER is functionally inactive. In our la- 
boratory, while studying a putative role of BER in the removal of 
rNMPs embedded in the DNA, we discovered that BER was not ac- 
tive on this type of lesion (7). In this context, several published re- 
ports have hypothesised that, among the many millions of rNMPs 
that are introduced into the mammalian genome per cell cycle (198), 
damaged rNMPs (such as the ribose monophosphate abasic site and 
oxidation) can also be incorporated into DNA. In fact, RNA mol- 
ecules, as well as rNMPs present in the nucleotide pool, are also 
susceptible to oxidative insults (108,212). Although not fully ex- 
plored, the generation of hydroxyl radicals from oxidative stress 
could be the cause of the conversion of the deoxyribose sugar into 
ribose in vitro and in vivo (212). This can happen both in the cellular 
nucleotide pool and directly into the DNA. Additional data are 
needed to support this hypothesis. Moreover, a significant generation 
of abasic sites has been demonstrated upon RNA oxidation and al- 
kylation (23). For these reasons, whereas the role of the RNase 
H2-initiated RER mechanism of DNA repair in recognising and 
cleaving rNMPs embedded in DNA is well-established (178,198), 
little is known regarding the possible involvement of the RER 
pathway, or other DNA repair pathways, in the removal of damaged 
rNMPs. Again, a role of the BER pathway was addressed in our la- 
boratory. For its abilities, BER may represent one of the best candi- 
dates to work on modified rNMP(s) during DNA repair. Although 
APE1, in contrast to RNase H2, does not work on rGMP embedded 
in DNA (7), it has nevertheless been demonstrated to cleave the ri- 
bose monophosphate abasic site incorporated in the DNA (Figure 1). 
In contrast with expectations, RNase H2 does not work on this dam- 
aged base, confirming an APE1-exclusive function. Additionally, we 
focused on the 8-oxo-guanosine (8-oxo-G)-modified base. First, we 
found an inability of human RNase H2 in recognising and cleaving 
this modified rNMP embedded in DNA. We then studied the BER 
pathway, in which one of the most known bifunctional glycosylases, 
active in processing the 8-oxo-dG and FapyG DNA lesions, is OGG1 
(213,214). Although OGG1 also interacts with undamaged G, it is 
specific enough to discriminate and not to process it (215). In our 
recent report (7), we found that OGG1 was able to recognise and 
bind the 8-oxo-G embedded in DNA, as efficiently as its canonical 
substrate (8-oxo-dG) (Figure 1). Moreover, when co-incubated with 
APE1, it showed no glycosylase activity, being unable to process the 
8-oxo-G and to generate a substrate suitable for APE1. Notably, we 
discovered and characterised the NIR activity of APE1 on the 8-
oxo-G substrate. APE1, although weakly, was able to cleave 8-oxo-
G using experimental conditions specific for NIR. Furthermore, as 
observed during canonical NIR activity, APE1 works as an 3′-
exonuclease on the newly generated 3′-OH terminus (Figure 1). 
We recently improved our knowledge in this topic by discovering 
that, although human and Archeal RNase H2/II proteins are not 
able to process the 8-oxo-G or the ribose monophosphate abasic 
sites embedded in DNA, they were able to bind these dam- aged 
bases. In contrast, we found that E.coli RNase HII possessed a high 
enzymatic activity on both the 8-oxo-G and ribose 
monophosphate abasic containing substrates, suggesting a loss of 
function during phylogenetic evolution (216). Recently, it has been 
found that rNMP(s) is also incorporated by DNA polymerase γ in 
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Increased levels of embedded ribonucleotides, affecting mtDNA sta- 
bility and impairing new rounds of mtDNA replication, may con- 
tribute to new pathogenic mechanisms (217–220). A recent work 
conducted on yeast has demonstrated that a repair mechanism for 
rNMPs mis-incorporated is lacking (221). Further studies are needed 
regarding the consequences of rNMP incorporation in mtDNA and  
its repair processing. 
 
BER enzyme signatures in cancer 
Because of the involvement of the BER pathway in cancer and be- 
cause of evidence regarding BER factor secretion (see paragraph 
below), extensive efforts have been directed to evaluate the prog- 
nostic and predictive tumour biomarker potential of BER enzymes 
(222) (Figure 2). Several studies described the alterations of the 
APE1 genetic sequence, expression and distribution in several tu- 
mours (223). In different types of solid tumours, an increased APE1 
expression is associated with lower survival rates and, at the same 
time, an aberrant nuclear and cytoplasmic localisation of APE1 is a 
sign of poor outcome (224). A study performed on a cohort of pa- 
tients with gallbladder cancer showed that high expression of APE1 
protein  was  positively  correlated  with  tumour  stage  and positive 
 
 
lymph node status; in contrast, no association with tumour differ- 
entiation and metastatic condition was detected (225). It should be 
noted that not only the protein level, but also the subcellular local- 
isation of APE1 was altered. APE1 displayed a nucleo-cytoplasmic 
localisation, especially in patients in which a higher level of protein 
was detected (225). Regarding hepatocellular carcinoma (HCC), an 
upregulation of APE1 occurred at the transcriptional level, which 
was linked with the progression of the disease (226). Moreover, fur- 
ther studies showed an enhanced APE1 protein expression in tumour 
tissue compared with healthy controls (227). Immunostaining ana- 
lysis revealed elevated levels of APE1 in pancreatic adenocarcinoma 
tissue (228), and also in prostate, esophageal, gastric, salivary gland 
carcinomas (229–232) and non-small-cell lung cancers (233). In all 
cases, this feature correlated with a lower survival of patients (231– 
233). Furthermore, in tumour tissues derived from ovarian cancer, 
several studies highlighted an altered overexpression and localisa- 
tion of APE1 (234,235). However, in different cohorts of ovarian 
cancer, there were conflicting studies regarding the correlation be- 
tween the subcellular localisation of APE1 and cancer outcomes 
(223). In colorectal cancer (CRC), increased APE1 levels and cyto- 
plasmic localisation in tumour tissue and colon cancer stem cells have 




Figure 2. Overview of the most common BER-related alterations and relevance as potential molecular biomarkers in cancer. Symbolic illustrations of organs are 
shown, in which the main alterations of BER enzymes or BER-related alterations are listed into the connected colored boxes. See the text for further information. 



























































































































in liver metastasis has been correlated with poor prognoses (238). 
Concerning breast cancer, conflicting data are available. Some ana- 
lyses reported that APE1 expression was higher in patients with 
triple negative breast cancer (TNBC), which was associated with 
tumour size (239), while another study reported that a decreased 
APE1 level was linked to aggressive histological features and triple 
negative phenotypes (240). Similarly, loss of APE1 expression and 
poor prognoses were found in glioma compared with normal brain 
tissue (241); however, an increase in the APE1 protein was observed 
in post-treatment glioblastoma tumours (242). Along with the ex- 
pression level of APE1, its acetylated status has also been considered 
because it modulates APE1 activity. In particular, elevated levels of 
acAPE1 in colon, lung and pancreatic cancer tissues, leading to an 
increased AP-endonuclease activity, have suggested the occurrence of 
a compensatory mechanism in response to genotoxic stress induced 
by chemotherapy to maintain tumour cell proliferation capacity 
(243). Decreased APE1 acetylation status was associated with TNBC 
(244), demonstrating how PTMs occurring on APE1 is related to 
cancer development (244). Finally, a transcriptome analysis revealed 
an increased expression of APE1 and other genes of its interactome 
in the lymphocyte T cells of childhood acute lymphoblastic leu- 
kemia (245). Notably, correlation analyses were performed to link 
the overexpression of APE1 and the levels of its interacting pro- 
teins. For example, a cytoplasmic overexpression of APE1 and of its 
interacting protein, NPM1, were found in different studies, such as  
in a cohort of patients with ovarian cancer (246) with serous ovarian 
adenocarcinomas (247), indicating an association with lymph node 
metastasis, chemoresistance and an overall poor prognosis. Another 
positive correlation was observed between retinoic acid nuclear re- 
ceptor (RARα) and APE1 in patients with multiple myeloma (248). 
Indeed, the binding of RARα to its DNA response elements (RARE)   
is dependent on the redox function of APE1 (249). However, an 
inverse association has been found between APE1 and the tumour 
suppressor, PTEN, in glioblastoma, colorectal, breast, cervical and 
non-small cell lung cancers (6). Notably, high levels of  PTEN  and 
low levels of APE1 mRNA expression were associated with better 
prognoses in human melanomas (250). Furthermore, not only pro- 
teins but also miRNAs have been shown to be correlated with APE1 
in tumours. Indeed, a negative correlation was found between miR- 
765 and APE1 expression in osteosarcoma patients. Specifically, a 
higher expression of miR-765 was associated with decreased APE1 
and good survival in response to cisplatin treatment (251). In add- 
ition, the downregulation of miR-513-5p was found in patients with 
osteosarcoma. The decreased level of miR-513-5p has been correl- 
ated with APE1 overexpression and radioresistance (252). Finally, 
an inverse correlation between APE1 and miR/priR-miR-221/222 
expression was found in a cohort of human cancer specimens, such 
as glioblastoma, colorectal, breast, cervical and non-small cell lung 
cancers (6). In this context, the possibility to create a screening panel 
of the biomarker interactomes, involved in tumour development, 
should be carefully evaluated. 
The expressions of other BER enzymes have been evaluated in 
the literature as potential biomarkers. For instance, OGG1 is esti- 
mated to be a prognostic biomarker of CRC patients survival; and 
low levels of OGG1 mRNA in marginal colon tissue were associated 
with longer survival in CRC patients following therapeutic surgery 
(253). Furthermore, low mRNA and protein levels of SMUG1 were 
associated with adverse clinic-pathological features in breast cancer 
patients (254). Regarding CRC, an overexpression of N-methylpurine 
DNA glycosylase (MPG), OGG1, APE1, Pol β, PARP1 and XRCC1 
was also shown to be linked with poor pathological outcomes 
(222,255); only the overexpression of MPG and Pol β, and not of 
XRCC1, were positively correlated with higher rates of tumour pro- 
liferation when each individual CRC case was taken into account 
(222). Moreover, an increased expression of Pol β was also ob- 
served in gastric, uterine, prostate, ovarian and thyroid carcinomas 
(256). Limited to Pol β, overexpression was also consistently asso- 
ciated with tumour stage of gallbladder cancer (225). Furthermore,  
a cancer-related isoform  of  PCNA  has  been  specifically  detected  
in prostate and breast cancer (257,258). Moreover, a positive cor- 
relation between the upregulation of FEN1 and aggressiveness in 
breast cancer patients has been observed (259). FEN1 has been also 
found overexpressed in testis, lung and brain tumours (260). In the 
case of XRCC1, its overexpression, in lung and liver-cancer patients, 
was associated with low expression of aldehyde dehydrogenase 2 
(ALDH2), resulting in a poor prognostic value, suggesting that an 
efficient DNA repair mechanism is required in the presence of high 
aldehyde metabolism (261). Finally, an increased expression of Lig   
I has been reported in breast and lung tumour tissues (262). 
Very importantly, along with the levels of the proteins, it is also 
fundamental to evaluate their activity, as biomarkers. The possi- 
bility to measure the DNA repair capacity (DRC) could provide a 
method to predict the outcome of a particular disease. For instance, 
5-fluorouracil (5-FU) is the main chemotherapeutic drug used against 
solid tumours. The BER pathway is involved in the DNA repair pro- 
cess in response to 5-FU lesions, thus, removing 5-FU and uracil me- 
tabolites from the DNA (263). A prospective study demonstrated 
the association between DRC of BER in response to 5-FU and pa- 
tient survival in a cohort affected by CRC. In the study, the overall 
survival was correlated with high activity of BER in non-malignant 
adjacent mucosa and low BER in tumour tissue in patients with 
TNM Stages II and III, together with good therapy response (264). 
Interestingly, APE1 enzymatic activity was also higher in gallbladder 
tumour patients than in chronic cholecystitis patients (225). Taking 
into account these results, Chaim et al. (265) developed a fluorescent- 
based multiplex flow-cytometric host cell reactivation assay, based 
on the transfection of reporter plasmids in primary T lymphocytes, 
that allowed measurement of the activity of BER enzymes, such as 
different glycosylases (OGG1, MPG, MUTYH and UNG) and APE1. 
The possibility to measure the activity of OGG1 and MPG through a 
DNA glycosylase-mediated cleavage of molecular beacons was dem- 
onstrated by Hu et al. (266). 
 
BER polymorphisms and cancer 
The identification of single-nucleotide polymorphisms (SNPs) in 
DNA repair genes has become increasingly important  since  they  
can determine a different DNA repair capacity and consequently 
generate higher frequency of mutations (267). Therefore, SNPs can 
be associated with a high susceptibility to cancer and with chemo- 
therapy and radiotherapy resistance (268). Different SNPs involved 
in carcinogenesis have been identified in the main DNA repair path- 
ways, such as BER, NER, MMR and double-strand breaks repair 
(DSBR) (267,269,270). For all these reasons, DNA repair pathway 
polymorphisms are of interest as predictive factors in the clinic. 
Here, we report the most frequent functional polymorphisms that 
have recently been published concerning the BER pathway enzymes 
(see Wallace et al. (14) for the complete list of  polymorphisms). 
Several evidences have been reported regarding the main BER 
DNA glycosylases, such as OGG1, NEIL3 and mutY DNA glycosylase 
(MUTYH). Several studies have been reported regarding the most 
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now, data regarding OGG1 Ser326Cys polymorphism  and  cancer  
has been conflicting, probably due to the susceptibly of the different 
populations and the different types of tumours that have been studied. 
Earlier evidence suggested that OGG1 Ser326Cys polymorphism did 
not increase the risk of developing lung cancer (271). Nevertheless, 
conflicting data of OGG1 Ser326Cys polymorphism was present for 
CRC (272,273) and breast cancer (274,275). However, a more  re- 
cent study has shown how OGG1 Ser326Cys heterozygous  geno- 
type (Ser/Cys) is associated with a decrease of bladder cancer risk  
in a cohort of a Belarusian population (276). In a follow-up study,  
the same research group demonstrated how this polymorphism 
could affect cancer-related genes and the methylation status in pa- 
tients diagnosed with bladder cancer. Indeed, the frequency of the 
oncogenic phosphatidylinositol 3-kinase (PIK3CA) mutations was 
reduced in smokers of heterozygous genotype (Ser/Cys) and minor 
allele (Cys) carriers. On the contrary, the same polymorphism correl- 
ated with an increased frequency of mutations in the RAS loci and 
affected the levels of runt-related transcription factor 3 (RUNX3) 
and ISL  LIM  homeobox  1  (ISL1)  methylation  (277).  In  addition,  
it has been shown that OGG1 Ser326Cys homozygous genotype 
(Cys/Cys) represents a risk factor for childhood leukaemia (278). An 
explanation is that the Cys/Cys genotype is associated with lower 
OGG1 activity, which translates to an increased AML relapse (279). 
Concerning polymorphisms involving other glycosylases, NEIL3 
Pro117Arg (rs7689099) has been suggested for its relevance in sus- 
ceptibility, survival and therapy outcome in patients with CRC from 
the Czech Republic and Austrian cohorts (280). Finally, MUTYH 
polymorphism Gln324His (rs3219489) (Gln/His and His/His) was 
associated with increased CRC risk in a Polish population (281) and 
Gln324His (His/His) was linked to an higher lung cancer risk in a 
Japanese population (271). 
Concerning the endonuclease APE1, the most frequent poly- 
morphism is Asp148Glu (rs3136820), covering about 46% of the 
population (14). Again, conflicting data are present in  the  litera- 
ture regarding bladder, breast, colorectal and lung cancer (14,270). 
Furthermore, a recent meta-analysis has not shown any associ-  
ation between the Asp148Glu polymorphism and prostate cancer; 
however, in the same study, when a hospital-based population was 
considered, the presence of Asp148Glu dominant variants (Glu/ 
Gluand  Asp/Glu) was proposed as a risk factor to develop pros-   
tate cancer (282). In addition, in a recent study, APE1 Asp148Glu 
was not considered as a risk factor for HCC in an Egyptian popula- 
tion (283). These discrepancies probably are attributable to the fact 
that the Asp148Glu variant exhibits normal endonuclease activity 
(284). However, increasing incidence of AP sites has been observed 
in leukocytes derived from breast cancer patients compared to con- 
trols, thus increasing the risk of cancer (285). Finally, a meta-analysis 
has suggested that the APE1 polymorphism rs1760944 T > G could 
have a protective role in cancer development among Asians (286). 
Few data are available regarding the association between PARP1, 
Pol β, FEN1 polymorphisms and tumours. Liu et al. (270) have re- 
ported the latest data regarding these BER enzyme polymorphisms 
and the risk of  CRC. 
Different studies concerning XRCC1 polymorphisms and the sus- 
ceptibility to cancer have been reported. In a Caucasian population, 
the risk of gliomas was associated with both the homozygous vari- 
ants of XRCC1 Gln399Gln and XRCC3 Met241Met (287). Another 
variant of XRCC1, Arg194Trp, was shown to be  a  risk  factor  for 
CRC in a Chinese and Kashmiri population with heterozygous (Arg/ 
Trp) and homozygous variants (Trp/Trp) (288,289). The same poly- 
morphism  was  considered  a  susceptibility  factor  for  HCV-related 
 
 
hepatocellular carcinoma progression in an Egyptian population; 
however, no association was found when Arg280His or Arg399Gln 
genotypes were taken into account (283). In a Chinese cohort, 
the polymorphism located at the promoter of XRCC1 (XRCC1 
rs3213245 C genotype) was associated with a decreased risk of cer- 
vical cancer, due to a transcriptional overexpression of XRCC1, as a 
consequence of the enhanced binding of the Sp1-Knox-20 complex 
to the promoter region. Moreover, a decreased expression of XRCC1 
has been observed in carriers of the XRCC1 rs3213245 T genotype, 
increasing the risk of cancer (290). BER polymorphism can affect 
the methylation status of some tumour suppressor genes, as previ- 
ously mentioned. For instance, focusing on XRCC1, in a study which 
considered a cohort of patients with bladder cancer, the XRCC1 
Arg399Gln (rs25487) heterozygous (Arg/Gln) genotype increased 
the frequency of p16 and TIMP3 methylation (277). 
 
Extracellular secretion of BER proteins: novel 
insights in cancer biology 
It has been widely reported how, in cancer cells, the activation of the 
BER pathway, in response to the chemotherapy treatment, promotes 
a resistant phenotype (291). Through the activation of repair mech- 
anisms, in fact, stressed cancer cells can escape from cell death and 
maintain their ability to grow (292). This is the reason why BER en- 
zymes are considered a good target for developing novel anti-cancer 
therapies. The chemoresistance phenomenon is not only connected 
with the activation of repair pathways in cancer cells, but also with 
the multifunctional role of the BER enzymes, particularly associ- 
ated with the regulation of gene expression (133,293). Another 
interesting aspect supporting the chemoresistance occurrence is the 
capability of drug treatments to induce a modulation of the immune 
responses (294). Some secreted factors are also responsible for the 
modulation of immune responses, acting in the extracellular tu- 
mour microenvironment, to affect the metabolism of the accepting 
cancer cells (293). This property suggests a new scenario regarding 
the dynamic molecular mechanisms that are activated by the se- 
creted factors that influence the behavior of the surrounding cancer 
cells. Specifically, it would be interesting to study some BER or BER- 
related proteins regarding their possible roles as damage associated 
molecular patterns (DAMP) proteins in tumour progression, such as 
the secreted protein high mobility group box 1 (HMGB1) (Figure     
1). HMGB1 is a nuclear DNA repair protein that acts as  a  chro-  
matin remodeling factor and as a transcriptional regulator, but it is 
also an extracellular protein, that can act as a chemokine and cyto- 
kine, having a role in cell signaling and inflammation (295,296). As a 
DNA repair protein, its accumulation is concomitant with oxidative 
DNA damage and, for this reason, it has been defined as an early 
DDR factor (297). It is also considered as a BER co-factor, because    
it is able to affect the activities of BER enzymes. HMGB1 stimulates 
APE1 endonuclease activity on AP sites, and promotes long-patch 
BER, through the stimulation of FEN1 flap cleavage activity (295).    
It is known that oxidative stress is responsible for HMGB1 trans- 
location, release and activity (298). These secreted proteins therefore 
have a pro-inflammatory role (299). Indeed, HMGB1 secretion is in- 
duced upon chemotherapeutic treatment, and due to its capability to 
stimulate the chemokine CXCL11, it contributes to the antitumour 
immune response (294,300). In contrast, current data elucidate how 
this secreted protein is also connected to cancer development, due to 
its role in the progression of esophageal squamous cell carcinoma 
(ESCC) (293). These data suggest the importance of activated para- 



























































































































and progression. Interestingly, other proteins whose role was ini- 
tially thought to be restricted only to the nuclear compartment and 
with the maintenance of DNA structure and with the regulation of 
gene expression, have been recently demonstrated to play a role in 
paracrine signaling. Even if these proteins lack the leader sequence 
that promotes the canonical secretion through the endoplasmic re- 
ticulum and Golgi apparatus (301), their secretion is clearly docu- 
mented. As secreted factors, the function of these proteins seems to 
be related to cytokines activity. One example is YB-1, an additional 
APE1-interacting protein, whose role as an extracellular mitogen 
was described in mesangial and monocyte cells after inflammatory 
challenges (302) (Figure 1). There are also consistent data about the 
secretion of the APE1 enzyme, whose elevated intracellular protein 
levels in cancer are linked to poor prognosis (141). APE1 confers 
resistance to chemotherapy or radiotherapy treatments in different 
kind of tumours like gliomas, breast cancer, HCC,  thyroid  cancer 
and osteosarcoma (226,303–305). Recent findings concerning APE1 
cytoplasmic relocation and poor prognostic correlation in HCC cells 
led to new investigations about the multiple functions of this BER 
enzyme and to its emergent role in cancer progression relative to its 
own localisation (141,226). Studies regarding its possible secretion 
were reported since 2004, when it was predicted that APE1 was also 
a non-classically secreted protein (306). Its extracellular secretion 
was later revealed in the plasma of endotoxemic rats (307), and in 
the same year, the regulation of APE1 secretion occurring through 
PTMs and inducing its extracellular release was characterised. It 
seems, in fact, that the acetylation of residues K6/K7 in the APE1 N-
terminal region promotes its secretion (308). APE1 acetylation as a 
post-translational modification promoting its extracellular release, 
was also verified in TNBC, in which APE1 secretion and its action 
as an autocrine and paracrine factor seems to promote the apop- 
tosis of cancer cells (309). Reports regarding APE1 functions as a 
secreted protein were also observed in monocytes, where an APE1 
extracellular role under inflammatory conditions and its capability 
to promote the production and secretion of IL-6 were proven (310). 
We recently demonstrated a role of extracellular APE1 in HCC 
(311), finding a positive correlation between serum and tissue APE1 
amounts in the HCC cohort analysed. These data prompted us to 
consider serum APE1 as a new diagnostic biomarker in HCC. We 
also showed that the exogenous APE1 protein was able to induce 
IL-6 and IL-8 expression in the JHH-6 HCC cell line, suggesting its 
role as a paracrine pro-inflammatory factor. Hence, these findings 
suggested that exogenous APE1 was able to modulate the inflamma- 
tory status of the tumour microenvironment, showing its possible 
role in cellular senescence and in tumour invasiveness (310–312). We 
believe that further characterisation of the roles of secreted BER pro- 
teins is required for an understanding of their role in tumour biology. 
 
Cancer organoids as a novel approach to 
translate BER proteins in personalised 
medicine 
Human cell lines and in vivo  animal  models  have  been  largely  
used to characterise the biochemical functions and the biological 
relevance of BER proteins, and are a well-known model in cancer 
translational research. However, a better knowledge of the  adult 
stem cells in combination with  three-dimensional  (3D)  cultures  




Figure 3. Protein–protein interaction network of proteins involved in DNA repair/stability and in RNA processing. Data, obtained from the InWeb_InBioMap 
platform (no network expansion, confidence score cut-off = 0.156 [recommended value]; (322)), shows the direct (solid lines) and indirect (dashed lines) 
interactions existing between BER (yellow nodes), nucleotide excision repair/DNA mismatch repair/non-homologous end joining (NER, MMR, NHEJ, red nodes), 
homologous recombination (HR, cyan nodes), telomeres (purple nodes) and RNA processing/binding (green nodes) proteins, as well as a few others (blue 
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system (313,314). Organoids consist of a novel 3D technology,  
which allows the establishment of long-term stem cell-based cul- 
tures. Organoids  represent  a  valuable  tool  to  study  the  biology  
of stem cells and to evaluate their contribution to tissue homeo- 
stasis. Organoids have numerous  valuable  applications  and  may  
be used to improve our knowledge about several  disease  path-  
ways (315,316), especially in cancer biology. Due to the intriguing 
mechanisms characterising tumour  aetiology,  different  studies 
have focused on personalised precision treatments for cancer. By 
using patient-derived tumour organoids (PDOs), studies have tried 
to understand and reproduce the disease complexity and hetero- 
geneity, for developing patient-specific therapies (317), because 
organoids reflect the key-features of the original patient’s tissue 
(316). Different types of analyses involving normal and tumour 
PDOs have been performed, such as genome, transcriptome (318) 
and proteome analyses (317), but DNA  repair  mechanisms  have 
not been extensively studied. Based on previous studies, normal 
organoids could be engineered to study DNA repair enzymes defi- 
ciencies and evaluate mutational signatures in cancer. To date, few 
studies regarding BER enzymes  and  PDOs  have  been  published.  
In a recent study, human normal intestinal organoids were engin- 
eered with the CRISPR-Cas9 genome editing system to delete key 
DNA repair genes, such as the  MMR  gene  MLH1  and  the  BER  
gene  NTHL1  (319).  This  approach  proved  that   MLH1   knock- 
out organoids reflected mismatch repair-deficiency found in CRC; 
moreover, the lack of NTHL1 was a predisposition to the devel- 
opment of a range of cancers, such as colorectal and breast cancer 
(319). Furthermore, the opportunity to perform drug-screening as- 
says on PDOs is very appealing, considering that chemoresistance 
can occur in patients (320). Indeed, we recently tested the APE1 
endonuclease inhibitor (Compound #3) on CRC PDOs, carrying a 
wild-type, and a stop-gain or missense mutant TP53, highlighting 
that the effectiveness of the inhibitor was dependent on the presence 
of wild-type or gained-of-function mutant p53 and independent of 
the null-mutant p53 (321). Therefore, we strongly believe that the 
use of these 3D-cell models should be carefully considered in trans- 




Forty years after the first characterisation of the BER glycosylases, 
integration of this pathway (Figure 3, yellow nodes)  within  the  
DDR (Figure 3, red and cyan nodes) has been somewhat elucidated. 
The recent discovery of a functional role of this highly conserved 
pathway in genomic stability, gene expression regulation and RNA 
processing/decay (Figure 3, purple, blue and green nodes) lays the 
foundations for the starting point of a new challenging field of re- 
search. These achievements will significantly contribute to our 
understanding of the complexity of BER and the DDR, in general. 
Moreover, these findings will help add further elements to the com- 
prehension of the role of BER in human physiology and pathology, 
possibly opening new unpredicted therapeutic perspectives. Many 
issues still remain to be addressed and are prompting researchers   
to continue their efforts to understand the crosstalk between DNA 
damage and gene expression regulation. This can be considered as a 
fundamental process responsible for the adaptive cellular mechan- 
isms to genotoxic damage, and is a concern regarding several pos- 
sible mechanisms of cancer chemoresistance. 
In the last 40 years, we have learned much regarding BER bio- 
chemistry and biology. However, a number of questions still remain 
to be elucidated. 
 
 
• Should we reinterpret the overall biological function of DDR and 
its role in cancer based on the data about the relevance of the 
non-canonical functions of DDR and BER     proteins? 
• Several BER and other DDR enzymes are catalytically active on 
different modified RNA substrates. Should we ascribe to them an 
important role in RNA decay or in the editing   mechanisms? 
• Might the unique ability of BER DNA glycosylases to recognise 
even subtle chemical modifications of nucleobases serve to distin- 
guish between normal and aberrant RNA  molecules? 
• Is there a concerted action between DNA glycosylases, APE1 and 
the downstream enzymes involved in decay/repair of damaged 
RNA  molecules? 
• Can the effects of BER enzymes, both on mRNA  and  ncRNA,  
alter the protein translational machinery, thus, contributing to 
chemoresistance through post-transcriptional regulation of gene 
expression? 
• Is the role of some DNA repair proteins in secreted exosomal 
particles due to their canonical or non-canonical  functions? 
In 2009, thanks to the use of unbiased proteomics and genomics 
strategies, we were able to propose the novel concept of non- 
canonical functions of APE1 in RNA metabolism. We strongly be- 
lieve that an integrated view of the canonical roles of BER proteins  
in DNA repair and in RNA functions will lead to new important and 
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open Architecture of The Human Ape1 
Interactome Defines Novel Cancers 
Signatures 
Dilara Ayyildiz1,4, Giulia Antoniali1,4, Chiara D’Ambrosio2,4, Giovanna Mangiapane1, 
Emiliano 1, Andrea Scaloni2, 1* & Silvano 3* 
APE1 is essential in cancer cells due to its central role in the Base Excision Repair pathway of DNA 
lesions and in the transcriptional regulation of genes involved in tumor progression/chemoresistance. 
Indeed, APE1 overexpression correlates with chemoresistance in more aggressive cancers, and 
APE1 protein-protein interactions (PPIs) specifically modulate different protein functions in cancer 
cells. Although important, a detailed investigation on the nature and function of protein interactors 
regulating APE1 role in tumor progression and chemoresistance is still lacking. The present work was 
aimed at analyzing the APE1-PPI network with the goal of defining bad prognosis signatures through 
systematic bioinformatics analysis. By using a well-characterized HeLa cell model stably expressing 
a flagged APE1 form, which was subjected to extensive proteomics analyses for immunocaptured 
complexes from different subcellular compartments, we here demonstrate that APE1 is a central 
hub connecting different subnetworks largely composed of proteins belonging to cancer-associated 
communities and/or involved in RNA- and DNA-metabolism. When we performed survival analysis 
in real cancer datasets, we observed that more than 80% of these APE1-PPI network elements is 
associated with bad prognosis. Our findings, which are hypothesis generating, strongly support the 
possibility to infer APE1-interactomic signatures associated with bad prognosis of different cancers; 
they will be of general interest for the future definition of novel predictive disease biomarkers. Future 
studies will be needed to assess the function of APE1 in the protein complexes we discovered. Data are 
available via ProteomeXchange with identifier PXD013368. 
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